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ABSTRACT
Natural product total synthesis provides an alternative method for obtaining
medicinally relevant compounds in a more efficient process with higher yields than what
nature can provide. Natural products pose significant synthetic challenges due to the
unique heterocyclic skeletons with fused and spirocyclic ring systems. Therefore, it is
paramount to develop efficient reaction methodologies targeting substructures such as
cyclic ureas and spiro[4.5]decanes which are prominent among marine natural products
and Lycopodium alkaloids, respectively. Presented here is a compilation of research
seeking to develop synthetic methods for the construction of cyclic moieties such as those
previously mentioned. The objectives that are addressed include: 1) Investigating the
vinylogous enolate reactivity of phenols to undergo intramolecular para-allylation with
pi-allyl palladium complexes to form functionalized spiro[4.5]decanes 2) The
development of synthetic strategies for the preparation of tri-substituted quinoline
scaffolds and subsequent derivatization toward establishing a library of heterocyclic
candidates for HIV-1 integrase inhibition and 3) Investigating a new synthetic tool for the
creation of carbon-nitrogen bonds to afford 1,2-diamines as the protected cyclic urea via
vinyl sulfoxide/carbodiimide annulation and sigmatropic rearrangement.
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CHAPTER I - INTRODUCTION
1.1 Natural Product Isolation
Throughout history and within various cultures, humans have utilized natural
remedies for treatment of a variety of ailments ranging from acute illnesses to chronic
conditions. Medicinally, these remedies have proven useful which has led to increased
interest in isolation of the specific compounds in naturally occurring species that exhibit
these properties. This process has been valuable for the discovery of a plethora of
molecules containing biologically relevant indications. Although isolation techniques
have revealed significant information about what nature can provide, there are two
limitations with harvesting these compounds from their native plants:
1. Extensive isolation procedures requiring considerable time, labor, and
resources.
2. Total plant composition comprising low percentages of the target
compound which leads to waste and endangerment of the plant.
In response to these issues, the chemical community has embarked on a myriad of
synthetic endeavors to mimick the complicated synthesis that nature has been able to
acheive.
Natural product total synthesis provides an alternative method for obtaining
medicinally relevant compounds in a more efficient process with higher yields than what
nature can provide. In addition, the synthetic methods developed can be utilized for a
myriad of applications including pharmaceutical research where the preparation of
analogues from a single key precursor is implemented for drug discovery. Among the
plethora of natural products that are known, a substantial amount contain unique
1

heterocyclic skeletons with fused and spirocyclic ring systems which present significant
challenges to the synthetic chemist. The ultimate goal is to discover efficient
methodologies for the synthesis of substructures within natural products. By doing so, the
total synthesis of natural products can become the desired alternative to harvesting from
natural sources.
1.2 Total Synthesis Milestones
In pursuit of these goals, the field of organic synthesis has made significant
progress over the past decades. A variety of synthetic acheivements that laid the
foundation for modern organic chemistry include the preparation of multicyclic
compounds such as morphine,1 quinine,2 penicillin V,3 and strychnin4 (Figure 1.1). Of
course, these select examples do not encompass all the classical syntheses that have
defined the field as it exists today.

Figure 1.1 Select classic natural product total syntheses.
One common theme shared among all of these natural products is the presence of
cyclic features. There are a variety of conformations presented which include
carbocycles, heterocycles, aromatics, fused and spirocyclic ring systems, and varying
stereochemical complexity. While some appear to contain higher complexity than others,
each molecule presents unique challenges that test the ingenuity and creativity of the

2

organic chemist. At times, the simplest molecule in appearance can harbor the most
significantly challenging synthetic task.
1.3 The Necessity for Cyclization Reactions
With it clear that cyclic moieties comprise a high percentage of structural features
among a multitude of chemical targets, it is paramount that methodolgy for the
construction of cyclic structures be continuously developed and refined. From the onset,
key cyclization reactions that have continued to influence the synthetic community
surfaced. An example can be found by the work of Otto Diels and Kurt Alder when they
discovered the [4+2] cycloaddition;5 a reaction that is still implemented in modern
synthesis. Additionally, the Stork-Eschenmoser hypothesis which stated the development
of exclusively trans polycyclic ring systems can be developed stereoselectively from
polyunsaturated trans olefins, serving as a foundation for the development of steroid
synthesis.
Other notable developments include the discovery of alkene6 and alkyne7
metathesis. Following the seminal publications, both systems were expanded into what is
now generally referred to as “ring closing metathesis”. Following these reports, J.E.
Baldwin established a set of guidelines for intramolecular ring closing reactions which
have sense been termed “Baldwin’s Rules”.8 The purpose of these rules was to establish
defining factors that govern both plausibility of a ring closure to occur and predicted
stereochemical outcomes. Although this select set of examples is not exhaustive, they are
preseneted as a highlight to the major contributions in the field and serve as an
introduction to the continued demand for novel alternative methods for constructing
cyclic molecules.
3

With the understanding that cyclization reactions hold a significant component for
the synthesis of natural products, this dissertation seeks to implement and expand on
these concepts. In the proceeding chapters, three individual projects are presented.
Although each section contains a unique and specialized niche, a broadened examination
reveals that all three ideas seek to expand on current applications of cyclization reactions
and contribute to the collective knowledge found within this widespread topic.
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CHAPTER II - APPLICATION OF TSUJI-TROST VARIANT OF THE WINSTEINMASAMUNE REACTION TOWARD THE SYNTHESIS OF MAGELLANINE
2.1 Introduction
2.1.1 Cyclopiane Terpenes
Terpenes are a class of natural products that are prominent among plants and
fungi and are often isolated from the essential oil extracts. Terpenes consist of only
hydrocarbons and follow a pattern of containing five-carbon units.9 In the late 1800s it
was observed by Otto Wallach that the building block for these units was isoprene which
contains the molecular formula C5H8 which is now referred to as the isoprene rule.10
Though examples containing oxygen in the form of alcohols, ketones, and aldehydes
have also been reported these are instead referred to as terpenoids due to diversion from
the established rule.
Though a wide variety of sub-classes for terpenes have been established, two are
of particular interest for this research (Figure 2.1):
1. Cyclopianes: Conidiogenone 2.3
2. Acoranes: Colletoic Acid 2.4

5

Figure 2.1 Spiro[4.5]decane architecture in natural products.
The reason for this selection resides in both the biological activity for these
families as well as the structural scaffold shared among each. To begin, the first report of
terpenes within the cyclopiane family was published by Roncal and co-workers in 2002
wherein conidiogenone was isolated from the fermentation broth of Penicillium
cyclopium.11 It was recognized that this terpene had the capability to induce
conidiogenesis (the aerial or aquatic transfer of spores via conidia) which could be
utilized to further understand this biological process of fungi. Following this initial
report, a variety of new cyclopianes have been discovered and have shown to have
diverse biological activity including antimicrobial indication against Staphylococcus
aureus,12 cytotoxicity against human Leukemia cells,13 and antiallergenics.14
In pursuit of synthetic preparations of desired cyclopianes, Hou and co-workers
recently reported a convergent synthesis of three cyclopianes via a key directed
semipinacol rearrangement step which afforded construction of both the C ring and the
quaternary carbon shared by ring C and A (Scheme 2.1).15 Through the previously stated

6

Lewis acid mediated cycloenlargement semipinacol rearrangement, tetracycle 2.6 was
developed from 2.5. An additional three steps which included an aldol cyclization
succeeded in the production of the tetracyclic core in 2.7.

Scheme 2.1 Construction of the tetracyclic core found in cyclopianes.
2.1.2 Acorane Terpenes
Acoranes present a unique family of sesquiterpenes due to the bicyclic
spiro[4.5]decane scaffold. The first reported discovery of the acorane family was by
Sorm and co-workers during their investigation of sweet flag oil wherein degradation
experiments of acorone 2.9 revealed the spirocyclic structure.16 Since this discovery, a
variety of spiro[4.5]decanes have been isolated and reported. In early studies, it was
postulated that acoranes acted as a key intermediate for the biosynthesis of tricyclic
skeletons such as cedrene 2.10 (Scheme 2.2).17

Scheme 2.2 Biosynthesis of cedrane.
Colletoic acid 2.4 (Scheme 2.3) presents a prime example of the utility for
medicinal applications of an acorane sesquiterpenoid. Following its discovery in 2008
and subsequent application as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor for
the treatment of type 2 Diabetes and metabolic syndrome,18 both the Rivas and Nakada
7

research groups have shown successful synthesis of the molecule.19-20 In pursuit of a
more effective treatment for metabolic syndrome, Rivas and co-workers utilized a late
stage palladium mediated intramolecular Heck coupling to furnish the spirocyclic carbon.
This served as the groundwork to produce an extensive table of colletoic acid derivatives
for inhibition studies.21

Scheme 2.3 Synthetic approaches to colletoic acid 2.4.
2.1.3 Lycopodium Alkaloids
Lycopodium alkaloids are a classification of structurally similar natural products
isolated from the species of club moss, Lycopodium. The first isolated Lycopodium
alkaloid, lycopodine 2.17, was discovered by Bödeker in 1881.22 This same alkaloid was
again isolated and structurally elucidated in 1938 by Achmatowicz and Uzieblo.23
Following these first reports, the interest in the lycopodium alkaloids significantly
increased. Throughout the past several decades, the isolation and elucidation of over 200
Lycopodium alkaloids have been reported. During the period of 1986-1990, a variety of
isolated Lycopodium alkaloids were discovered to possess potent acetylcholinesterase
8

inhibition activity. The most potent of these is huperazine A which was isolated from
Huperzia serrata.24
The structures of the Lycopodium alkaloids have the same basic skeleton of two
2-propylpiperidine units and are divided into four major classes: lycodine, lycopodine,
fawcettimine, and the miscellaneous group which are represented by lycodine,
lycopodine, fawcettimine, and phlegmarine, respectively (Figure 2.2).25 It is important to
recognize that among the over 200 Lycopodium alkaloids isolated, there are a plethora of
variations to these core structures and further detail into these variations are outlined in a
review by Gang, et al.26

Figure 2.2 Major lycopodium alkaloid classes.
2.1.4 Isolation of Magellanine and the Structure Elucidation
Magellanine, a member of the fawcettimine class, was first isolated from
Lycopodium magellanicum by Castillo and coworkers in 1976 and was fully elucidated
utilizing NMR, IR, MS, and UV-Vis techniques27. The molecular formula was
determined to be C17H25NO2 through combustion analysis and mass spectrometry. The IR
spectrum contained noteworthy signals at 3330, 3150-2400, and 1650 cm-1 which implied
the presence of both an alcohol and ketone functionality. It was further confirmed that the
ketone was α,β-unsaturated from the UV-Vis spectrum containing λmax at 237 nm.
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A 1H NMR spectrum (220 MHz) identified the presence of an N-methyl group as
a singlet integrating to three protons at 2.23 ppm and a vinylic methyl group integrating
for three protons at 1.94 ppm. Furthermore, a proton geminal to a secondary hydroxyl
group was located at 4.21 ppm with an integration of one proton. Decoupling
experiments successfully confirmed the presence of the vinylic methyl group to be
located on the β position of the α,β-unsaturated ketone. It was also determined via
decoupling that the secondary hydroxyl was located between a methine and methylene
unit.
The mass spectrum was then utlilized to identify fragmentation patterns of the
molecule. The daughter tree was compared to that of paniculatine and found to have
significant similarities. Of particular note is the nitrogen containing ions with m/z at 57,
58, 70, 71, 96, 97, 110, and 111 which were representative of the piperidine ring
fragmentations also found with paniculatine (Figure 2.3). Finally, X-Ray crystallography
was utilized to confirm spectroscopic observations and determine relative
stereochemistry.

Figure 2.3 Key daughter ions of magellanine and paniculatine.
2.1.5 Prior Total Syntheses of Magellanine
Following the isolation and structural elucidation of magellanine, a variety of
methods have been reported for the preparation of this Lycopodium alkaloid. The first
account of a successful total synthesis came from Overman and co-workers wherein a 2510

step sequence was implemented consisting of a key stereocontrolled tetracycle formation
via a Prins-Pinacol spirocyclization (Scheme 2.4).28

Scheme 2.4 Overman total synthesis.
Shortly after the first synthesis, Paquette and co-workers described the second
successful preparation of magellanine in seventeen steps. The utility of this report is
found in the construction of the tricyclic core via a tandem Michael addition diquinane
synthesis (Scheme 2.5).29

Scheme 2.5 Paquette total synthesis.
In the early 2000s two research groups utilized a Pauson-Khand reaction as a
method for installation of two cyclic portions in a single step. The first report by Ishizaki
in 2005 produced the tricyclic core from enyne 2.35 with a total step count of thirteen to
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develop magellanine (Scheme 2.6).30 Two years later, the Mukai group implemented
similar chemistry for the construction of the tetracyclic precursor 2.38.31

Scheme 2.6 Ishizaki and Mukai total syntheses.
The prevalent feature of all prior examples is the construction of the piperidine
ring (ring D) in a late-stage synthetic strategy. With the intention of developing a concise
preparation of magellanine-type alkaloids, Sarpong and co-workers implanted a synthesis
which incorporates the D ring as a dimethoxypiperidine. The power of this design resides
in the palladium catalyzed pyridine C-H functionalization for the completion of the
tetracyclic core (Scheme 2.7).32 A similar construction strategy was implemented by the
Yang group wherein the D ring was delivered from readily available arecoline and a sight
selective aldol condensation was performed as the key tetracycle-forming step.33
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Scheme 2.7 Sarpong and Yang total syntheses.
2.2 Research Hypothesis
It is hypothesized that a Tsuji-Trost variant of the Winstein-Masamune
dearomatization can be implemented as an approach to the synthesis of the stereogenic
quaternary carbon present within Lycopodium alkaloids. Furthermore, the development
of a terminal alkene from this process can supply a functional handle for construction of
the tricyclic core.
2.3 Research Design and Methods
2.3.1 New Methodology Proposed by Our Research
With previous attempts at the synthesis of magellanine, we sought to design a
novel method toward the preparation of the tricyclic core contained within the
Lycopodium alkaloids. Shown in Scheme 2.8 is the retrosynthetic analysis of the key
steps to our proposed methodology. It was envisioned that the core could be prepared via
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free radical cyclization of halohydrin 2.45 which could be prepared via reaction of
spirocycle 2.46 and a halogen electrophile. Synthesis of 2.46 to develop the stereogenic
quaternary carbon would be achieved via a Tsuji-Trost variant of the WinsteinMasamune phenolic allylation of para-substituted phenol 2.47. Preparation of 2.47 could
be achieved from the alkylation of malonate 2.48 with prepared bis-electrophile 2.49.

Scheme 2.8 Retrosynthetic analysis of the tricyclic core.
2.3.2 Winstein-Masamune Phenolic Dearomatization
The first of two key steps in the forward synthesis of our method is the TsujiTrost variant of the Winstein-Masamune phenolic allylation. Therefore, it is pertinent to
briefly discuss the original work by Winstein and the proceeding extension of the
conditions by Masamune (Scheme 2.9). In the first attempt by Winstein, a parasubstituted phenol 2.50 was reacted with potassium tert-butoxide in tert-butanol to afford
spiro[4.5]decane 2.51. This concept was further extended by Masamune when tricyclic
structure 2.53 was successfully prepared from tetrahydronapthalene 2.52. This reaction
presents several chemical aspects that prove the power of this transformation. First, there
is a unique observation that the aromatic portion of the molecule is being treated as a
vinylogous enolate. Second, this vinylogous enolate reactivity treats the para position as
14

the nucleophilic component for an intramolecular SNAr- displacement reaction. The third
and most significant aspect is the loss of aromaticity to produce a sterically congested
quaternary carbon. Accompanying these strengths is one notable limitation that the
displacement reaction is performed on a sp3 hybridized carbon which prevents
proceeding functionalization at that location.

Scheme 2.9 Winstein-Masamune phenolic dearomatization.
2.3.3 Tsuji-Trost Variant for Phenolic Dearomatization
To address this shortcoming, a Tsuji-Trost variant can be implemented. Seminal
work by Tsuji showed the ability to substitute π-allylpalladium chloride with
nucleophiles such as enamines, diethyl malonate, and ethyl acetoacetate.34 With this
discovery, Trost and co-workers were able to demonstrate alkylation of π-allylpalladium
complexes with soft nucleophiles (Scheme 2.10).35

Scheme 2.10 Tsuji-Trost allylation.
The power of this discovery portrays the ability to now perform nucleophilic addition to
allylic positions. Therefore, it was postulated that developing a hybrid of both reactions
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could provide a remedy for the shortcoming previously discussed in para-phenolic
alkylations.
Recently, two independent publications by the Hamada36 and You37 groups
utilizing palladium (2.57→2.59) and iridium catalysis (2.58→2.60) have effected a TsujiTrost 5-exo-trig allylation variant of the classic Winstein-Masamune reaction. The use of
phenol nucleophiles as vinylogous enolates in the intramolecular Tsuji-Trost allylation
had been relatively unexplored over the past half century. Therefore, a Tsuji-Trost
Winstein-Masamune (TTWM) phenolic allylation would be an ideal solution for the
syntheses of molecules such as 2.59-2.60 (Scheme 2.11) as a vinyl group is deposited at
the electrophilic carbon for post-cyclization modifications.

Scheme 2.11 Hamada and You variant of the Tsuji-Trost allylation.
Shown in Scheme 2.12 is the proposed catalytic cycle for the development of
spiro[4.5]decanes. The proposed mechanism is based on that of known mechanism for
the Tsuji-Trost reaction and begins with the formation of the pi-allyl complex 2.61
resulting in the loss of carbon dioxide and methoxide ion. Methoxide then re-enters the
cycle and deprotonates phenol 2.62. With the palladium complex forming a Zimmerman
Traxler chair-like transition state (2.63), the para-carbon of the phenoxide attacks at the
electrophilic center and produces the desired spirocycle 2.46.
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Scheme 2.12 Catalytic cycle for Pd(0) mediated phenolic allylation.
2.4 Results and Discussion
2.4.1 Preparation of the Spirocyclic Precursor
Outlined in Scheme 2.13 is the synthesis of the spirocyclic precursor. All
synthetic steps preceding the spirocyclization of 2.47 to 2.46 have been successfully
performed with minimal optimization or troubleshooting required. Briefly, Knoevenagel
condensation of 4-hydroxybenzaldehyde 2.65 with dimethylmalonate was carried out in
toluene in the presence of piperidine and catalytic acetic acid at reflux to afford
benzylidene malonate 2.66 in 99% yield. Subsequent hydrogenation of the olefin with
hydrogen gas in the presence of 10% palladium on carbon in methanol smoothly afforded
reduced malonate 2.48 in 97% yield. The phenol was protected as the tertbutyldimethylsilyl ether with TBSCl, imidazole and catalytic DMAP in DMF giving silyl
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ether 2.67 in 95% yield. At this stage the allylic carbonate was installed via alkylation of
the sodium enolate with the bis-electrophile 2.49. The silyl protecting group of 2.68 was
quantitatively cleaved with TBAF in THF at ambient temperature giving the desired
phenol 2.47 in 96% yield. Preparation of the TTWM precursor was achieved in five steps
with an overall yield of 86%.

Scheme 2.13 Synthesis of the spirocyclic precursor 2.47 and bis-electrophile 2.49.
2.4.2 Synthesis of the Spiro[4.5]decane
With gram quantities 2.47 in hand, the main focus of this research began with
screening of conditions for optimal spirocyclization using a Pd(0) catalyst. Initial
conditions for spirocyclization utilized a Pd(0) catalyst with triphenylphosphine as a
ligand. Dichloromethane proved to be an effective solvent and was utilized for most
attempts during the initial reaction screening. Although the spirocyclization successfully
18

showed progression to the expected product, the low conversion prompted further
examination of conditions. Due to difficulty in separation of starting material and
product, it was necessary for full conversion.
In addition to palladium, we also examined iridium (I) and (II) catalysts. These
catalysts were less effective and were therefore not considered in further investigations.
Consequently, screening of available palladium (0) complexes was implemented to
identify the catalyst that yielded the quickest and highest conversion (Table 2.1). All
reactions were performed for six hours at room temperature on a 50 mg scale in order to
maintain standard conditions and ensure accurate percent conversions were observed by
crude NMR. The conversions observed from the six hour period could then be
extrapolated in order to estimate a necessary reaction time to achieve full conversion.
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Table 2.1
Catalyst screening for spirocyclization

Entry
1
2
3
4
5
6
7
8
9
a

Catalyst
Pd2(dba)3
Pd2(dba)3•CHCl3
Pd(PPh3)4
Pd2(dba)3
Pd2(dba)3•CHCl3
Pd(PPh3)4
Pd2(dba)3
Pd2(dba)3
Pd2(dba)3

Vendor/Lot
Strem/30047
Aldrich/30036
Aldrich/30026
Strem/40101
Aldrich/30058
Aldrich/30046
Aldrich/30031
Aldrich/40101
Aldrich/40101

Solvent
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
MeCN
CHCl3

Ligand
PPh3
PPh3
PPh3
PPh3
PPh3
PPh3
PPh3
PPh3
PPh3

Temp.
ambient
ambient
ambient
ambient
ambient
ambient
ambient
ambient
ambient

%Conv.a
37%
19%
9%
42%
29%
13%
39%
38%
28%

Note: All entries were reacted for six hours prior to filtration and NMR analysis. Crude NMR analysis was utilized to determine

percent conversion via comparison of starting material peak at 4.65 ppm (1H) and product peak at 5.00 ppm (1H).

The percent conversion of the spirocyclization was measured via NMR, HPLC,
and GC with NMR proving to be the preferred method. Other techniques proved either
less accurate or more time consuming than NMR. HPLC analysis indicated that the
product and starting material exhibited different extinction coefficients at different
wavelengths which resulted in inaccurate comparisons. A GC method for identification of
the product peak was difficult to determine and was considered time consuming. NMR
showed to have both the needed accuracy via signal integration and resulted in the quick
acquisition time making it the preferred technique. 1H NMR was utilized for
determination of the percent conversion by choosing peaks associated with the starting
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material (4.65 ppm, allylic CH2) and the product (5.00 ppm, vinyl CH2) that both
integrated for two protons.
Through these experiments, Pd2(dba)3 was the most effective catalyst and was
therefore used in a solvent screen to determine the best reaction media for the
spirocyclization. The solvents examined included: dichloromethane, chloroform, 1,2dichloroethane, THF, acetonitrile, toluene, and 1,4-dioxane. By selecting these solvents, a
wide range of polarity and dielectric constants were explored. Dichloromethane was
identified as the most suitable solvent and was therefore implemented in all proceeding
experiments.
With the catalyst chosen and suitable solvent identified, a reaction was performed
at an increased scale of 200 mg and was stirred at ambient temperature for twenty four
hours. It was believed that with a 42% conversion at six hours, twelve hours would be
sufficient to approach 100% conversion. A conversion of 55% was observed, so the
reaction was allowed to continue for the full twenty four hours. No further conversion
occurred after twenty four hours so the reaction was stopped. It was likely that the
palladium was being inactivated with residual oxygen in the solvent and reaction flask,
preventing continuation of the catalytic cycle.
With this conclusion, it was pertinent to identify another method that may allow
for shorter reaction times to minimize the effect that residual oxygen may have on the
reaction. Therefore, the reaction was irradiated via microwave conditions with the
Biotage® Initiator+ microwave reactor. Within five minutes at 80°C, TLC analysis
showed complete consumption of starting material with a product spot appearing at the
same location as previously seen with the reactions performed at ambient temperature.
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NMR analysis revealed that the product was neither starting material nor the desired
product. Two-dimensional NMR techniques and LRMS were implemented to provide
insight into the structure of the unknown product. It was determined via NMR that the
carbonate functionality had been lost due to absence of the proton signal at 54.9 ppm
associated with the methyl protons and absence of the carbon signal at 155.9 ppm
associated with the sp2-hybridized carbonyl carbon (Figure 2.4).

Figure 2.4 NMR evidence for loss of carbonate functionality in intermediate 2.47.
It was postulated that a Claisen-type [3,3]-sigmatropic rearrangement catalyzed
by the heat of the reaction (Scheme 2.14). Following this rearrangement, the palladium
catalyst would then insert between the new C-O bond resulting in the expected
elimination of the carbonate as carbon dioxide and methoxide. A subsequent β-hydride
elimination then occurs to form diene 2.74.
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Scheme 2.14 Mechanistic hypothesis for formation of diene 2.74.
Both 1-dimensional and 2-dimensional NMR techniques were utilized to elucidate
the structure of 2.74. Proton NMR provided evidence of the presence of five alkene
protons located at 6.35 ppm, 6.15 ppm, 6.04 ppm, 5.24 ppm, and 5.15 ppm. The presence
of the terminal alkene was confirmed from the signals at 5.24 and 5.15 ppm (H10) via
HSQC which proved both signals were coupled with the same carbon. Further
confirmation was found in the coupling constants with a cis-coupling of 16.8 Hz and
trans-coupling of 10.1 Hz for the proton at 5.24 and 5.15 ppm, respectively. The
assignment of C8 and C9 required the use of HMBC which showed long range coupling
of H8 with C6 while H9 did not express this coupling. Therefore, it was concluded that
the connection sequence was C10-C9-C8. This conclusion has been further supported by
mathematical calculation through Spartan prediction software utilizing the Hartree-Fock
3-21G method which indicates complimentary splitting patterns and peak shifts.
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Figure 2.5 HMBC correlation confirming connectivity of diene 2.74.
Based on the development of the undesired diene, the microwave conditions were
altered. The reaction was heated to 40°C to prevent the thermally initiated Claisen
rearrangement. After 20 minutes of microwave radiation, complete cyclization occurred.
Having established appropriate conditions, the reaction scale was increased to 500 mg to
confirm reproducibility. Larger scale batches required extended reaction times of 40
minutes and contained minor amounts of diene 2.47 after purification.
Despite using sufficiently degassed solvent, the efficiency of the microwave
reaction with Pd2(dba)3 was diminishing with every new reaction. Over a twenty minute
period in the reactor, the color of the solution was changing from an orange yellow color
to a deep amber or green yellow. Eventually, no changes were observed via TLC and
crude NMR showed no loss of starting material or the formation of the spirocycle
intermediate. To address the issue with diminishing efficiency of the palladium catalyzed
spirocyclization, new procedures were implemented. To ensure that the Pd (0) catalyst
was not quenched, the reaction vial was loaded with triphenylphosphine and the catalyst
then immediately sealed. The vial was then evacuated via syringe through the septum and
charged with dry nitrogen. Phenol 2.47 was prepared in a separate recovery flask that was
also evacuated and charged with dry nitrogen. Dichloromethane was degassed for twenty
minutes with dry nitrogen and 2.47 was then dissolved in the solvent and transferred to
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the reaction vial via syringe. The vial was then heated at 40°C for 40 minutes in the
Biotage® Initiator+ microwave reactor.
This new procedure proved to be successful in achieving 100% conversion of
starting material. Of note is the color difference of the crude solution with a successful
reaction against the color of a crude solution of a reaction with poor conversion. When
100% conversion is achieved, the solution appears to be a golden yellow color while
unsuccessful reactions appear purple-dark amber colored. In response to this success, all
bottles containing Pd2(dba)3 were tested with this new procedure and all catalyst batches
achieved full conversion of starting material. The next issue to be addressed is the percent
recovery of product. At best, a 50% recovery has been achieved on a 50 mg scale (40%
was also achieved with a 250 mg scale). Table 2.2 outlines all conditions attempted with
the microwave reactor.
Table 2.2
Microwave reactor conditions for spirocyclization
Entry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Catalyst
Pd2(dba)3
Pd2(dba)3
Pd2(dba)3
[Ir(cod)Cl]2
[Ir(cod)Cl]2
[Ir(cod)Cl]2
[Ir(cod)Cl]2
[Ir(cod)Cl]2
Pd2(dba)3
Pd2(dba)3
Pd2(dba)3
Pd2(dba)3
Pd2(dba)3
Pd2(dba)3
Pd2(dba)3
Pd2(dba)3

Vendor/Lot
Strem/40101
Strem/40101
Strem/40101
Aldrich/30068
Aldrich/30068
Aldrich/30068
Aldrich/30069
Aldrich/30069
Strem/40101
Aldrich/30031
Aldrich/30047
Strem/40101
Strem/40101
Strem/40101
Strem/40101
Strem/40101

Scalea
100 mg
75 mg
1.5 g
50 mg
50 mg
50 mg
50 mg
50 mg
50 mg
50 mg
50 mg
250 mg
500 mg
500 mg
500 mg
1.0 g
25

Time (min)
5
20
20
10
10
10
150
90
40
40
40
40
40
40
40
40

Temp.
80ºC
40ºC
40ºC
50ºC
60ºC
70ºC
120ºC
70ºC
40ºC
40ºC
40ºC
40ºC
40ºC
40ºC
40ºC
40ºC

%Yieldb
24%
n/a
28%
n/r
n/r
n/r
n/a
n/r
60%
98%c
60%c
40%
40%
40%
5%
20%

Table 2.2 (continued)
17
18
19
20

Pd2(dba)3
Pd2(dba)3
Pd2(dba)3
Pd2(dba)3

Aldrich/30047
Aldrich/30047
Aldrich/30047
Aldrich/30047

250 mg
250 mg
250 mg
660 mg

40
40
40
40

40ºC
40ºC
40ºC
40ºC

11%
36%
39%
25%

Note: aScale based on milligrams of phenol 2.47 added. bIsolated via purification on a silica column eluted with hexanes-ethyl acetate
solvent gradient. cContains diene byproduct.

An issue with product isolation was being observed in the spirocyclization
reaction at 50, 250, and 500 mg scales resulting in complete conversion but an isolated
yield of 40% or less. Several methods to probe for the disappearance of the remaining
60% of material were conducted. First, all material was flushed through the Cellite® plug
that acted as the palladium filter. This was done by first flushing as normally performed
using dichloromethane. This filtrate was then collected and a separate flush using ethyl
acetate was collected in a separate flask. Both filtrates were checked for presence of
product and only the dichloromethane flush contained product. It was postulated that the
spirocycle was binding to the Cellite® so this step of the workup was removed. Removal
of this step and subsequent addition of a saturated ammonium chloride quench and water
extraction again afforded only a 40% yield. A complete list of attempted conditions for
improved recovery of product is described in Table 2.3.
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Table 2.3
Spirocyclizations with alternative Pd (0) catalysts and conditions

27
a

Entry
1

Catalyst
Pd(PPh3)4

Vendor/Lot
Strem/40101

Scale
274 mg

2

Pd(PPh3)4

Strem/40101

200 mg

3

Pd(PPh3)4

Oakwood

170 mg

4
5

Pd(PPh3)4
Oakwood
Pd2(dba)3•CHCl3 Aldrich/30036

531 mg
282 mg

6

Pd2(dba)3•CHCl3 Aldrich/30036

168 mg

7

Pd2(dba)3•CHCl3 Aldrich/30036

210 mg

8c

Pd2(dba)3•CHCl3 Aldrich/30036

221 mg

9

Pd(dba)2

Aldrich/30051

265 mg

10

Pd(dba)2

Aldrich/30051

241 mg

11

Pd(dba)2

Aldrich/30051

522 mg

Conditions
µw; 40 min;
40ºC
µw; 40 min;
40ºC
µw; 40 min;
40ºC
2.5 hr; 50ºC
µw; 40 min;
40ºC
12 hr;
ambient
µw; 40 min;
40ºC
µw; 40 min;
40ºC
16 hr;
ambient
45 min;
ambient
24 hr;
ambient

Workup
hexane precipitation

%Recovery
50%a

n/a

48%a

Et2O precipitation

50%a

n/a
Celite filtration

n/a
29%

Celite filtration

46%b

Celite filtration

n/a

Celite filtration

n/ad

Celite filtration

20%

Celite filtration

40%

Celite filtration

27%

Contains reagent impurities. bReported as percent conversion: calculated via qNMR with DMF as an internal standard. cReacted in 1,4-dioxane. dContains presence of diene byproduct as

impurity.

A qNMR study was implemented to determine what the percent composition of
the spirocycle was in the crude mixture. To perform this, a sample containing a known
amount of crude residue was dissolved in 600 µL of CDCl3 and 10 µL of DMF was
added to the solution. The singlet at 8.1 ppm associated with DMF was compared to the
terminal alkene signal of the spirocycle located at 5.0 ppm.
With no success in yield improvements with workup procedures and the
observation that increasing reaction scales resulted in diminished yields, several reactions
were prepared at once and combined in bulk for purification. Implementing this batch
approach resulted in a significant decrease of the isolated yields and implied that product
loss may be occurring at the purification stage. Therefore, all collected fractions were
concentrated and the contents were analyzed via NMR. A total of three separate fractions
were collected during the purification of one of the 500 mg reactions. The first fraction
contained triphenylphosphine (55 mg), the second contained product (150 mg) and the
third fraction, obtained via 10% methanol in dichloromethane flush, contained residual
Pd2(dba)3 and coordinated triphenylphosphine ligand.
Knowing this, alternative purification methods were utilized. First, EDTA was
used as an agent for binding and removing all residual palladium from the crude mixture.
If successful, it would have been possible to run a shorter silica plug rather than a full
column length (10-11 cm height). Reduced contact with the silica could have resulted in
less product loss and higher recoveries. It was also reasoned that treating the silica gel
with 1% triethylamine may prevent product loss on the column.
Performing these alternative purification methods did not result in improved
purification. Scavenging for residual palladium still resulted in a 40% yield while base
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treating silica with trimethylamine caused complete degradation of material on the
column. Therefore, a final attempt at completely avoiding purification via
recrystallization attempts included precipitation of the crude material into either hexanes
or cold diethyl ether. Both systems resulted in a white, tacky precipitate while keeping
the spirocycle product in solution. The yields were not further improved via these
precipitation methods and residual triphenylphosphine still remained following NMR
analysis.
Despite the issue of isolation, enough product was produced to perform a
complete structural elucidation. This was achieved with the aid of 2D NMR techniques.
COSY was used to identify the cyclohexenone (Hc-Hf, Hd-Hg) and cyclopentane (HhHe-Hj-Hn) spin systems (Figure 4). The diastereotopic protons of the cyclopentane ring
(Hm and Hn) were identified via COSY coupling and confirmed via HSQC and the
geminal coupling constants (1J = 14.7, 14.0). To determine the stereochemistry at Cj,
NOESY was utilized. Correlation of Hj with Hc confirmed Hj to be located on the bottom
face of the cyclopentane (Table 2.4).
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Table 2.4
Structural elucidation of spirocycle 2.46

Position
a
b
b’
c
d
e
f
g
h

δC
185.9
172.4
172.1
153.0
148.9
133.8
130.1
129.3
117.8

i
j
k
k’
l
m

58.5
53.5
53.3
53.2
52.1
43.6

n

38.6

δH
6.73
6.85
5.41
6.29
6.27
h1: 5.01
h2: 4.99
2.84
3.80
3.79
m1: 2.68
m2: 2.45
n1: 2.67
n2: 2.56

COSY
d,f
c,g
h1, h2, j
d,f
c,g
e
e
e, n1, n2
m2
m1
j, n2
j, n1

HMBC (H to C)
a, d, l, m
a, d, l, m
l, n
g, l
f, l
e, j
e, j
c, d, e, h, l, m, n
b, b'
b, b'
b, b', c, d, i, j, k, k', n
b, b', c, d, i, j, k, k', n
b, b', e, i, j, k, k', m
b, b', e, i, j, k, k', m

NOESY
f, j, n1
g, n2
h
c
d
e
e
c, n1, n2
n1
c, j
d, j

Additional evidence supporting the structure of the spirocycle can be found in the
1

H NMR splitting tree (Figure 2.6). Specifically looking at the coupling of Hg with Hi it

was realized that one of the two proton signals was not contributing to the splitting
pattern located at 2.6 ppm. Further investigation of the structure via 3-dimensional
modeling revealed that a dihedral angle of 90º existed between Hg and Hi. According to
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the Karplus equation, a 90º dihedral angle prevents coupling between the associated
protons which explains the observed splitting pattern.

Figure 2.6 1H analysis of spirocycle 2.46.
2.4.3 Formation of the Tricyclic Core
With the obtained product, several reactions were attempted towards the synthesis
of the tricyclic core of Magellanine. It was envisioned that formic acid may be able to
perform this cyclization in one step. Protonation of 2.46 at the unsaturated ketone would
activate position d on the cyclohexenone ring (Table 2.5). The resulting formate ion
would then attack the internal carbon (position e) of the alkene, pushing electon density
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to the terminal carbon (position h). This would then incur an intramolecular nucleophilic
attack on the electrophilic carbon of the cyclohexenone ring. All attempted reaction
conditions for this process are outlined in Table 2.5.
Table 2.5
Attempted acid promoted intramolecular polyolefin cyclization

Entry
1
2
3
4
5

Reagent
none
sodium formate
sodium formate
sodium formate
sodium formate

Solvent
THF
formic acid
formic acid
formic acid
formic acid

Temp.
ambient
ambient
78ºC
100ºCa
100ºCa

Time
24 hr
24 hr
24 hr
20 min
40 min

Note: a Reactions performed in a microwave reactor.

Another process was a two-step method which first involves a stereoselective
halohydrin or selenyhydrin formation. Next, via free radical chemistry, the cyclization
will occur. A summary of conditions for the selenylhydrin formation is provided in Table
2.6.
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Table 2.6
Conditions for selenylhydrin formation

Entry
1
2
3
4
5
6
7

Equivalents
1.0
1.0
1.0
2.0
1.5
2.0
1.5

Solvent
THF/H2O
THF/H2O
THF/H2O
MeCN/H2O
MeCN/H2O
MeCN/H2O
MeCN/H2O

Temp.
ambient
95ºCa
50ºC
ambient
ambient
ambient
ambient

Time
24 hr
11 min
24 hr
24 hr
4 hr
6 hr
10.5 hr

%Yield
50%
0%
n/ab
62%
87%
42%
35%

Note: a Reaction performed in a microwave reactor. b crude material was used immediately in proceeding reactions without
purification

Success was observed in the selenylhydrin formation which resulted in focus
diverting from the halohydrin conditions and optimizing the work with phenyl selenyl
chloride. NMR analysis showed key changes with the upfield shift of the terminal alkene
sp2 proton signals of x located at 5.4 ppm to 3.2 ppm and the sp2 carbon signal at 117.7 to
the sp3 hybridized carbon signal at 35.7 ppm. Both diastereomer products were produced,
resulting from the chiral center formed at the secondary alcohol. Although the
diastereomers were separable by chromatography, little effort was made to do this
because later oxidation of the alcohol to the ketone will remove the stereochemistry and
an enantioselective reduction can then be performed to afford only the desired
stereoisomer. To provide further proof that only diastereomers were formed, the products
were separated via chromatography and analyzed via HRMS.
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With selenylhydrin 2.45a in hand, focus turned to the final step in the synthesis of
the tricyclic core using free radical chemistry. Both thermal and light induced conditions
were examined with the initial experiments utilizing tributyltin hydride and AIBN as the
initiator (Scheme 2.15).

Scheme 2.15 Proposed free radical cyclization of 2.45a with tributyltin hydride and
AIBN.
With no success in production of the tricycle via free radical initiated chemistry of
the selenylhydrin, efforts returned to the implementation of halohydrins for the free
radical chemistry. Starting with NBS, the reaction was performed according to the
conditions in Table 2.7.
Table 2.7
Conditions for halohydrin formation

Entry
1
2
3
4
5
6
7

Reagent
NBS
NBS
NBS
NBS
NBS
NIS
NIS

Equivalents
1.0
2.0
2.0
1.5
2.0
3.0
3.0

Solvent
THF
Acetone/H2O
MeCN/H2O
THF/H2O
MeCN/H2O
MeCN/H2O
MeCN/H2O
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Temp.
ambient
0ºC-ambient
0ºC-ambient
0ºC-ambient
0ºC-ambient
0ºC-ambient
0ºC-ambient

Time
23 hr
22 hr
22 hr
25 hr
22 hr
22 hr
22 hr

%Yielda
19%
50%b
50%b
14%
55%
56%
32%

Table 2.7 (continued)
8
9

NIS
NIS

3.0
3.0

MeCN/H2O
MeCN/H2O

0ºC-ambient
0ºC-ambient

18 hr
1.5 hr

n/ac
n/ac

Note: a All reported yields contain a mixture of diastereomers. b Entries were combined and purified as a single sample. c The crude
residue was utilized in the proceeding reactions without purification

With the bromohydrin in hand, an attempt at the tricycle formation via free radical
conditions was performed. The initial conditions utilized thermally initiated
azaisobutyronitrile and tributyltin hydride. Although complete conversion to product
occurred within 45 minutes, NMR analysis implied the desired tricyclic structure was not
produced. Upon complete analysis via 1D and 2D NMR, ESI-MS, and IR, it was
determined that re-aromatization of the cyclohexadienone and subsequent formation of a
trans-alkene afforded 2.76 (Figure 2.7).

Figure 2.7 2-D NMR correlations for allylic alcohol 2.76.
During the reaction screening using tin hydride reagents, we observed smooth
conversion of the starting material to a more polar spot by TLC (Rf = 0.30 (1:1 hexanesacetone) but examination of the 1H NMR revealed a different structure containing an
internal alkene functionality (implied from 1H NMR signals at 5.74 and 5.62 ppm). The
byproduct was fully elucidated with 2D NMR and was determined to be a rearomatized
phenol containing an allylic alcohol. COSY was used to identify the spin systems in the
structure located at the alkene (Hl → Hf → Hc → Hh) and the phenol (Hg → Hd). HSQC
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and HMBC confirmed the connectivity of the phenol. The trans conformation of the
conjugated diene was established based on the coupling constants (3Jc,f = 15.7 Hz).
Additionally, 13C chemical shifts supported the presence of the phenol (155 ppm) and
primary alcohol (63 ppm).
It was postulated that attack of the tin radical to the ketone oxygen results in
rearomatization of the molecule. Subsequently, the spirocycle is ring opened and
ultimately the hydroxyl group was transferred to the primary location and a trans alkene
was formed. With this understood, free radical conditions free of the tin radical were
necessary. Therefore, triethylborane was implemented to perform the radical chemistry.
This resulted in product that showed no presence of rearomatization and loss of the
iodohydrin proton signals. The resultant product was fully characterized via NMR
techniques to reveal the presence of a tricyclic core.

Figure 2.8 Possible product structure from triethylborane conditions.
The spin systems were confirmed via COSY which showed the presence of four
unique systems: (1) n→k→p→g, (2) f→o, (3) e→d→f, and (4) m. The long range
coupling of d→f can be explained by the w coupling as denoted in Figure 2.8. One
distinction with the COSY spectrum is the lack of correlation with g→f which, upon
observation, should show a coupling interaction.
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Further analysis via HSQC and HMBC provided the necessary evidence to label
all carbons appropriately and to identify long range C-H interactions. The HMBC is
particularly crucial in confirming the appropriate connectivity. Specifically, 2J correlation
with Hg→Cf confirms the connectivity where COSY had implied separated systems.
Furthermore, no correlations to Ce, though Ho→Ce would be expected and Hk and Hl
show all expected correlations confirming the location of those signals at centralized
positions in the system.
The main issues remaining to be resolved include signal p which has a H signal at
4.2 ppm but a C signal at 21 ppm which implies presence of an electronegative group for
the proton spectrum but no such chemical environment for the carbon. Also, several of
the proton signals are shifted further downfield than would be expected and no
explanation has been identified for this phenomena. Ultimately, it was clear this reaction
would not produce the desired product and therefore was no further analysis was
performed for the structure’s elucidation.
Independent reports from the Beckwith and Clive groups have demonstrated the
utility of tri-n-butylgermanium hydride to selectively generate carbon radicals from alkyl
iodides in the presence of cyclohexadienones.38 We were pleased that treatment of iodide
2.45c with tri-n-butylgermanium hydride and AIBN in refluxing toluene furnished the
desired tricyclic compound in 43% yield.
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Scheme 2.16 Comparison of tin and germanium hydride products
Given the geometrical constraints of this system, the primary carbon radical is
forced to add to the electron deficient -carbon of the proximal alkene of the
spiro[4.5]cyclohexadienone from the bottom face. This addition forces cis ring fusion in
the bicyclo[4.3.0]nonane, whereas addition from the top face would give a strained trans
ring junction. The ensuing stabilized radical is then quenched by nBu3GeH and
concomitantly sets the correct desired trans relationship between Hf and Hk. Based on the
stereochemistry of the spirocycle 2.46, the stereochemistry of Hk (pointing down) is
conserved. It should be noted that the radical addition to the distal olefin would result in
an energetically disfavored trans ring junction about the bicycle[3.3.0]octane
substructure.

Scheme 2.17 Stereochemical outcome during tricycle formation
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The structure of 2.44 was fully elucidated using extensive 1D and 2D NMR
experiments. 1H NMR gave initial indication of successful conversion based on the loss
of the proton signal associated with cyclohexenone protons at 6.30 ppm. A total loss of
two protons was observed from that region implying successful addition to that location.
In addition, COSY correlations were able to identify two isolated spin systems located at
the α,β-unsaturation (He→Hd) and tracing around the tricyclic system
(Hg→Hf→Hn→Hh→Hk→Ho) (Figure 2.9). Support for the stereochemistry at position f
was found through “W” coupling of Hf with Hd which would only be possible with Hf in
the cis conformation.

Figure 2.9 COSY correlations for tricycle 2.44.
Note: Structure of the major diastereomer is shown.

2.5 Future Work
With a proof of concept established utilizing the Tsuji-Trost variant of the
Winstein-Masamune phenolic allylation, a total synthesis of magellanine is proposed
(Scheme 2.18). In this proposal, the D ring is present from the outset via use of
isonicotinic acid. As designed, the A ring can be installed and the precursor to the
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spirocyclization reaction can be constructed within six steps with a total of eight steps to
afford the tetracyclic core.

Scheme 2.18 Proposed synthetic route to magellanine.
2.6 Summary and Conclusion
This chapter presented a methodology study for the development of palladium
catalyzed phenolic allylation. The resultant spiro[4.5]decane was then applied as the
synthetic precursor for the synthesis of the tricyclic core present within natural products
of the Lycopodium alkaloid family. At both key stages, intermediates were fully
characterized via spectroscopic methods and structure, connectivity, and threedimensional orientation were confirmed. Through the described method, a new route to
the production of spirocyclic terpenes and magellanine-type alkaloids has been presented.
This report provides the foundation for an alternative route to the development of desired
biologically active natural products.
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2.7 Experimental
2.7.1 General Methods
2.7.1.1 Experimental Techniques
Unless otherwise noted, all reactions were carried out using flame-dried glassware
and standard syringe, cannula, and septa techniques, when necessary. Tetrahydrofuran
(THF), diethyl ether (Et2O), hexanes, dichloromethane (CH2Cl2), and toluene (PhCH3)
were dried by passage through a column of activated alumina on an mBraun SPS.
Triethylamine (Et3N), N,N-dimethylformamide (DMF), and acetonitrile (MeCN) were
dried by passage through a column of activated alumina on an Innovative Technologies
system. Trimethylsilyl chloride and Hunig’s base were distilled from calcium hydride
under argon. Pyridine was distilled from potassium hydroxide under nitrogen. Analytical
thin layer chromatography was performed using Sorbent Technologies 250 m glassbacked UV254 silica gel plates. The plates were first visualized by fluorescence upon 254
nm irradiation then by iodine chamber. The plates were then dipped in one of the
following stains followed by heating: p-anisaldehyde, phosphomolybdic acid, vanillin,
ceric ammonium molybdate, potassium iodoplatinate, ninhydrin or bromocresol green.
Flash column chromatography was performed using Sorbent Technologies 40-63 μm,
pore size 60 Å silica gel with solvent systems indicated. Solvent removal was effected
using a Buchi R3 rotary evaporator with a V900 diaphragm pump (~ 10 mmHg). All
yields refer to isolated material that is chromatographically (TLC or HPLC) and
spectroscopically (1H NMR) homogenous.
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2.7.1.2 Characterization
All melting points were taken with a Thomas Hoover melting point apparatus and
are uncorrected. Infrared spectra were recorded on a Nicolet Nexus 470 FTIR
spectrometer as neat liquids, oils, solids or as thin films formed from evaporation of
NMR solvent over the ATR plate. HPLC were recorded on an Agilent 1260 Infinity using
a Poroshell 120 EC-C18 (3.0 x 50 mm, 2.7 micron) column with a binary gradient of
0.1%TFA in H2O (A) and 0.1%TFA in CH3CN (B): [0 min: A (95%), B (5%); 7 min: A
(5%), B (95%); 8 min: A (5%), B (95%)] monitoring 214, 254, and 280 nm. Lowresolution mass spectra were recorded on a ThermoFinnigan LXQ ESI-LCMS by use of
chemical ionization (CI). High-resolution mass spectra were recorded either at the Old
Dominion University College of Science Major Instrumentation Center (COSMIC) on a
Bruker 12 Tesla APEX-Qe FTICR-MS with an Apollo II ion source or The Ohio State
University Campus Chemical Instrumentation Center (CCIC). Combustion analysis was
performed at Atlanitic Microlabs on samples taken from the bulk of the material.
2.7.1.3 NMR Parameters
Proton nuclear magnetic resonance spectra were recorded on a Bruker UltraShield
Plus 400 MHz spectrometer and are recorded in parts per million from internal
chloroform (7.26 ppm), benzene, or dimethylsulfoxide on the  scale and are reported as
follows: chemical shift [multiplicity (s=singlet, d=doublet, t=triplet, q=quartet,
qu=quintet, m=multiplet), coupling constant(s) in hertz, integration, interpretation]. 13C
NMR data were recorded on a Bruker UltraShield Plus 400 MHz spectrometer and are
reported as follows: chemical shift (multiplicity as determined from DEPT (CH, CH3 up
and CH2 down) and/or HSQC experiments.
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2.7.2 Synthesis of Intermediates
dimethyl 2-(4-hydroxybenzyl)malonate (2.48): To a degassed solution of
dimethyl 2-(4-hydroxybenzylidene)malonate (5.0 g, 21.2 mmol, 1.0 equiv)
dissolved in methanol (60 mL) was added palladium, on 10% carbon (100.0
mg, 0.8 mmol, 0.04 equiv). Hydrogen gas was bubbled through the solution until
reaction completion was observed via TLC. The suspension was filtered through a
Büchner funnel filled with Cellite® and rinsed with methanol (four 50-mL portions). The
yellow filtrate was collected and concentrated in vacuo to yield 4.9 g of reduced malonate
2.48 as a brown-yellow oil (97% yield). No further purification was performed. 1H NMR
(CDCl3, 400 MHz) δ: 7.03 (dd, J = 8.4 Hz, 2H), 6.73 (dd, J = 8.4 Hz, 2H), 3.70 (s, 6H),
3.64 (t, J = 7.9 Hz, 2H), 3.14 (d, J = 7.8 Hz, 1H).
dimethyl 2-(4-((tert-butyldimethylsilyl)oxy)benzyl)malonate (2.67): To a
solution of dimethyl 2-(4-hydroxybenzyl)malonate (9.8 g, 41.1 mmol, 1.0
equiv.) dissolved in dimethylformamide (100 mL) was added tertbutyldimethylsilyl chloride (6.2 g, 41.2 mmol, 1.0 equiv.) and 4dimethylaminopyridine (10.0 g, 82.3 mmol, 2.0 equiv.). The reaction was stirred at
ambient temperature for one hour and thirty minutes before an additional equivalent of
tert-butyldimethylsilyl chloride was added. After an additional one hour and thirty
minutes, the reaction was diluted with ethyl acetate (100 mL) and was washed with water
(three 100-mL portions). The aqueous phase was extracted with ethyl acetate (200 mL).
The combined organic phase was dried over magnesium sulfate, vacuum filtered, and
concentrated in vacuo to yield 30 g of a crude brown liquid. The residue was
chromatographed over 200 g of silica gel (13 cm height by 5 cm diameter) eluted with
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hexanes-ethyl acetate (500 mL 9:1 in 50 mL fractions → 250 mL 4:1 in 50 mL fractions
→ 200 mL 1:1 in 75 mL fractions → 600 mL 100% ethyl acetate in 200 mL fractions):
fractions 5-8 contained protected malonate 2.67 as a yellow oil (13.8 g, 95% yield. IR
(Thin Film) 1736, 1608 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 7.04 (dd, J = 8.4 Hz, 2H),
6.74 (dd, J = 8.4 Hz, 2H), 3.68 (s, 6H), 3.62 (t, J = 7.8 Hz, 1H), 0.97 (s, 9H), 0.17 (s, 6H);
13C NMR (CDCl3, 100 MHz) δ: 169.3 (s), 154.5 (s), 130.4 (s), 129.8 (d), 120.1 (d), 53.9
(d), 52.5 (q), 34.1 (t), 25.6 (q), 18.2 (s), -4.4 (q); LRMS (ESI), m/z calc. for C18H28O5Si
[M+Na]+ 375.16, found 375.27.
(Z)-dimethyl 2-(4-((tert-butyldimethylsilyl)oxy)benzyl)-2-(4((methoxycarbonyl)oxy)but-2-en-1-yl)malonate(2.68): To a
suspension of sodium hydride (340.4 mg, 8.5 mmol, 1.5 equiv.) in
tetrahydrofuran (5.0 mL) was added a solution of dimethyl 2-(4((tert-butyldimethylsilyl)oxy)benzyl)malonate (2.0 g, 5.7 mmol, 1.0
equiv) in tetrahydrofuran (5.0 mL) via cannula. The reaction was stirred at ambient
temperature for fifteen minutes before a solution of (Z)-4-((methoxycarbonyl)oxy)but-2en-1-yl methanesulfonate (1.6 g, 7.1 mmol, 1.25 equiv.) in tetrahydrofuran (5.0 mL) was
added via cannula. The solution became highly viscous, and additional tetrahydrofuran
(10 mL) was added. After one hour the reaction was diluted with ethyl acetate (25 mL)
and washed with water (two 25-mL portions). The aqueous phase was extracted with
ethyl acetate (25 mL). The combined organic phases were dried over magnesium sulfate,
vacuum filtered, and concentrated in vacuo to yield 2.8 g of a crude yellow oil. The
residue was chromatographed over 40 g of silica gel (13 cm height by 3 cm diameter)
eluted with hexanes-ethyl acetate (200 mL 10:1 → 100 mL 4:1 → 50 mL 1:1 → 50 mL
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100% ethyl acetate) in 10 mL fractions. The product rich fractions were pooled and
evaporated to afford 2.68 as a clear, colorless oil (1.7 g, 62%). IR (Thin Film) 1734, 1604
cm-1; 1H NMR (CDCl3, 400 MHz) δ: 6.91 (dd, J = 8.5 Hz, 2H), 6.72 (dd, J = 8.5 Hz, 2H),
5.72 (dt, J = 11.4, 6.4 Hz, 1H), 5.63 (dt, J = 11.2, 7.2 Hz, 1H), 4.63 (d, J = 6.5 Hz, 2H),
3.79 (s, 3H), 3.71 (s, 6H), 3.19 (s, 2H), 2.59 (d, J = 7.0 Hz, 2H), 0.97 (s, 9H), 0.17 (s,
6H); 13C NMR (CDCl3, 100 MHz) δ: 171.1 (s), 155.7 (s), 154.8 (s), 130.8 (d), 128.7 (d),
128.1 (s), 126.7 (d), 120.0 (d), 63.5 (t), 58.8 (s), 54.8 (q), 52.5 (q), 37.8 (t), 30.3 (t), 25.7
(q), 18.2 (s), -4.5 (q); LRMS (ESI), m/z calc. for C24H36O8Si [M+Na]+ 503.21, found
503.32.
(Z)-dimethyl-2-(4-hydroxybenzyl)-2-(4((methoxycarbonyl)oxy)but-2-en-1-yl)malonate (2.47): To a
solution of (Z)-dimethyl 2-(4-((tert-butyldimethylsilyl)oxy)benzyl)-2(4-((methoxycarbonyl)oxy)but-2-en-1-yl)malonate (3.0 g, 6.2 mmol,
1.0 equiv) in tetrahydrofuran (100 mL) was added tetrabutylammonium fluoride (1M in
tetrahydrofuran) (7.5 mL, 7.5 mmol, 1.2 equiv.) over three minutes at 0°C. The reaction
was stirred for ten minutes then concentrated in vacuo. The residue was chromatographed
over 50g of silica gel (7 cm height by 3 cm diameter) eluted with hexanes-ethyl acetate
(100 mL 4:1 → 100 mL 2:1 → 50 mL 1:1 → 200 mL 100% ethyl acetate) in 10 mL
fractions. Product rich fractions were pooled and evaporated to afford 2.47 as a yellow
oil (1.3 g, 53% yield). 1H NMR (CDCl3, 400 MHz) δ: 6.91 (dd, J = 8.5 Hz, 2H), 6.71
(dd, J = 8.5 Hz, 2H), 5.72 (dtd, J = 11.2, 7.2 Hz, 1H), 5.65 (dtd, J = 11.2, 6.5 Hz, 1H),
4.63 (dd, J = 6.5 Hz, 2H), 3.79 (s, 3H), 3.80 (s, 3H), 3.73 (s, 6H), 3.19 (s, 2H), 2.60 (dd, J
= 7.0 Hz, 2H); 13C NMR (CDCl3, 100 MHz) δ: 171.3 (s), 155.9 (s), 154.7 (s), 130.9 (d),
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128.6 (d), 127.2 (s), 126.7 (d), 115.4 (d), 63.5 (t), 58.9 (s), 54.9 (q), 52.6 (q), 37.8 (t),
30.2 (t); LRMS (ESI), m/z calc. for C18H22O8 [M+Na]+ 389.12, found 389.24.
(E)-dimethyl 2-(buta-1,3-dien-1-yl)-2-(4-hydroxybenzyl)malonate
(2.74): To a 0.5-2.0 mL Biotage microwave reactor vial containing (Z)dimethyl 2-(4-hydroxybenzyl)-2-(4-((methoxycarbonyl)oxy)but-2-en-1yl)malonate (75.0 mg, 0.20 mmol, 0.2 equiv), triphenylphosphine (11.0
mg, 0.04 mmol, 0.2 equiv), and tris(dibenzylideneacetone)dipalladium (0) (19.0 mg, 0.02
mmol, 0.1 equiv) in dichloromethane (1.0 mL). The vial was sealed and heated to 80°C
for five minutes in a Biotage® Initiator+ microwave reactor. The suspension was filtered
through a Pasteur pipette filled with Celite® and rinsed with dichloromethane (2.0 mL).
The filtrate was collected and concentrated in vacuo. The residue was chromatographed
over 50 g of silica gel (1.25 cm diameter by 11.0 cm height) eluted with hexanes-ethyl
acetate (50 mL 10:1 → 50 mL 8:1 → 25 mL 4:1 → 25 mL 2:1 → 25 mL 1:1 → 25 mL
1:2) in 5 mL fractions. The product rich fractions were pooled and evaporated to afford
2.74 (24 mg, 40% yield) as a yellow oil. 1H NMR (CDCl3, 400 MHz) δ: 6.92 (d, J = 8.5
Hz, 2H), 6.67 (d, J = 8.5 Hz, 2H), 6.33 (ddd, J = 16.9, 10.0, 10.0 Hz, 1H), 6.15 (dd, J =
16.0, 10.0 Hz, 1H), 6.04 (d, J = 16.0 Hz, 1H), 5.20 (dd, J = 16.8, 10.1 Hz, 2H), 3.73 (s,
6H), 3.33 (s, 2H); 13C NMR (CDCl3, 100 MHz) δ: 170.7 (s), 154.8 (s), 136.2 (d), 132.6
(d), 131.2 (d), 130.3 (d), 127.3 (s), 118.5 (t), 115.1 (d), 61.0 (s), 52.8 (q), 41.6 (t).
dimethyl 8-oxo-4-vinylspiro[4.5]deca-6,9-diene-2,2-dicarboxylate
(2.46): To a sealed 0.5-2.0 mL Biotage microwave reactor vial
containing triphenylphosphine (36.0 mg, 0.14 mmol, 0.2 equiv) and
tris(dibenzylideneacetone)dipalladium (0) (60.0 mg, 0.07 mmol, 0.1
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equiv) under nitrogen was added a degassed solution of (Z)-dimethyl 2-(4hydroxybenzyl)-2-(4-((methoxycarbonyl)oxy)but-2-en-1-yl)malonate (250 mg, 0.68
mmol, 1.0 equiv) in dichloromethane (1.5 mL) via syringe. The reaction was heated to
40°C for forty minutes in a Biotage® Initiator+ microwave reactor. The suspension was
filtered through a Pasteur pipette filled with Celite® and rinsed with dichloromethane
(2.0 mL). The orange-yellow filtrate was collected and concentrated in vacuo. The
residue was chromatographed over 160 g of silica gel (10.5 cm height by 2.25 cm
diameter) eluted with hexanes-ethyl acetate (150 mL 10:1 → 100 mL 8:1 → 75 mL 6:1
→ 75 mL 4:1 → 50 mL 2:1 → 50 mL 1:1) in 10 mL fractions. The product rich fractions
were pooled and evaporated to afford 2.46 as a white solid (80 mg, 40% yield). IR (Thin
Film) 1728, 1662, 1624 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 6.85 (dtd, J = 10.3, 3.0 Hz,
1H), 6.73 (dd, J = 10.0, 3.0 Hz, 1H), 6.29 (dtd, J = 10.1, 1.9 Hz, 1H), 6.27 (dd, J = 10.1,
1.9 Hz, 1H), 5.41 (m, 1H), 5.01 (dd, J = 18.0, 1.1, 1H), 4.99 (dd, J = 9..3, 1.1 Hz, 6H),
3.80 (s, 3H), 3.79 (s, 3H), 2.84 (dd, J = 6.8, 6.0, 1H), 2.68 (d, J = 14.6 Hz, 1H), 2.67 (d, J
= 14.0 Hz, 1H), 2.56 (dd, J = 13.9, 13.9 Hz, 1H), 2.45 (d, J = 14.8 Hz, 1H); 13C NMR
(CDCl3, 100 MHz) δ: 185.9 (s), 172.4 (s), 172.1 (s), 153.0 (d), 148.9 (d), 133.8 (s), 130.2
(d), 129.3 (d), 117.8 (t), 58.5 (s), 53.5 (q), 53.3 (q), 53.2 (t) 52.1 (t), 43.6 (t), 38.6 (t);
HRMS (CI), m/z calc. for C24H36O8Si [M+Na]+ 313.1046, found 313.1053; Elemental
Analysis calc. C-66.19, H-6.25, found C-65.99, H-6.25.
dimethyl 4-(1-hydroxy-2-(phenylselanyl)ethyl)-8oxospiro[4.5]deca-6,9-diene-2,2-dicarboxylate (2.45a): To a
solution of dimethyl 8-oxo-4-vinylspiro[4.5]deca-6,9-diene-2,2dicarboxylate (57.0 mg, 0.2 mmol, 1.0 equiv) in acetonitrile (0.5 mL)
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was added water (0.1 mL, 0.5 mmol, 2.8 equiv) and phenyl selenyl chloride (43.0 mg, 0.2
mmol, 1.1 equiv). The reaction was stirred at ambient temperature for six hours before an
additional equivalent of phenyl selenyl chloride was added. After a total of 18 hours the
reaction was quenched with saturated ammonium chloride (1.0 mL). The organic phase
was diluted with ethyl acetate (1.0 mL) and was washed with water (1.0 mL) then brine
(1.0 ml). The aqueous phase was extracted with ethyl acetate (1.0 mL). The combined
organic phase was dried over sodium sulfate, vacuum filtered, and concentrated in vacuo
to yield a brown oil. The crude residue was chromatographed over 10 g of silica gel (1
cm diameter by 10 cm height) eluted with hexanes-ethyl acetate (50 mL 10:1 → 40 mL
8:1 → 30 mL 6:1 → 25 mL 4:1 → 20 mL 2:1 → 20 mL 1:1 → 20 mL 1:2) in 20 mL
fractions for fractions 1-6 and 10 mL fractions for all remaining fractions collected. The
product rich fractions were pooled and evaporated to afford single diastereomer of 2.45a
(27 mg, 30% yield) as a brown oil, a mixture of diastereomers of 2.45a (13 mg, 14%
yield) as a brown oil, and a single diastereomer of 2.45a (16 mg, 18% yield) as a purple
oil. IR (Thin Film) 3276, 1705 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 7.44 (m, 1H), 7.26
(m, 2H), 6.90 (dd, J = 10.3, 3.0 Hz, 1H), 6.71 (dd, J = 10.0, 3.0 Hz, 1H), 6.18 (dd, J =
10.1, 1.9 Hz, 1H), 6.14 (dd, J = 10.1, 1.9 Hz, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 3.77 (m,
1H), 3.06 (dd, J = 6.6, 1.2 Hz, 2H), 2.94 (dd, J = 9.7, 5.8, 1H), 2.75 (d, J = 6.6, 1.2 Hz,
2H), 2.68 (dd, J = 14.6, 1H), 2.45 (d, J = 14.8 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ:
185.4 (s), 172.1 (s), 171.7 (s), 153.1 (d), 148.4 (d), 133.4 (d), 130.1 (d), 129.5 (d), 128.9
(d), 128.5 (s), 127.9 (d), 60.7 (d), 57.2 (s), 53.5 (d), 53.4 (q), 53.3 (q), 50.5 (s), 44.7 (t),
34.6 (t), 35.4 (t); LRMS (ESI), m/z calc. for C22H24O6Se [M+Na]+ 331.12, found 331.24.

48

dimethyl 4-(2-bromo-1-hydroxyethyl)-8-oxospiro[4.5]deca-6,9diene-2,2-dicarboxylate (2.45b): To a solution of dimethyl 8-oxo-4vinylspiro[4.5]deca-6,9-diene-2,2-dicarboxylate (0.05 g, 0.172 mmol)
in a cosolvent of acetonitrile (0.285 mL, 0.172 mmol) and water (0.285 mL, 0.172 mmol)
cooled to 0°C was added N-bromosuccinimide (0.062g, 0.344 mmol). The reaction was
allowed to warm to ambient temperature overnight. The reaction was determined
complete via HPLC and TLC (1:1 Hex-EtOAc; UV/I2) after a total of 22 hours. The
reaction mixture was quenched with 10% aqueous sodium thiosulfate (1 mL) and washed
with brine (1 mL). The organic phase was filtered through a pipette filled with Celite®
and sodium sulfate plug. The filtrate was concentrated in vacuo to afford a clear oil. The
crude residue was purified by flash column chromatography over a 4 g silica column
using an Isco CombiFash. The product rich fractions were pooled and evaporated to
afford 2.45b (0.037 g, 55%) as a clear oil. IR (Thin Film) 3404, 1708 cm-1; 1H NMR
(CDCl3, 400 MHz) δ: 6.95 (dd, J = 10.2, 3.0 Hz, 1H), 6.89 (dd, J =9.9, 3.1 Hz, 1H), 6.35
(dd, J = 10.1, 1.8 Hz, 1H), 6.29 (dd, J = 9.9, 1.9 Hz, 1H), 3.95 (m, 2H), 3.80 (m, 2H),
3.78 (s, 6H), 2.88 (m, 1H), 2.75 (d, J = 14.4, 1H), 2.72 (m, 1H), 2.59 (m, 1H), 2.29 (d, J =
14.6, 1H); 13C NMR (CDCl3, 100 MHz) δ: 185.5 (s), 172.0 (s), 171.8 (s), 154.7 (d),
147.1 (d), 130.1 (d), 129.1 (d), 66.2 (t), 57.6 (s), 56.6 (d), 53.5 (q), 53.4 (q), 52.6 (d), 51.0
(s), 44.9 (t), 37.4 (t); HRMS (CI), m/z calc. for C16H19BrO6 [M+Na]+ 795.0622, found
795.0626.
dimethyl 4-(1-hydroxy-2-iodoethyl)-8-oxospiro[4.5]deca-6,9-diene2,2-dicarboxylate (2.45c): To a solution of dimethyl 8-oxo-4vinylspiro[4.5]deca-6,9-diene-2,2-dicarboxylate (0.051 g, 0.176 mmol)
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in a co-solvent of water (0.285 mL, 0.176 mmol) and acetonitrile (0.176 mmol, 0.285
mL) cooled to 0° C was added N-iodosuccinimide (0.119 g, 0.527 mmol).The reaction
was allowed to warm to ambient temperature and was determined complete after 1.5
hours. The reaction was quenched with 10% aqueous sodium thiosulfate (1 mL) and
washed with brine (1 mL). The organic phase was filtered through a pipette filled with a
Celite® and sodium sulfate plug and concentrated in vacuo to afford 2.45c as a yellowbrown oil. Due to the instability of this material, the crude mixture was utilized in the
proceeding step without further purification. 1H NMR (CDCl3, 400 MHz) δ: 6.95 (m,
1H), 6.88 (m, 1H), 6.32 (m, 2H), 4.03 (m, 1H), 3.72 (m, 1H), 3.78 (s, 6H), 2.88 (m, 1H),
2.73-2.55 (m, 3H), 2.29 (d, J = 14.6 Hz, 1H).
(E)-dimethyl 2-(4-hydroxybenzyl)-2-(4-hydroxybut-2-en-1yl)malonate (2.76): To a 25 mL roundbottom flask flushed with
nitrogen was added (E)-2,2'-(diazene-1,2-diyl)bis(2methylpropanenitrile) (1.484 mg ,9.04 µmol). A solution of dimethyl
(4R)-4-(2-bromo-1-hydroxyethyl)-8-oxospiro[4.5]deca-6,9-diene-2,2-dicarboxylate
(0.035 g, 0.090 mmol) in toluene (1.506 mL, 0.090 mmol) was then added and the
solution was heated to reflux. Tri-n-butyltin hydride (0.049 mL, 0.181 mmol) was added
in a single portion and the reaction was stirred at reflux for one hour. The solution was
cooled to ambient temperature and was concentrated in vacuo. The crude residue was
purified by flash column chromatography over 4 g of silica gel using an Isco CombiFlash
eluted with hexanes-ethyl acetate in 8.0 mL fractions. The product rich fractions 39-41
were pooled and evaporated to afford (E)-2.76 (20 mg, 72%) as a clear oil. IR (Thin
Film) 3276, 1705 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 6.92 (d, J = 8.5 Hz, 1H), 6.71 (d,
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J =8.5 Hz, 1H), 6.24 (s, 1H, O-H), 5.74 (dt, J = 15.5, 5.7 Hz, 1H), 5.62 (dt, J = 15.5, 5.7
Hz, 1H), 4.12 (m, 2H), 3.71 (s, 6H), 3.15 (s, 2H), 2.55 (d, J = 6.8 Hz, 2H),; 13C NMR
(CDCl3, 100 MHz) δ: 171.4 (s), 155.1 (s), 133.8 (d), 131.0 (d), 127.3 (s), 126.2 (d), 115.3
(d), 63.2 (t), 59.3 (s), 52.5 (q), 37.4 (t), 34.9 (t); HRMS (CI), m/z calc. for C16H20O6
[M+Na]+ 331.1152, found 331.1154.
(3aR,4S,5aR)-dimethyl 4-hydroxy-7-oxo-3a,4,5,5a,6,7-hexahydro1H-cyclopenta[c]indene-2,2(3H)-dicarboxylate (2.44): To an oven
dried 10-20 mL Biotage microwave reactor vial was added AIBN (1.002
mg, 6.10 µmol). The vial was immediately sealed then evacuated and charged with
nitrogen three times. A solution of dimethyl (4R)-4-(1-hydroxy-2-iodoethyl)-8oxospiro[4.5]deca-6,9-diene-2,2-dicarboxylate (0.053 g, 0.122 mmol) in toluene (12.21
mL, 0.122 mmol) was added and the reaction heated to 110°C. While the reaction was
heating, tri-n-butylgermanium hydride (0.067 mL, 0.244 mmol) was added to the vial in a
single portion. The reaction was stirred at 110°C for 17 hours. The solution was cooled to
ambient temperature and concentrated in vacuo to afford a yellow oil (55 mg). The
residue was chromatographed over 4 g of silica gel eluted with hexanes-ethyl acetate (25
mL 4:1→ 25 mL 2:1→ 25 mL 1:1→ 25 mL 1:2→ 25 mL 1:4) in 3 mL fractions. The
product rich fractions 16-18 were pooled and evaporated to afford dimethyl 2.44 (16.2
mg, 43%) as a clear oil. 1H NMR (CDCl3, 400 MHz) δ: 5.87 (dd, J = 10.2, 0.6 Hz, 1H),
5.44 (dd, J = 10.2, 2.7 Hz, 1H), 3.80 (ddd, J = 12.2, 5.2, 5.2, 1H), 3.60 (tdd, J = 3.0, 3.0,
3.0 Hz, 1H), 3.53 (dd, J = 11.7, 4.8 Hz, 1H), 3.39 (dd, J = 12.0, 12.0 Hz, 1H), 3.28 (s,
3H), 3.25 (s, 3H), 2.91 (dd, J = 14.0, 7.1 Hz, 1H), 2.59 (dd, J = 13.6, 13.6 Hz, 1H), 2.43
(dd, J = 16.8, 3.2 Hz, 1H), 2.36 (d, J = 15.1 Hz, 1H), 2.32 (d, J = 13.4 Hz, 1H), 2.22 (dd, J
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= 16.8, 3.0 Hz, 1H), 2.08 (d, J = 15.0 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ: 194.1 (s),
171.8 (s), 171.7 (s), 149.3 (d), 129.7 (d), 73.4 (d), 68.2 (t), 56.1 (s), 52.35 (q), 52.31 (q),
50.5 (d), 47.9 (s), 42.3 (t), 39.6 (t), 36.9 (t), 22.7 (d); LRMS (ESI), m/z calc. for C16H20O6
[M+Na]+ 331.1152, found 331.11.
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CHAPTER III – INVESTIGATION OF SYNTHETIC STRATEGIES FOR THE
DEVELOPMENT OF HETEROCYCLIC SMALL MOLECULE HIV-1 INTEGRASE
INHIBITORS
3.1 Introduction
3.1.1 The Global and National Health Issue
Following the first report of Human Immunodeficiency Virus (HIV)39 it has
remained a global epidemic. Shown in Table 3.1 is the 2017 report from the World
Health Organization (WHO) outlining several statistics with regard to the virus.40 Of
particular note is the estimated 36.7 million people living with the virus. In addition, the
Centers for Disease Control and Prevention (CDC) released a 2017 report outlining
statistics for the United States. In this report, it was estimated that 39,782 US residents
were infected and diagnosed with HIV in 2016 with 15,458 HIV related deaths in 2015.41
Table 3.1
Global statistics for HIV-1 infections

Africa
Americas
South-East
Asia
Europe
Eastern
Mediterranean

Estimated number of
people (all ages) living
with HIV (million)

Number of deaths
due to HIV/AIDS
(million)

Number of new
HIV infections
(million)

25.6

0.72

1.2

[22.9−28.6]

[0.59−0.89]

[0.98–1.3]

3.3

0.054

0.15

[2.9−3.8]

[0.044−0.065]

[0.13–0.18]

3.5

0.13

0.15

[2.5−8.2]

[0.12−0.22]

[0.11–0.18]

2.4

0.049

0.22

[2.3−2.6]

[0.040−0.056]

[0.21–0.23]

0.36

0.017

0.37

[0.29−0.5]

[0.014−0.024]

[0.029–0.057]
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Table 3.1 (continued)
1.5

0.039

97 000

[1.2−2.0]

[0.025−0.066]

[0.046–0.17]

36.7

1.0

1.8

[30.8−42.9]

[0.83−1.2]

[1.6–2.1]

Western
Pacific
(WHO) Global

Fortunately, the amount of new infections reported globally is down 40% from
2000 with the death toll being reduced by 33%.40 Regardless of these diminishing values,
the virus continues to develop drug resistant strains which requires continued research to
gain deeper understandings of the virus’ life cycle and potential inhibitors for improved
treatments of infected patients.
3.1.2 The Origins of HIV
The origins of HIV-1 have been geographically traced to equatorial West Africa
where zoonic transmissions via simian immunodeficiency viruses (SIV) occurred.42 This
proposed origin is based on several factors including genetic similarities between HIV
and SIV, geographic coincidence, and plausible occurrences for transmission which
include hunting and pet ownership.43 With additional simian-derived viruses having been
recorded for traversing the cross-species line,44-46 it was reasonable to presume HIV was
capable of performing the same action.
3.1.3 Life Cycle of the Virus
Within the life cycle of HIV-1, there are multiple targets with which researchers
have explored for restriction of viral replication. These targets have spanned across the
full spectrum of the replication cycle from host-cell entry to release and maturation of
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new virions. Specific stages currently exploited include: 1) Cell wall fusion/entry, 2)
RNA reverse transcription, 3) DNA integration, 4) and maturation.47
HIV-1 integrase (IN), the enzyme responsible for integration of viral DNA
(vDNA) into the host DNA, is essential for virus replication and represents an important
multifunctional therapeutic target.48 IN has been determined to contain three main
sections: the N-terminus domain (NTD), C-terminus domain (CTD), and the catalytic
core domain (CCD).49-50 These three domains work in conjunction to form a tetramer
structure where viral DNA and target chromosomal DNA are bound to IN.51-54
Additionally, a necessary component for tetramer association and viral DNA integration
is cellular chromatin-associated protein lens epithelium-derived growth factor
(LEDGF/p75).55 Specifically, LEDGF functions as a tether wherein it binds to both HIV
and target chromatin to facilitate integration.56-58
The integration of vDNA occurs in two stages at the active site located within the
CCD. The first stage forms the target capture complex (TCC) which involves trapping of
the target followed by subsequent cleavage of the vDNA 3′ ends. Completion of this
leads to a strand transfer complex (STC) which cleaves the target DNA and covalently
links the 3′ ends.59 The three amino acid residues required for the strand transfer include
aspartates 64 and 116 and glutamate 152. In addition, these residues coordinate with two
divalent magnesium cofactors to perform 3′ processing.60
3.1.4 Current Available Treatments
After the development of anti-retroviral treatments, HIV diagnosis transitioned
from a death sentence to a manageable disease which provided prolonged lifetimes and
better living conditions for infected patients. Specifically, Highly Active Anti-Retroviral
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Therapy (HAART) was developed as an effective treatment method. Through this
therapy, a single pill containing a cocktail of medications is administered. The variety of
medications target various stages in the viral lifecycle.54 One example of this is Genvoya
which contains a combination of four individual medications: elvitegravir (integrase
inhibitor), tenofiovir alafenamide (Nucleoside/Nucleotide Reverse Transcriptase Inhibitor
(NRTI)), emtricitabine (Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTI)),
cobicistat (pharmacokinetic enhancer) (Figure 3.1).

Figure 3.1 Contents of Genvoya.
Currently, there are three FDA approved compounds available for IN via strand
transfer inhibition: Raltegravir (RAL), Elvitegravir (EVG), and Dolutegravir (DVG).
RAL was developed by Merck and approved in 2007 making it the first treatment
available. Following this, Gilead produced EVG and received approval in 2012 with
GlaxoSmithKline close thereafter with approval of DVG in 2013. Although these
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treatments are effective, drug resistant strains have emerged against RAL and EVG due
to HIV’s high turnover and mutation rates.61 Currently, there are no reports of resistance
to DVG though the development of a mutation is virtually imminent.
Development of mutations within the active site of HIV IN makes it pertinent to
pursue alternative inhibition sites on the enzyme. HIV IN functions as a tetramer wherein
a dimer is formed at the CCD interface for vDNA interaction. Furthermore, LEDGF/p75
interacts at this CCD dimer within an allosteric binding pocket via the C-terminal
integrase binding domain (IBD).62-64 This binding pocket has become of significant
interest as an IN alternative target option.65 Previous studies66-68 have demonstrated that
the binding of inhibitors to the IN dimer interface at the IBD binding site immediately
triggers an aberrant multimerization of the enzyme, effectively blocking its functions and
viral replication. Two reported candidates that target the LEDGF binding pocket include
quinoline scaffolds 3.569 and 3.6 (BI 224436)70 (Figure 3.2).

Figure 3.2 Biaryl multisubstituted quinolines.
Examination of the crystal structure for 3.5 within the binding pocket reveals the
amino acids of interest in the northern region of the pocket (Figure 3.3).71 Specifically,
the northern aromatic component of the substrate resides in proximity to tryptophan 132
and leucine 102. Therefore, we commenced an investigation to identify relevant
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stereoelectronic interactions within this pocket. The inhibition data for compounds 3.5
and 3.6 inspired our research group to further investigate a library of 4-biaryl quinolines
through systematic structure activity relationship studies.

Figure 3.3 Ribbon representation of the integrase CCD dimer.
Shown in this crystal structure is 3.6 within the target binding pocket and amino acid W132. The yellow and cyan portions each
represent a single unit of the dimer.

3.2 Research Hypothesis
It was hypothesized that relevant stereoelectronic interactions within the
hydrophobic region of the binding pocket could be identified through examination of a
series of 4-biaryl quinolines.
3.3 Research Design and Methods
3.3.1 The Quinoline Scaffold
Quinolines represent approximately 2% of FDA approved prescription drugs,72
there are numerous methods for synthesizing this heterocycle. Most typically,
unsubstituted,73 mono-substituted,74 di-substituted,75-77 and tri-substituted rings78-80 have
been prepared from aniline, indole and isatin derivatives (Figure 3.4). Variations of these
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methods include: (1) electrophilic,81-82 oxidative,83 and free radical cyclizations,84 (2)
allene cycloadditions,85[9] and (3) iodine catalyzed,86 and aza-Wittig cascade reactions.87

Figure 3.4 Summary of synthetic methods for construction of quinolines.
Biaryl quinolines such as 3.5 and 3.6 have been shown to exhibit inhibitory
activity against the HIV-integrase enzyme.70 Examination of these shows a quinoline
framework substituted at the 2, 3, 4 and 7 positions. Structure activity relationship studies
have indicated that the 2-methyl and 3-acetic acid residue are crucial to maintaining the
potency of this scaffold. Given the lack of commercially available material for the
quinolines, we sought to modify existing literature methods for preparation of quinoline
scaffold 3.12 (Figure 3.5). To that end, we envisioned elaboration of the aryl ring.
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Figure 3.5 Existing literature methods for preparation of the desired quinoline scaffold.
3.3.2 Retrosynthetic Analysis
With the target quinoline scaffold set, a retrosynthetic analysis was designed.
Final stages of the synthesis to produce 3.21 would incorporate cyanohydrin formation
and hydrolysis followed by tert-butyl ether formation of a secondary alcohol to install the
acetic acid residue on the eastern fragment. Aldehyde 3.22 could be developed via
DIBAL-H reduction of an ethyl ester followed by a Parikh-Doering oxidation.
Installation of the northern aromatic component would be accomplished under standard
Suzuki coupling conditions. 4-bromoquinoline 3.23 would be developed via bromination
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of 4-hydroxyquinoline 3.19. Synthesis of quinoline 3.19 could be produced via base
initiated condensation of ethyl acetoacetate with isatoic anhydride 3.17 which could be
prepared from reaction of commercially available anthranilic acids 3.20 and triphosgene.

Scheme 3.1 Retrosynthetic analysis of quinoline 3.21.
3.4 Results and Discussion
3.4.1 Execution of First Generation Design
At the onset of this reaction sequence, development of quinoline 3.19 was
successfully realized utilizing triphosgene as the acylating agent for production of isatoic
anhydride 3.17 followed by subsequent condensation with ethyl acetoacetate. From this
point, it was envisioned that bromination with phosphorus tribromide would prepare
scaffold 3.23 and set the stage for Suzuki coupling with aromatic boronic acids. Initial
reaction screenings were attempted with para-chlorophenylboronic acid due to a need to
develop a substrate that could be compared to previously reported quinoline 3.5. Once
installed, oxidation/reduction chemistry would be performed to first reduce ethyl ester
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3.24 to primary alcohol 3.25 followed by oxidation to aromatic aldehyde 3.22. This
would then prepare the scaffold for subsequent cyanohydrin formation and hydrolysis to
produce the α-hydroxy acetic acid residue 3.27. Finally, ether formation with perchloric
acid and tert-butyl acetate would install the tert-butyl ether residue to produce the target
quinoline 3.21.

Scheme 3.2 First generation synthetic scheme
3.4.2 Challenges of Generation 1
The synthesis of 3.15 has been published in two-steps from 4-bromoaniline 3.8a
and diethyl acetylsuccinate 3.16 in 36% yield.88 Our attempts to repeat and scale-up this
procedure beyond a few hundred milligrams were met with inconsistent results and
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variable yields. In our experience this route is less advantageous due to: (1) the need for a
prolonged room temperature condensation reaction time (> 5 days in a dessicator with
phosphorus pentoxide) to form the initial vinylogous amide; (2) the use of expensive
diphenyl ether, which has a nauseating odor, at 0.01 molar dilution at reflux (259ºC) to
effect the ring closure via electrophilic aromatic substitution; and (3) the aqueous workup
of this method which does not reliably produce a precipitate that can be filtered easily.

Scheme 3.3 Synthetic conditions by Avetisyan and co-workers.
We therefore sought to employ the Coppola quinoline synthesis method through
the acylation of active methylene compounds with isatoic anhydrides followed by
dehydrative intramolecular cyclization.89 The anhydride 3.17 is readily accessed by
treatment of anthranilic acid 3.20 with one equivalent of triphosgene in tetrahydrofuran.
This procedure improves upon the existing published protocol which relies on toxic
phosgene gas90 as the acylating agent replacing it with the non-volatile, easy to weigh
solid triphosgene. The operationally simple reverse aqueous quench and aging avoids
extraction with organic solvent and produces 3.17 as solid material that is easily collected
by vacuum filtration (Table 3.2).
Table 3.2
Synthesis and reaction yields of isatoic anhydrides
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Entry

Isatoic Anhydride

R1

R2

R3

Yielda

1

3.17a

H

H

H

81%

2

3.17b

Br

H

H

90%

3

3.17c

I

H

H

91%

4

3.17d

OH

H

H

82%

5

3.17e

NO2

H

H

75%

6

3.17f

H

Br

H

89%

7

3.17g

H

NO2

H

91%

8

3.17h

H

H

Br

81%

Note: a Isolated yield of homogenous material

The structures of the isatoic anhydrides 3.17a-h were assigned utilizing 2D NMR
techniques heteronuclear single quantum coherence (HSQC) and heteronuclear multiple
bond correlation (HMBC). The most deshielded ring proton resonance for 3.17a was
located at position 5 (7.92 ppm). With this as the benchmark, substitution at position 6
was compared. Addition of an electron withdrawing group (NO2, anhydride 3.17e) or
donating group (OH, anhydride 3.17d) had the expected effect of deshielding (Δppm =
0.64) and shielding (Δppm = -0.70) at position 5, respectively. Additionally, substitution
at position 7 afforded similar shifts but with diminished effect.
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Table 3.3
1

H NMR data for isatoic anhydrides in DMSO-d6

Entry

1

Isatoic
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Anhydride

1

1

3.17a

11.75

-

-

2

3.17b

11.86

-

3

3.17c

-

4

3.17d

5

2 3 4

H Position δ ppm (J Hz)

5

6

7

8

9

10

-

7.92 (7.9)

7.26 (8.1, 0.9)

7.75 (8.0, 7.2, 1.5)

7.17 (8.0)

-

-

-

-

7.10 (8.7)

-

7.89 (8.7, 2.3)

7.99 (2.3)

-

-

-

-

-

8.13 (1.6)

-

8.01 (8.5, 1.8)

6.96 (8.5)

-

-

-

-

-

-

8.13 (1.6)

-

8.01 (8.5, 1.8)

6.96 (8.5)

-

-

3.17e

12.35

-

-

-

8.56 (2.6)

-

8.52 (9.0, 2.6)

7.30 (9.1)

-

-

6

3.17f

11.83

-

-

-

7.83 (8.4)

7.42 (8.4, 1.6)

-

7.30 (1.6)

-

-

7

3.17g

12.09

-

-

-

8.16 (8.6)

7.96 (8.6, 2.2)

-

7.86 (9.1)

-

-

8

3.17h

11.08

-

-

-

7.95 (7.8, 1.4)

7.19 (7.8, 7.8)

8.02 (7.9, 1.4)

-

-

-

Table 3.4
13

C NMR data for isatoic anhydrides in DMSO-d6

Entry

C Position δ ppm

13

Isatoic
Anhydride

1

2

3

4

5

6

7

8

9

10

1

3.17a

- 147.5 - 160.3 129.4 124.0 137.4 115.8 141.9 110.7

2

3.17b

- 146.7 - 158.8 117.6 114.5 139.3 130.5 140.6 112.4

3

3.17c

- 147.2 - 159.1 136.9

4

3.17d

- 147.4 - 160.4 112.8 153.8 126.1 117.2 134.4 111.2

5

3.17e

- 147.0 - 159.1 125.0 142.9 131.7 117.1 146.5 111.6

6

3.17f

- 147.3 - 159.8 131.2 126.9 130.7 118.2 142.9 110.2

7

3.17g

- 147.1 - 159.2 131.4 117.8 152.4 110.7 142.5 115.9

8

3.17h

- 147.0 - 159.6 129.1 125.0 140.6 113.4 140.0 108.4

86.5

145.3 118.1 141.4 113.1

The Coppola conditions for cyclodehydration reaction employing 3.17a-h with
the sodium enolate of ethyl acetoacetate in DMA were used to prepare quinolines 3.19ah. Operationally the reaction is robust and can be carried out without rigorous exclusion
of moisture or degassing protocols. To our advantage, product isolation was achieved via
water precipitation and filtration. Drying of products overnight under high vacuum
afforded desired quinolines without requiring additional purification.
Table 3.5
Synthesis and reaction yields of quinolines
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Entry

Quinoline

R1

R2

R3

Yield

1

3.19a

H

H

H

58%

2

3.19b

Br

H

H

80%

3

3.19c

I

H

H

77%

4

3.19d

OH

H

H

69%

5

3.19e

NO2

H

H

82%

6

3.19f

H

Br

H

97%

7

3.19g

H

NO2

H

66%

8

3.19h

H

H

Br

47%

Analysis of the quinoline NMR data shows strong correlation with previously
reported observations for substituted quinolines.91 The structures were again assigned
utilizing HSQC and HMBC. The most deshielded ring proton resonance for 3.19a was
again located at position 5 (8.06 ppm) and was therefore utilized as the benchmark for
comparison with the substituted quinolines. Addition of an electron withdrawing group
(NO2, quinoline 3.19e) or donating group (OH, quinoline 3.19d) at position 6 had the
expected effect of deshielding (Δppm = 0.73) and shielding (Δppm = -0.68) at position 5,
respectively. Additionally, substitution at position 7 afforded similar shifts but with
diminished effect.
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Table 3.6
1

H NMR data for quinolines in DMSO-d6

1

Entry Quinoline
1 2 3 4

5

H Position δ ppm (J Hz)
6

7

8

9

10

7.35 (8.0, 7.1, 1.0)

7.68 (8.4, 7.0, 1.5)

7.54 (8.0)

-

-
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1

3.19a

-

-

-

- 8.06 (8.1, 1.4)

2

3.19b

-

-

-

-

8.13 (2.3)

-

7.82 (8.8, 2.3)

7.51 (8.8, 1.0)

-

-

3

3.19c

-

-

-

-

8.34 (2.0)

-

7.93 (8.7, 2.1)

7.36 (8.7)

-

-

4

3.19d

-

-

-

-

7.38 (2.8)

-

7.16 (8.8, 2.8)

7.42 (8.8)

-

-

5

3.19e

-

-

-

-

8.79 (2.6)

-

8.44 (9.1, 2.7)

7.71 (9.2)

-

-

6

3.19f

-

-

-

-

7.97 (8.6)

7.48 (8.6, 1.8)

-

7.71 (1.8)

-

-

7

3.19g

-

-

-

-

8.28 (8.8)

8.08 (8.9, 2.2)

-

8.39 (2.0)

-

-

8

3.19h

-

-

-

- 8.12 (8.0, 1.4)

7.31 (7.8, 7.8)

8.02 (7.8, 1.4)

-

-

-

Table 3.7
13

C NMR data for quinolines in DMSO-d6

Table x. 13C NMR data (DMSO-d6) for Quinolines x

Entry

C Position δ ppm

13

Quinoline
1

2

3

4

5

6

7

8

9

10

3.19a

- 149.3 115.3 173.8 125.5 124.2 132.7 118.4 141.9 110.7

2

3.19b

- 149.9 115.5 172.5 127.6 116.8 135.4 121.1 138.5 126.5

3

3.19c

- 150.1 115.5 172.3 133.9

4

3.19d

- 147.9 113.7 173.3 108.2 154.5 122.6 120.0 133.0 126.5

5

3.19e

- 151.3 116.7 172.9 127.9 117.8 139.4 114.7 149.8 128.4

6

3.19f

- 150.2 115.7 173.3 127.8 127.1 124.0 121.0 141.0 125.9

7

3.19g

- 151.0 116.5 173.3 122.0 143.5 126.9 120.4 143.4 124.2

8

3.19h

- 150.4 116.5 173.3 125.5 125.2 136.7 126.6 137.5 111.3
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1

88.6

140.6 121.3 139.3 126.9

A plausible mechanism for the formation of the quinoline is shown in Scheme
3.4. After initial formation of the enolate of ethyl acetoacetate with sodium hydroxide,
water is generated in the reaction mixture serving as a proton transfer agent. The resultant
sodium enolate regioselectively attacks the more electrophilic ester carbonyl of the
isatoic anhydride forming a tetrahedral intermediate 3.28. Subsequent collapse of the sp3
hybridized carbon to the ketone with concomitant expulsion of carbon dioxide and proton
transfers affords the amino ketone 3.29. The aniline nitrogen then attacks the ketone
carbonyl via intramolecular 6-exo-trig cyclization with loss of water to afford the
quinoline 3.19.

Scheme 3.4 Mechanistic proposal for development of quinoline 3.19.
With a series of quinoline substrates in hand, we continued forward with the
installation of the aromatic group on the northern region of the molecule. To begin, the
unsubstituted quinoline 3.19a was utilized to develop the synthetic route for proceeding
substrates to follow. 4-bromoquinoline 3.23 was readily prepared in 76% yield via
bromination of 4-hydroxyquinoline 3.19a with the use of phophorous tribromide. It was
observed to be a highly exothermic reaction which required dropwise addition on larger
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scales to prevent extreme exotherms. Suzuki coupling to install the northern aromatic
residue was readily achieved utilizing tetrakis(triphenylphosphine)palladium (0) catalyst
at ambient temperatures to produce 3.24 at 66% yield.

Scheme 3.5 Synthesis of biaryl quinoline 3.24.
Reduction of ethyl ester 3.24 proved to be a challenging chemical transformation
when utilizing a variety of standard reducing agents including lithium aluminum hydride,
Red-Al, and sodium borohydride. None of these reagents effectively converted the ester
to alcohol 3.25. When attempted with diisobutyl aluminum hydride, conversion was
observed though challenges remained with product isolation which resulted in varied and
inconsistent yields that showed diminishing returns as scales increased. With primary
alcohol 3.25 prepared, a Parikh-Doering oxidation utilizing pyridine sulfur trioxide
complex was successfully performed to convert the alcohol to aromatic aldehyde 3.22.

Scheme 3.6 Synthesis of aromatic aldehyde 3.22.
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With the aldehyde in hand, examination of the cyanohydrin was pursued (Table
3.8). Initial conditions utilizing potassium cyanide (Table 3.8, Entries 1-5) proved unable
to completely convert starting material 3.22 to product 3.26. Upon implementation of
trimethylsilylcyanide with a zinc iodide catalyst, full conversion was successfully
observed. Unfortunately, silica gel purification let to reversion to the starting aldehyde.
Additionally, both acidic and alkaline conditions resulted in development of aldehyde
starting material. It was postulated that reversion was achieved through an elimination
mechanism wherein the cyanide was acting as the leaving group to produce the aldehyde.
Table 3.8
Reaction conditions for development of cyanohydrin 3.26

Entry
1
2
3
4
5
6
7

CN Source
KCN
KCN
KCN
KCN
KCN
TMSCN
TMSCN

Additive
HCl
NH4Cl
NaHSO3
NaOH
NaHCO3
ZnI2
ZnI2

Solvent
EtOH
Et2O
EtOAc
THF
THF
DCM
DCM

Time (hr)
48
16
48
22
21
5.5
16

% Conv.a
20%
20%
40%
16%
79%
100%
100%

Note: a Determined via HPLC: Rt 3.22 = 5.3 min; Rt 3.26 = 4.9 min

To remedy the instability of the cyanohydrin, a one-pot method was attempted
(Scheme 3.7). It was postulated that conversion to the cyanohydrin in a
dichloromethane/tert-butylacetate co-solvent followed by subsequent addition of Tf2NH
could produce the cyanide with the benzylic t-butylether residue installed. Through this
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method the cyanohydrin would be “trapped”, imparting stability and preventing
undesired elimination and reversion to the aldehyde. Attempts to perform this chemistry
were unsuccessful in producing desired cyanide 3.30.

Scheme 3.7 One-pot trapping method for development of cyanide 3.30.
To this end, it was determined that diminishing reaction yields at the reduction
stage and stability challenges with the cyanohydrin formation would not make this a
viable synthetic route for the facile development of an extensive drug candidate library.
Therefore, an alternative method was designed that involved the formation of acid
chloride 3.31 (Scheme 3.8). Starting from ethyl ester quinoline 3.24, base hydrolysis and
subsequent acid chloride formation with oxalyl chloride was performed to develop 3.31
as a white solid. Proceeding attempts to install the cyanohydrin and hydrolyze to α-keto
acetic acid 3.32 were unsuccessful as no reaction was observed.

Scheme 3.8 Alternative conditions for cyanohydrin formation.
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3.4.3 Second Generation Synthesis
With the previous route having presented significant challenges, we sought to
employ chemistry from the Boehringer Ingelheim process group as an alternative method
to install the acetic acid side chain.92 Beginning with 4-hydroxy-2-methylquinoline
(Scheme 3.9) transformations were performed at positions 3 and 4. Development of 2iodo and 2-bromoquinolines (3.34a and 3.34b, respectively) was achieved via addition of
the associated halo-succinimide in the presence of acetic acid which was readily scaled to
15 grams. Installation of chlorine at position 4 utilized phosphorous oxychloride in the
presence of triethylamine with greater success observed with the 3-bromoquinoline and
could also be easily scaled up to multigram scales. A reverse quench by pouring the crude
reaction into ice water with vigorous stirring followed by slow addition of solid sodium
hydroxide effectively neutralized any phosphate intermediates to afford 3.35a and 3.35b
as solids.

Scheme 3.9 Synthesis of 3-haloquinolines 3.35a-b.
In the proceeding step, a selective halogen-metal exchange was implemented to
install the necessary ethyl oxalate at position 3. Specifically, a copper (I) bromide
dimethylsulfide complex mediated Grignard was implemented (Table 3.9). In our hands,
this reaction with isopropyl magnesium chloride was unsuccessful using 3-iodoquinoline
3.35a (Entries 1-11). What was often observed was complete conversion but only a
development of de-halogenated byproduct 3.40. When performing the same reaction
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utilizing 3-bromoquinoline 3.35b, we were unable to achieve full conversion to the αketo ester 3.39. Additionally, increased scales of this reaction proved problematic as the
development of the same de-halogenated quinoline by-product became prevalent beyond
a 500 mg scale.
Table 3.9
Condition screening for the Grignard reaction

Entry
1
2
3
4
5
6
7
8
9
10
11
13
14
15
16
17

X
I
I
I
I
I
I
I
I
I
I
I
Br
Br
Br
Br
Br

Temp.
-4
-4
-54
-54
-54 to -4
-4
-4
-4
-54
-54
-78
-54
-54→-4
0→rt
0
0

18
19

Br 0
Br -78

Catalyst
CuBr•SMe2
CuBr•SMe2
CuBr•SMe2
CuBr•SMe2
CuBr•SMe2
CuBr•SMe2
CuBr•SMe2
CuBr•SMe2
CuBr•SMe2
none
none
CuBr•SMe2
CuBr•SMe2
CuBr•SMe2
CuBr•SMe2
CuBr•SMe2

Electrophile
3.36
3.38
3.38
3.36
3.38
3.38
3.38
3.38
3.38
3.38
3.38
3.38
3.38
3.38
3.38
3.38

%Yield
no reaction
no reaction
no reaction
0%a
0%a
0%a
0%a
0%a
0%a
0%a
0%a
no reaction
0%
29%b
no reaction
no reaction

CuBr•SMe2
none

3.38
3.38
75

no reaction
0%

Comments
used n-BuLi
used 1.0
equivalent of
catalyst
used n-BuLi

Table 3.9 (continued)
20

Br 0

CuBr•SMe2

3.38

no reaction

NMR study
with THF-d8

Note: a Isolated material was de-iodinated quinoline 3.40. b Yield based on recovered starting material.

To reconcile the incomplete conversions, isopropyl magnesium chloride lithium
chloride complex was implemented and proved successful in consuming all starting
material when followed by quench with ethyl chlorooxolate (Table 3.10). Unfortunately,
challenges remained with development of de-halogenated quinoline which prevented
scaling these reactions beyond a 1.0 g scale.
Table 3.10
Grignard reactions using isopropyl magnesium chloride lithium chloride complex

Entry
1
2
3
4
5
6

Scale
0.4 mmol
2.0 mmol
2.0 mmol
0.4 mmol
2.0 mmol
4.0 mmol

%Yield
22%
35%
12%
30%
0%
47%a

Comments

Used electrophile 3.36
Used electrophile 3.36

Note: a Based on purity of 75% determined via NMR analysis

The proceeding sodium borohydride reduction produced α-hydroxy ester 3.41 in
77% yield (Scheme 3.10). Subsequent trans-halogenation to the 4-iodo quinoline 3.42
followed by palladium (0) catalyzed Suzuki coupling to afford 4-phenyl quinoline 3.43
were successful with an overall 63% yield. Ether formation via perchloric acid in tertbutylacetate could achieve 71% conversion at best with normal phase purification able to

76

separate pure product in 71% yield based on recovered starting material. Saponification
in aqueous sodium hydroxide then afforded the desired quinoline acetic acid 3.21 in a
moderate 40% yield.

Scheme 3.10 Late stage synthesis of biaryl quinoline 3.21.
With an established synthetic route for the construction of the necessary quinoline
scaffold, the procedures were altered in order to streamline the development of a
candidate library. As shown in Scheme 3.11, the perchloric acid mediated tert-butyl ether
synthesis was switched with the Suzuki coupling. This rearrangement implements a late
stage derivatizing step where a wide variety of aromatics can be installed from a common
intermediate. Ultimately, this allows for bulk preparation of bench-stable iodoquinoline
3.45 leaving only two remaining steps and the necessity for one purification.

Scheme 3.11 Final steps for quinoline library development.
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Shown in Table 3.11 is a summary of a subset of biaryl quinolines that have been
synthesized via the discussed route. Additionally, EC50 values for IN inhibition
developed through two individual assays are presented. The 4-phenylquinoline (3.21a,
R1=H) was utilized as the reference point for relative comparison of substituted phenyl
rings. Substitution for a methyl group (3.21e, R1=CH3) resulted in a six-fold decrease in
the EC50 value. Additionally, loss of potency occurred when methyl hydrogens were
substituted with fluorine (3.21d, R1=CF3). There was a three-fold loss in potency
observed between entries 4 and 5 (4-trifluoromethyl 3.21d and 4-methyl 3.21e,
respectively). This suggests an incompatibility of the polar trifluoromethyl within the
hydrophobic pocket. In addition, halogen substitution (entries 2 and 3) showed
improvement in potency with para-chloro-4-phenylquinoline 3.21c having the most
effective interaction among the series with an EC50 of 100 nM.
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Table 3.11
SAR study of para-substituted biaryl quinolines
Entry Quinoline
1
2
3b
4
5
6
7
11
12
13

3.21a
3.21b
3.21c
3.21d
3.21e
3.21f
3.21g
3.21h
3.21i
3.21j

14

3.21k

R1
H
F
Cl
CF3
CH3
CN
COCH3
C6H5
NHCOCH3

%Yield
3.44a
55%
67%
63%
51%
49%
80%
63%d
59%
67%
80%

%Yield
3.21a
40%
76%
40%
99%
51%
34%c
57%
77%
9%
78%

72%

78%

EC50 Multimerization
(µM)
1.32±0.53
0.49±0.04
0.10±0.02
0.72±0.06
0.24±0.11
2.97±0.81
1.39±0.48
No Activity
8.41±0.73
0.08±0.01

No Activity

Note: a Isolated yield of homogenous material. b Follows original synthetic route with the yields reported associated with the Suzuki
and hydrolysis step, respectivetly. c Required normal phase purification with dichloromethane-methanol. d Achieved 90% conversion
by HPLC camparison of iodoquinoline 3.45 (4.6 min) and product 3.44g (5.7 min).

Originally, we postulated that electron density at the aromatic ring was a
significant factor but the presence of chlorine intriguingly interrupted this trend. We
examined additional factors including size restrictions, steric interactions, and substrate-π
interactions which may contribute significantly to protein affinity. Closer scrutiny of the
trends revealed to us that electron density of the ring has minimal, although observable
effect, with the size and steric interactions exhibiting the dominating factor for successful
protein affinity. This was corroborated by entries 6-12 which contain substituents with
increased sterics relative to entries 1-5.
Still, steric interactions did not provide sufficient explanation for the increased
potency in 3.21c. Further understanding for diversion from the standard trend can be
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found in the stabilizing effect of chlorine-π interactions. A theoretical study elaborates on
the significance of these interactions wherein chlorine participates in dispersive
interactions with the π-systems of phenylalanine, histidine, and tryptophan residues.93
The result of this interaction is a stabilizing effect of -2.01 kcal/mol, attributing to
increased protein affinity. As shown in Figure 3.6 the chlorine resides within 4Å of
tryptophan 132 allowing for this stabilizing Cl-π interaction to occur, providing evidence
for the improved affinity.

Figure 3.6 Three-dimensional and two-dimensional representation of the binding pocket.
A. The computer model was generated by BIOVIA Discovery Studio® and denotes the distance between chlorine and W132 (blue
dotted line). B. A two-dimensional representation of the binding pocket with the yellow and green sections representing the individual
units of the integrase dimer.

In addition to the study of phenyl substitution, heterocyclic and bicyclic systems
were also examined (Table 3.11; entries 11, 13, and 14). When testing biphenyl 3.21h no
activity was observed. This supports the hypothesis that large substrates will exceed the
available volume within the binding pocket. This is reiterated with para-cyano-4phenylquinoline 3.21f which showed no ability to bind within the pocket. The presence
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of tryptophan 132 defines the available space in this pocket and the previously mentioned
substrates, which exhibit rigid sp and sp2-hybridized carbon systems, exceed this threedimensional space and therefore have restricted access to the binding pocket. The most
promising candidate from this series was the 2,3-benzo[b][1,4]dioxane 3.21j which
showed an EC50 of 80 nM.
3.5 Future Work
Much of the presented work has utilized only quinoline substrates that contain no
additional functionality on the western ring (positions 5-8). It can be postulated that
certain functionalities, such as halogens bromine and iodine, would be implausible
candidates for this method. Namely, the shortcoming would be derived in the Grignard
reaction for the installation of the acetic acid residue. It is apparent that additional
halogens would compete with the reaction, further reducing the yield of the desired αketo ester. Additionally, the Grignard reaction presents a time-consuming and low
yielding step which develops a bottleneck to produce the iodohydrin in bulk quantities.
To remedy this limitation, it would be of interest to revisit the first generation
synthesis where development of the cyanohydrin presented significant challenges.
Presented in Scheme 3.12 is the altered conditions to the original route. It was discovered
that utilizing a lithium chloride catalyzed cyanosilylation was successful under ambient
temperatures to produce a stable cyanosilane. Implementing Pinner Reaction conditions
would then develop the needed α-hydroxy ester 3.46. From that point standard chemistry
previously described can be implemented for library development.
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Scheme 3.12 Alternative synthetic route for future substrate development.
3.6 Summary and Conclusion
Despite the marked improvements for treatment of HIV, the virus continues to
produce resistance to standard treatment options. Additionally, the presented statistics
show that it remains an aggressive virus that effects the lives of millions each year.
Presented in this chapter is a method and proceeding discussion regarding the
development of novel treatments containing a quinoline scaffold. A process for the
construction of the quinoline core and subsequent functionalization has been established
and subsequently utilized to afford a library of treatment candidates. Despite the progress
with this work, deficiencies do exist and have been briefly described. Therefore, an
alternative synthesis is required and proposed for the improvement and expansion to a
more general method that is amenable to various functionality on the quinoline core.
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3.7 Experimental
3.7.1 Synthesis of Intermediates
1H-benzo[d][1,3]oxazine-2,4-dione (3.17a): To a single neck 500 mL
roundbottom flask was added anthranilic acid (72.9 mmol, 10 g) and
tetrahydrofuran (2.441 mol, 200 mL) which resulted in a dark brown solution.
Triphosgene (72.9 mmol, 21.64 g) was added to the mixture which resulted in a tan color
suspension. The flask was equipped with a condensing column and the reaction was
heated to 70 °C and stirred at 800 rpm for 12 hours. The reaction was cooled to room
temperature and was poured into a 600 mL beaker containing 300 mL of distilled water
and was stirred vigorously for one hour using an overhead mechanical stirrer. A white
precipitate formed and was vacuum filtered through a Büchner funnel. The solid was
collected and stirred in 100 mL of methanol for 30 minutes. The slurry was then collected
via vacuum filtration through a Büchner funnel to afford 1H-benzo[d][1,3]oxazine2,4(1H)-dione (9.61 g, 81%) as a white solid. mp 249-250 ºC; IR (solid) cm-1 1724; 1H
NMR (DMSO-d6, 400 MHz) δ: 11.75 (s, 1H, N-H), 7.92 (d, J = 7.9 Hz, 1H), 7.75 (dd, J
= 8.0, 7.2, 1.5 Hz, 1H), 7.26 (d, J = 7.9 Hz, 1H), 7.17 (dd, J = 8.1, 0.9 Hz, 1H); 13C
NMR (DMSO-d6, 100 MHz) δ: 160.3 (s), 147.5 (s), 141.9 (s), 137.4 (d), 129.4 (d), 124.0
(d), 115.8 (d), 110.7 (s).
6-bromo-1H-benzo[d][1,3]oxazine-2,4-dione (3.17b): mp >260 ºC; IR
(solid) cm-1 3169, 1754, 1691; 1H NMR (DMSO-d6, 400 MHz) δ: 11.86
(s, 1H, N-H), 7.99 (d, J = 2.3 Hz, 1H), 7.89 (dd, J = 8.7, 2.3 Hz, 1H), 7.10 (d, J = 8.7 Hz,
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1H); 13C NMR (DMSO-d6, 100 MHz) δ: 158.8 (s), 146.7 (s), 140.6 (s), 139.3 (d), 130.5
(d), 117.6 (d), 114.5 (s), 112.4 (s).
6-iodo-1H-benzo[d][1,3]oxazine-2,4-dione (3.17c): mp >260 ºC; IR
(solid) cm-1 3169, 1751, 1695; 1H NMR (DMSO-d6, 400 MHz) δ: 11.82
(s, 1H, N-H), 8.13 (d, J = 1.6 Hz, 1H), 8.01 (dd, J = 8.5, 1.8 Hz, 1H), 6.96 (d, J = 8.5 Hz,
1H); 13C NMR (DMSO-d6, 100 MHz) δ: 159.1 (s), 147.2 (s), 145.3 (s), 141.4 (d), 136.9
(d), 118.1 (d), 113.1 (s), 86.5 (s).
6-hydroxy-1H-benzo[d][1,3]oxazine-2,4-dione (3.17d): mp >260 ºC;
IR (solid) cm-1 3269, 1771, 1695; 1H NMR (DMSO-d6, 400 MHz) δ:
11.51 (s, 1H, N-H), 9.87(s, 1H, O-H), 7.22 (s, 1H), 7.20 (m, 1H) 7.03 (d, J = 8.4 Hz, 1H);
13C NMR (DMSO-d6, 100 MHz) δ: 160.4 (s), 146.7 (s), 140.6 (s), 139.3 (d), 130.5 (d),
117.6 (d), 114.5 (s), 112.4 (s).
6-nitro-1H-benzo[d][1,3]oxazine-2,4-dione(3.17e): mp >260 ºC; IR
(solid) cm-1 3169, 1747, 1695; 1H NMR (DMSO-d6, 400 MHz) δ: 12.35
(s, 1H, N-H), 8.56 (d, J = 2.6 Hz, 1H), 8.52 (dd, J = 9.0, 2.6 Hz, 1H), 7.30 (d, J = 9.1 Hz,
1H); 13C NMR (DMSO-d6, 100 MHz) δ: 159.1 (s), 147.0 (s), 146.5 (s), 142.9 (s), 131.7
(d), 125.0 (d), 117.1 (d), 111.6 (s).
7-bromo-1H-benzo[d][1,3]oxazine-2,4-dione (3.17f): mp >260 ºC; IR
(solid) cm-1 3169, 1772, 1700; 1H NMR (DMSO-d6, 400 MHz) δ: 11.83
(s, 1H, N-H), 7.83 (d, J = 8.4 Hz, 1H), 7.42 (dd, J = 8.4, 1.6 Hz, 1H), 7.30 (d, J = 1.6 Hz,
1H); 13C NMR (DMSO-d6, 100 MHz) δ: 159.8 (s), 147.3 (s), 142.9 (s), 131.2 (d), 130.7
(s), 126.9 (d), 118.2 (d), 110.2 (s).
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7-nitro-1H-benzo[d][1,3]oxazine-2,4-dione (3.17g): mp >260 ºC; IR
(solid) cm-1 3173, 1781, 1695; 1H NMR (DMSO-d6, 400 MHz) δ: 12.09
(s, 1H, N-H), 8.16 (d, J = 8.6 Hz, 1H), 7.96 (dd, J = 8.6, 2.2 Hz, 1H), 7.86 (d, J = 2.2 Hz,
1H); 13C NMR (DMSO-d6, 100 MHz) δ: 159.2 (s), 152.4 (s), 147.1 (s), 142.5 (s), 131.4
(d), 117.8 (d), 115.9 (s), 110.7 (d).
8-bromo-1H-benzo[d][1,3]oxazine-2,4-dione (3.17h): mp 99-201 ºC; IR
(solid) cm-1 1716; 1H NMR (DMSO-d6, 400 MHz) δ: 11.08 (s, 1H, N-H),
8.02 (dd, J = 7.9, 1.4 Hz, 1H), 7.95 (dd, J = 7.8, 1.4 Hz, 1H), 7.91 (dd, J =
7.8 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz) δ: 159.6 (s), 147.0 (s), 140.6 (d), 140.0
(s), 129.1 (d), 125.0 (d), 113.4 (s), 108.4 (s).
ethyl 4-hydroxy-2-methylquinoline-3-carboxylate (3.19a): To a 100
mL single-necked round bottom flask was added 2Hbenzo[d][1,3]oxazine-2,4(1H)-dione (5 g, 30.6 mmol), ethyl 3-oxobutanoate (7.7 mL,
61.3 mmol), and N,N-dimethylacetamide (50 mL). Sodium hydroxide (1.2 g, 30.6 mmol)
was added to the flask, which resulted to an olive-green color. The reaction was equipped
with a reflux condenser and stirred at 100°C for 12 hours. The reaction was cooled to
ambient temperature then was poured into a 600 mL beaker containing 200 mL of
distilled water and was vigorously stirred for 30 mins using an overhead mechanical
stirrer. The white precipitate was vacuum filtered through a Büchner funnel and was
rinsed with 50 mL of distilled water. The solid was collected and dried overnight under
high vacuum to afford ethyl 4-hydroxy-2-methylquinoline-3-carboxylate (4.1 g, 57.85%)
as a white solid. mp 224-228 ºC; IR (solid) cm-1 2873, 1717; 1H NMR (DMSO-d6, 400
MHz) δ: 8.06 (dd, J = 8.1, 1.4 Hz, 1H), 7.68 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.54 (d, J =
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8.0 Hz, 1H), 7.35 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 4.24 (q, J = 7.1, 2H), 2.34 (s, 3H), 1.28
(t, J = 7.1, 3H); 13C NMR (DMSO-d6, 100 MHz) δ: 173.8 (s), 167.2 (s), 149.3 (s), 139.6
(s), 132.7 (d), 125.5 (d), 125.0 (s), 124.2 (d), 118.4 (d), 115.3 (s), 60.7 (t), 18.6 (q), 14.6
(q); HRMS Anal. Calcd. for C8H5NO3: C, 67.52; H, 5.67. Found C, 66.68; H, 5.73.
ethyl 6-bromo-4-hydroxy-2-methylquinoline-3-carboxylate
(3.19b): White Solid; mp >260ºC; IR (solid) cm-1 2904, 1704; 1H
NMR (DMSO-d6, 400 MHz) δ: 12.04 (s, 1H, O-H), 8.13 (d, J = 2.3 Hz, 1H), 7.82 (dd, J
= 8.8, 2.3 Hz, 1H), 7.51 (dd, J = 8.0, 1.0 Hz, 1H), 4.25 (q, J = 7.1, 2H), 2.39 (s, 3H), 1.28
(t, J = 7.1, 3H); 13C NMR (DMSO-d6, 100 MHz) δ: 172.5 (s), 166.9 (s), 149.9 (s), 138.5
(s), 135.4 (d), 127.6 (d), 126.5 (s), 121.1 (d), 116.8 (s), 115.5 (s), 60.9 (t), 18.7 (q), 14.6
(q).
ethyl 4-hydroxy-6-iodo-2-methylquinoline-3-carboxylate (3.19c):
White Solid; mp >260ºC; IR (solid) cm-1 2904, 1704; 1H NMR
(DMSO-d6, 400 MHz) δ: 12.04 (s, 1H, O-H), 8.13 (d, J = 2.3 Hz, 1H), 7.82 (dd, J = 8.8,
2.3 Hz, 1H), 7.51 (dd, J = 8.0, 1.0 Hz, 1H), 4.25 (q, J = 7.1, 2H), 2.39 (s, 3H), 1.28 (t, J =
7.1, 3H); 13C NMR (DMSO-d6, 100 MHz) δ: 172.5 (s), 166.9 (s), 149.9 (s), 138.5 (s),
135.4 (d), 127.6 (d), 126.5 (s), 121.1 (d), 116.8 (s), 115.5 (s), 60.9 (t), 18.7 (q), 14.6 (q).
ethyl 4,6-dihydroxy-2-methylquinoline-3-carboxylate (3.19d):
White Solid; mp >260ºC; IR (solid) cm-1 3365, 1705; 1H NMR
(DMSO-d6, 400 MHz) δ: 11.74 (s, 1H, O-H), 9.74 (s, 1H, O-H) 7.42 (d, J = 8.8 Hz, 1H),
7.38 (d, J = 2.8 Hz, 1H), 7.16 (dd, J = 8.8, 2.8 Hz, 1H), 4.22 (q, J = 7.1, 2H), 2.36 (s, 3H),
1.27 (t, J = 7.1, 3H); 13C NMR (DMSO-d6, 100 MHz) δ: 173.3 (s), 167.6 (s), 154.5 (s),
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147.9 (s), 133.0 (s), 126.5 (s), 122.6 (d), 120.0 (d), 113.7 (s), 108.2 (d), 60.6 (t), 18.5 (q),
14.6 (q).
ethyl 4-hydroxy-2-methyl-6-nitroquinoline-3-carboxylate (3.19e):
Yellow Solid; mp >260ºC; IR (solid) cm-1 1708; 1H NMR (DMSOd6, 400 MHz) δ: 8.79 (d, J = 2.6 Hz, 1H), 8.44 (d, J = 9.1, 2.7 Hz, 1H), 7.71 (d, J = 9.2
Hz, 1H), 4.28 (q, J = 7.1, 2H), 2.43 (s, 3H), 1.29 (t, J = 7.1, 3H); 13C NMR (DMSO-d6,
100 MHz) δ: 173.3 (s), 166.4 (s), 151.0 (s), 143.5 (s), 143.4 (s), 126.9 (d), 124.2 (s),
122.0 (d), 120.4 (d), 116.5 (s), 61.1 (t), 18.7 (q), 14.6 (q).
ethyl 7-bromo-4-hydroxy-2-methylquinoline-3-carboxylate
(3.19f): White Solid; mp >260ºC; IR (solid) cm-1 3073, 1711; 1H
NMR (DMSO-d6, 400 MHz) δ: 7.97 (d, J = 8.6 Hz, 1H), 7.71 (d, J = 1.8 Hz, 1H), 7.48
(dd, J = 8.6, 1.8 Hz, 1H), 4.24 (q, J = 7.1, 2H), 2.38 (s, 3H), 1.27 (t, J = 7.1, 3H); 13C
NMR (DMSO-d6, 100 MHz) δ: 173.3 (s), 167.0 (s), 150.2 (s), 141.0 (s), 127.8 (d), 127.1
(d), 125.9 (s), 124.0 (s), 121.0 (d), 115.7 (s), 60.8 (t), 18.9 (q), 14.6 (q).
ethyl 4-hydroxy-2-methyl-7-nitroquinoline-3-carboxylate (3.19g):
Yellow Solid; mp >260ºC; IR (solid) cm-1 1722; 1H NMR (DMSOd6, 400 MHz) δ: 12.32 (s, 1H, O-H), 8.39 (d, J = 2.0 Hz, 1H), 8.28 (d, J = 8.8 Hz, 1H),
8.08 (dd, J = 8.9, 2.2 Hz, 1H), 4.27 (q, J = 7.1, 2H), 2.44 (s, 3H), 1.29 (t, J = 7.1, 3H);
13C NMR (DMSO-d6, 100 MHz) δ: 172.9 (s), 166.6 (s), 151.3 (s), 149.8 (s), 139.4 (s),
128.4 (s) 127.9 (d), 117.8 (d), 116.7 (s), 114.7 (d), 61.1 (t), 18.9 (q), 14.6 (q).
ethyl 8-bromo-4-hydroxy-2-methylquinoline-3-carboxylate (3.19h):
White Solid; mp 133-135ºC; IR (solid) cm-1 3526, 3400, 1715; 1H NMR
(DMSO-d6, 400 MHz) δ: 10.56 (s, 1H, O-H), 8.12 (dd, J = 8.0, 1.4 Hz,
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1H), 8.02 (dd, J = 7.8, 1.4 Hz, 1H), 7.31 (dd, J = 7.8 Hz, 1H), 4.27 (q, J = 7.1, 2H), 2.51
(s, 3H), 1.29 (t, J = 7.1, 3H); 13C NMR (DMSO-d6, 100 MHz) δ: 173.3 (s), 166.8 (s),
150.4 (s), 137.5 (s), 136.7 (d) 126.6 (s), 125.5 (d), 125.2 (d), 116.5 (s), 111.3 (s), 61.1 (t),
18.7 (q), 14.5 (q).
3-bromo-2-methylquinolin-4-ol (3.34b): To a 100 mL roundbottom flask
was added 2-methylquinolin-4-ol (1.2 g, 7.5 mmol), N-bromosuccinimide
(1.3 g, 7.5 mmol), and acetic acid (34 mL, 7.5 mmol). The reaction was stirred at 60°C
and within 15 minutes the white slurry obtained a yellow tint and increased in viscosity.
The reaction was determined complete after 30 minutes via HPLC and TLC, was cooled
to ambient temperature, and diluted with cold distilled water (20 mL). This mixture was
filtered through a Hirsch funnel and the precipitate was washed with cold water (10 mL),
saturated sodium bicarbonate (10 mL), and acetone (20 mL). The precipitate was dried by
pulling air for 15 minutes and was collected to afford 3-bromo-2-methylquinolin-4-ol
(1.6 g, 92%) as a yellow solid. No further purification was performed. mp >260 ºC; IR
(solid) cm-1 2731 (br); 1H NMR (CDCl3, 400 MHz) δ: 8.10 (dd, J = 8.1, 1.2 Hz, 1H),
7.67 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.35 (ddd, J = 8.0, 7.0, 1.0
Hz, 1H), 2.56 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ: 171.4 (s), 149.3 (s), 139.4 (s),
132.2 (d), 125.7 (d) 124.0 (d), 123.3 (s), 118.6 (d), 106.4 (s), 22.0 (q).
3-bromo-4-chloro-2-methylquinoline (3.35b): To a 50 mL roundbottom
flask was added 3-bromo-2-methylquinolin-4-ol (13.1 g, 55 mmol) and
phosphorus oxychloride (25.6 mL, 275 mmol). The reaction was stirred at 80°C for 2
hours before determining complete with HPLC. The reaction was cooled to ambient
temperature and was slowly poured into a 250 mL beaker full of ice (about 100 g). The
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residual material in the flask was rinsed with water and was added to the beaker. The
beaker was maintained at 0°C while the solution was neutralized with sodium hydroxide
pellets and vigorous stirring. Slow addition was required to prevent extreme exotherms.
Once neutral, the solution contained a yellow precipitate. The slurry was stirred for an
additional three hours at ambient temperature then filtered through a Buchner funnel. The
precipitate was collected and dried under vacuum overnight to afford 3-bromo-4-chloro2-methylquinoline (13.8 g, 98%) as a yellow solid. No further purification was
performed. mp 54-56 ºC; IR (solid) cm-1 2913; 1H NMR (CDCl3, 400 MHz) δ: 8.14 (d, J
= 8.1 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.72 (ddd, J = 8.3, 6.7, 1.2 Hz, 1H), 7.51 (dd, J =
7.4 Hz, 1H), 2.89 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ: 158.2 (s), 146.4 (s), 142.0 (s),
130.3 (d), 129.1 (d) 127.5 (d), 125.9 (s), 124.5 (d), 119.8 (s), 27.4 (q).
ethyl 2-(4-chloro-2-methylquinolin-3-yl)-2-oxoacetate (3.39): To a
flame dried 50mL 3-neck roundbottom flask equipped with a low
temperature thermometer was added 3-bromo-4-chloro-2-methylquinoline (1.0 g, 4
mmol), copper(I) bromide-dimethyl sulfide complex (41 mg, 0.20 mmol), and
tetrahydrofuran (7 mL). The solution was cooled to 0⁰C in an ice bath.
Isopropylmagnesium chloride lithium chloride complex (7.7 mL, 10 mmol, 1M in THF)
was added dropwise over 30 minutes via syringe pump. During addition, the solution
changed from a clear, light yellow to a green/yellow solution to black. The reaction was
stirred at 0°C for an additional five minutes following complete addition. An additional
100 mL 3-neck roundbottom flask was prepared with ethyl 2-chloro-2-oxoacetate (0.728
mL, 8 mmol) and tetrahydrofuran (7 mL) and was cooled to 0°C. The Grignard cuprate
was added to the 100 mL flask via cannula at a rate that kept the solution temperature
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below 10°C. The reaction was stirred at 0°C for 15 minutes before determining complete
via HPLC. The reaction was quenched with saturated ammonium chloride (10 mL) and
was stirred for 15 minutes then transferred to a separatory funnel and the aqueous phase
was removed. The organic phase was washed with saturated sodium bicarbonate (10 mL).
The combined aqueous phase was extracted with ethyl acetate (10 mL). The combined
organic phase was washed with brine (10 mL), dried over magnesium sulfate, vacuum
filtered and concentrated in vacuo to afford a brown oil. The residue was
chromatographed using via automated purification over 40 g of silica gel eluted with
hexanes-ethyl acetate using a linear gradient. Product rich fractions were pooled and
evaporated to afford ethyl 2-(4-chloro-2-methylquinolin-3-yl)-2-oxoacetate (700 mg,
47%) as a yellow oil. IR (thin film) cm-1 1736, 1713; 1H NMR (CDCl3, 400 MHz) δ:
8.21 (dd, J = 8.4, 0.9 Hz, 1H), 8.07 (d, J = 8.4, 1H), 7.84 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H),
7.66 (ddd, J = 8.2, 7.0, 1.0 Hz, 1H), 3.98 (s, 3H), 2.69 (s, 3H); 13C NMR (CDCl3, 100
MHz) δ: 186.8 (s), 161.2 (s), 155.5 (s), 148.5 (s), 141.0 (s) 132.1 (d), 129.2 (d), 128.9 (s),
127.8 (d), 124.0 (d), 123.8 (s), 53.7 (q), 23.8 (q).
ethyl 2-(4-chloro-2-methylquinolin-3-yl)-2-hydroxyacetate (3.41):
To a 25 mL roundbottom flask was added ethyl 2-(4-chloro-2methylquinolin-3-yl)-2-oxoacetate (525 mg, 1.9 mmol), tetrahydrofuran (5 mL), and
ethanol (50 µL). The solution was cooled to 0°C then sodium borohydride (71 mg, 1.9
mmol) was added. The reaction was stirred at 0°C for 30 minutes before observing
complete conversion by HPLC. The reaction was diluted with water (5 mL) and was
neutralized with 1N HCl (1-2 mL). The aqueous phase was extracted with
dichloromethane (two 3-mL portions). The organic phase was washed with brine (5 mL),
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dried over sodium sulfate, gravity filtered, and concentrated in vacuo to afford a yellow
oil (711 mg). The residue was chromatographed via automated purification over 12 g of
silica gel eluted with a linear gradient of hexanes-ethyl acetate. Product rich fractions
were pooled and evaporated to afford ethyl 2-(4-chloro-2-methylquinolin-3-yl)-2hydroxyacetate (409 mg, 77%) as a yellow solid. mp 54-56 ºC IR (thin film) 3074, 1745
cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.24 (dd, J = 8.4, 0.9 Hz, 1H), 8.07 (d, J = 8.4, 1H),
7.77 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.62 (ddd, J = 8.2, 7.0, 1.0 Hz, 1H), 6.00 (s, 1H, OH), 4.28 (qd, J = 7.2, 1.4; 1H), 2.80 (s, 3H), 1.22 (t, J = 7.1, 3H); 13C NMR (CDCl3, 100
MHz) δ: 173.0 (s), 158.3 (s), 147.1 (s), 143.5 (s), 130.9 (d), 128.5 (d), 128.0 (s), 127.3
(d), 125.2 (s), 124.7 (d), 69.3 (d), 62.9 (t), 23.9 (q), 14.0 (q).
ethyl 2-hydroxy-2-(4-iodo-2-methylquinolin-3-yl)acetate (3.42):
To a 25 mL roundbottom flask was added ethyl 2-(4-chloro-2methylquinolin-3-yl)-2-hydroxyacetate (409 mg, 1.5 mmol) and tetrahydrofuran (5.0
mL). Hydrochloric acid (1.5 mL, 6.141 mmol, 4M in dioxane) was added to the flask and
the reaction was stirred at ambient temperature for 40 minutes. The solution was
concentrated in vacuo and the residue was diluted in acetonitrile (5.0 mL) then
transferred to a 10-20 mL microwave vial. Sodium iodide (4.4 g, 29.2 mmol) was added
and the vial was sealed. The reaction was heated to 90°C and monitored via HPLC. After
3 hours the reaction was cooled to ambient temperature and the solvent was removed in
vacuo. The red residue was diluted with ethyl acetate (10 mL) and was washed with
saturated sodium bicarbonate (6 mL), 10% sodium thiosulfate (6 mL), and brine (6 mL).
The organic phase was dried over magnesium sulfate, vacuum filtered, and concentrated
in vacou to afford a yellow oil (693 mg). The product was utilized in the proceeding
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reaction without purification. The reaction was determined complete via LRMS [m/z (I)
= 280, m/z (VI) = 372]. The MS solution used was a 50/50 THF/MeOH solvent with
trace NaCl and the samples were analyzed using the LXQ-ESI with direct injection. IR
(thin film) 3061, 1741 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.24 (dd, J = 8.4, 0.9 Hz,
1H), 8.07 (d, J = 8.4, 1H), 7.77 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.62 (ddd, J = 8.2, 7.0, 1.0
Hz, 1H), 6.00 (s, 1H, O-H), 4.28 (qd, J = 7.2, 1.4; 1H), 2.80 (s, 3H), 1.22 (t, J = 7.1, 3H);
13C NMR (CDCl3, 100 MHz) δ: 173.0 (s), 158.3 (s), 147.1 (s), 143.5 (s), 130.9 (d), 128.5
(d), 128.0 (s), 127.3 (d), 125.2 (s), 124.7 (d), 69.3 (d), 62.9 (t), 23.9 (q), 14.0 (q).
ethyl 2-(4-(4-chlorophenyl)-2-methylquinolin-3-yl)-2hydroxyacetate (3.43): To a 10-20 mL microwave vial was added
(4-chlorophenyl)boronic acid (251 mg, 1.6 mmol), potassium
carbonate (606 mg, 4.4 mmol), and tetrakis(triphenylphosphine)palladium (0) (84 mg,
0.73 mmol). The vial was sealed immediately then evacuated and charged with nitrogen
three times. Ethyl 2-hydroxy-2-(4-iodo-2-methylquinolin-3-yl)acetate (543 mg, 1.5
mmol) in N,N-dimethylformamide (4 mL) and water (1 mL) was added to the vial via
syringe. The reaction was heated to 90°C for one hour before determining complete via
HPLC. The reaction was cooled to ambient temperature then diluted with distilled water
(4 mL). The slurry was filtered through a Celite plug and the filtrate was collected. The
aqueous phase was extracted with ethyl acetate (two 3-mL portions). The combined
organic phase was washed with brine (5 mL), dried over magnesium sulfate, vacuum
filtered, and concentrated in vacuo to afford a brown liquid. The residue was
chromatographed via automated purification over 12 g of silica gel eluted with hexanesethyl acetate on a linear gradient in 8 mL fractions. Product rich fractions were pooled
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and evaporated to afford ethyl 2-(4-(4-chlorophenyl)-2-methylquinolin-3-yl)-2hydroxyacetate (329 mg, 63%) as an orange solid. mp 161-164 ºC IR (thin film) 3061,
1741 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.05 (d, J = 8.4 Hz, 1H), 7.69 (ddd, J = 8.3,
6.8, 1.4 Hz, 1H), 7.51 (ddd, J = 8.6, 6.6, 1.5 Hz, 1H), 7.40 (ddd, 8.2, 6.9, 1.1 Hz, 1H)
7.31-7.29 (m, 3H), 5.22 (s, 1H), 4.21 (qd, J = 10.8, 7.2, 2H), 2.74 (s, 3H), 1.21 (t, J = 7.1,
3H); 13C NMR (CDCl3, 100 MHz) δ: 173.8 (s), 158.1 (s), 147.9 (s), 147.0 (s), 134.6 (s),
134.5 (s), 131.6 (d), 130.8 (d), 129.8 (d), 128.9 (d), 128.7 (d), 127.4 (s), 126.5 (d), 126.23
(d), 126.21 (s), 69.8 (d), 62.7 (t), 23.9 (q), 14.1 (q).
ethyl 2-(tert-butoxy)-2-(4-(4-chlorophenyl)-2-methylquinolin-3yl)acetate (3.44c): To a 5 mL conical vial was added ethyl 2-(4-(4chlorophenyl)-2-methylquinolin-3-yl)-2-hydroxyacetate (329 mg, 0.9
mmol) and tert-butyl acetate (3.1 mL, 0.9 mmol) which developed an orange/yellow
slurry. Perchloric acid (238 µL, 2.8 mmol) was then added which resulted in an
immediate color change to a dark orange/brown solution. The reaction was stirred at
ambient temperature for three hours and resulted in a 71% conversion by HPLC. The
reaction was diluted with water (1 mL) and quenched via dropwise addition of saturated
sodium bicarbonate until pH 7 was reached. The aqueous phase was extracted with ethyl
acetate (three 3-mL portions). The combined organic phase was washed with saturated
sodium bicarbonate (5 mL) and brine (5 mL), dried over magnesium sulfate, vacuum
filtered, and concentrated in vacuo. The residue was chromatographed over 4 g of silica
gel eluted with hexanes-ethyl acetate (25 mL 9:1→25 mL 4:1→25 mL 2:1→25 mL 1:1)
in 3 mL fractions. Product rich fractions were pooled and evaporated to afford ethyl 2(tert-butoxy)-2-(4-(4-chlorophenyl)-2-methylquinolin-3-yl)acetate (271 mg, 71%) as a
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yellow oil. IR (thin film) cm-1 1750; 1H NMR (CDCl3, 400 MHz) δ: 8.05 (d, J = 8.1 Hz,
1H), 7.66 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 7.53 (m, 2H), 7.46 (m, 1H), 7.37 (ddd, 8.3, 6.8,
1.2 Hz, 1H), 7.29-7.26 (m, 2H), 5.10 (s, 1H), 4.19 (dq, J = 10.8, 7.2 Hz, 2H), 2.85 (s,
3H), 1.23 (t, J = 7.1, 3H), 1.00 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 172.4 (s), 159.4
(s), 146.8 (s), 145.2 (s), 134.7 (s), 134.6 (s), 132.3 (d), 131.2 (d), 129.6 (s), 129.3 (d),
128.8 (d), 128.7 (d), 128.3 (d), 126.3 (d), 126.1 (s), 125.9 (d) 76.1 (s), 70.8 (d), 61.4 (t),
28.1 (q), 24.9 (q), 14.1 (q).
2-(tert-butoxy)-2-(4-(4-chlorophenyl)-2-methylquinolin-3-yl)acetic
acid (3.21c): To a 0.5-2.0 mL microwave vial was added a 0.3 molar
solution of ethyl 2-(tert-butoxy)-2-(4-(4-chlorophenyl)quinolin-3yl)acetate (39 mg, 0.1 mmol) in ethanol (333 µL, 0.1 mmol). Aqueous sodium hydroxide
(75 µL, 0.150 mmol, 2N) was added and the vial was sealed. The reaction was heated to
60°C. After a total of 3.5 hours the reaction was neutralized with 1N HCl and the
aqueous phase was extracted with ethyl acetate (0.5 mL). The organic phase was dried
through a pasteurre pipette containing a magnesium sulfate plug and concentrated in
vacuo. The residue was chromatographed over 4 g of silica gel elued with methanoldichloromethane (25 mL 1% MeOH→ 25 mL 2% MeOH→ 25 mL 3% MeOH→ 25 mL
4% MeOH→ 25 mL 5% MeOH) in 3 mL fractions. Product rich fractions were pooled
and evaporated to afford 2-(tert-butoxy)-2-(4-(4-chlorophenyl)quinolin-3-yl)acetic acid
(14 mg, 40%) as a white solid. mp 122-125 ºC, IR (thin film) 1730, 3060 cm-1; 1H NMR
(CDCl3, 400 MHz) δ: 8.16 (d, J = 8.3 Hz, 1H), 7.71 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 7.68
(m, 1H), 7.56 (dd, J = 9.2, 2.1, 1H), 7.54 (dd, J = 9.2, 2.1, 1H), 7.43 (ddd, J = 8.3, 6.7,
0.8, 1H), 7.37 (dd, 8.3, 0.8 Hz, 1H), 7.29 (dd, J = 8.1, 2.2, 1H), 5.24 (s, 1H), 2.89 (s, 3H),
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1.02 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 172.1 (s), 158.2 (s), 147.5 (s), 135.2 (s),
133.8 (s), 132.8 (d), 130.9 (d), 130.3 (d), 129.3 (s), 128.8 (s), 128.3 (d), 127.7 (d), 126.7
(d), 126.5 (d), 126.0 (s) 77.9 (s), 70.6 (d), 28.2 (q), 24.1 (q).
ethyl 2-(tert-butoxy)-2-(4-iodo-2-methylquinolin-3-yl)acetate
(3.45): To a 5.0 mL conical vial was added ethyl 2-hydroxy-2-(4iodo-2-methylquinolin-3-yl)acetate (91 mg, 0.25 mmol) and tertbutyl acetate (817 µL, 0.25 mmol). Perchloric acid (44 µL, 0.74 mmol) was then added to
the vial and the reaction was stirred at ambient temperature. After a total of 3 hours, the
reaction was quenched with water (1 mL) and was neutralized to pH 7.0 with saturated
sodium bicarbonate. The solution was extracted with ethyl acetate (three 1-mL portions)
and the combined organic phase was washed with saturated sodium bicarbonate (1 mL)
and brine (1 mL), dried over sodium sulfate, gravity filtered, and concentrated in vacou to
afford a yellow oil (110 mg). The residue was chromatographed over 4 g of silica gel
eluted with hexanes-ethyl acetate (25 mL 4:1→ 25 mL 2:1→ 25 mL 1:1) in 5 mL
fractions. Product rich fractions were pooled and evaporated to afford ethyl 2-(tertbutoxy)-2-(4-iodo-2-methylquinolin-3-yl)acetate (78 mg, 74%) as a yellow oil. IR (thin
film) 1750 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.12 (dd, J = 8.4, 1.0 Hz, 1H), 7.95 (dd,
J = 8.3, 0.8, 1H), 7.69 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.56 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H),
5.93 (s, 1H), 4.18 (dq, J = 10.8, 7.1 Hz; 1H), 2.83 (s, 3H), 1.26 (s, 9H), 1.18 (t, J = 7.1
Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ: 171.3 (s), 158.8 (s), 146.7 (s), 136.9 (s), 133.2
(d), 130.1 (d), 129.4 (s), 128.8 (d), 127.5 (d), 120.5 (s), 80.2 (d), 76.7 (s), 61.6 (t), 28.3
(q), 24.7 (q), 14.1 (q).
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General Procedure for the Preparation of 4-Aryl Quinolines (3.44a-k): To a 0.5-2.0
mL microwave vial was added ethyl 2-(tert-butoxy)-2-(4-iodo-2-methylquinolin-3yl)acetate (100 mg, 0.25 mmol), boronic acid (0.50 mmol), potassium carbonate (0.70
mmol), and tetrakis(triphenylphosphine)palladium(0) (0.05 mmol). The vial was
immediately sealed then evacuated and charged with nitrogen three times.
Dimethylformamide (800 µL) and water (80 µL) were then added via syringe. The
reaction was heated to 90ºC for a total of 3-16 hours and were monitored via HPLC and
TLC. The reaction was cooled to ambient temperature then diluted with water (1 mL) and
ethyl acetate (2 mL). The aqueous phase was removed and the organic phase was filtered
through a Celite® plug. The filtrate was washed with water (five 1-mL portions), dried
over magnesium sulfate, gravity filtered, and concentrated to afford a crude oil. The
residue was chromatographed over 12 g of silica gel eluted with hexanes-acetone
(9:1→4:1→2:1). Product rich fractions were pooled and evaporated to isolate the 4-aryl
quinoline products.
ethyl 2-(tert-butoxy)-2-(2-methyl-4-phenylquinolin-3-yl)acetate
(3.44a): yellow oil; IR (solid) cm-1 1749; 1H NMR (CDCl3, 400
MHz) δ: 8.05 (d, J = 8.4 Hz, 1H), 7.64 (ddd, J = 8.3, 4.4, 3.8 Hz, 1H),
7.55-7.48 (m, 4H), 7.34-7.31 (m, 3H); 13C NMR (CDCl3, 100 MHz) δ: 172.6 (s), 159.4
(s), 146.8 (s), 146.5 (s), 136.2 (s), 130.7 (d), 129.9 (d), 129.6 (s), 129.2 (d), 128.5 (d),
128.45 (d), 128.4 (d), 128.0 (d), 126.7 (d), 126.3 (s), 125.7 (d), 76.0 (s), 70.8 (d), 61.3 (t),
28.1 (q), 24.9 (q), 14.1 (q).
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ethyl 2-(tert-butoxy)-2-(4-(4-fluorophenyl)-2-methylquinolin-3yl)acetate (3.44b): yellow oil; IR (solid) 1752 cm-1; 1H NMR
(CDCl3, 400 MHz) δ: 8.04 (d, J = 8.3 Hz, 1H), 7.66 (ddd, J = 8.3, 6.7,
1.5 Hz, 1H), 7.50 (m, 1H), 7.37 (ddd, J = 8.3, 6.7, 1.5 Hz, 1H), 7.32-7.29 (m, 2H), 7.257.21 (m, 2H), 5.12 (s, 1H), 4.19 (qd, J = 10.8, 7.1 Hz, 2H), 2.85 (s, 3H), 1.23 (t, J = 7.1
Hz, 3H), 0.99 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 172.5 (s), 163.9 (s), 161.5 (s),
159.4 (s), 146.8 (s), 145.5 (s), 132.6 (d, 3J = 8 hz), 132.1 (s), 131.6 (d, 3J = 8.0 hz),
128.5 (s, 1J = 350 Hz), 129.3 (d), 128.6 (d), 126.4 (d), 125.9 (d), 115.6 (d, 2J = 21 Hz),
115.1 (d, 2J = 21 Hz), 76.1 (s), 70.8 (d), 61.4 (t), 28.1 (q), 24.9 (q), 14.1 (q).
ethyl 2-(tert-butoxy)-2-(2-methyl-4-(4(trifluoromethyl)phenyl)quinolin-3-yl)acetate (3.44d): yellow oil;
1H NMR (CDCl3, 400 MHz) δ: 8.07 (d, J = 8.4 Hz, 1H), 7.82 (m,
2H), 7.68 (m, 2H), 7.49 (m, 1H), 7.38 (ddd, J = 8.0, 6.4, 0.8 Hz, 1H), 7.22 (d, J = 8.2 Hz,
1H), 5.03 (s, 1H), 4.20 (dq, J = 10.8, 7.1 Hz, 2H), 2.87 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H),
1.00 (s, 9H) ; 13C NMR (CDCl3, 100 MHz) δ: 172.2 (s), 159.4 (s), 146.7 (s), 145.0 (s),
140.2 (s), 131.4 (d), 130.7 (s, 2J = 32 Hz), 130.2 (d), 129.5 (d), 127.6 (s, 1J = 370 Hz),
128.6 (d), 126.2 (d), 125.8 (s), 125.5 (d, 3J = 3.6 Hz), 124.9 (d, 3J = 3.6 Hz), 76.2 (s), 70.8
(d), 61.5 (t), 28.0 (q), 24.8 (q), 14.1 (q).
ethyl 2-(tert-butoxy)-2-(2-methyl-4-(p-tolyl)quinolin-3-yl)acetate
(3.44e): yellow oil; IR (solid) 1750 cm-1; 1H NMR (CDCl3, 400
MHz) δ: 8.03 (d, J = 8.4 Hz, 1H), 7.64 (ddd, J = 8.3, 6.2, 2.1 Hz, 1H),
7.39-7.32 (m, 5H), 7.22-7.20 (m, 1H), 5.19 (s, 1H), 4.19 (dq, J = 10.7, 7.1 Hz, 2H), 2.84
(s, 3H), 2.49 (s, 3H), 1.23 (t, J = 7.1 Hz, 3H), 0.98 (s, 9H); 13C NMR (CDCl3, 100 MHz)
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δ: 172.7 (s), 159.4 (s), 146.8 (s), 146.7 (s), 138.2 (s), 133.1 (s), 130.6 (d), 129.8 (d), 129.7
(s), 129.2 (d), 129.1 (d), 128.6 (d), 128.5 (d), 126.8 (d), 126.5 (s), 125.6 (d), 76.0 (s), 70.8
(d), 61.3 (t), 28.1 (q), 24.8 (q), 21.4 (q), 14.1 (q).
ethyl 2-(tert-butoxy)-2-(4-(4-cyanophenyl)-2-methylquinolin-3yl)acetate (3.44f): Black oil; IR (solid) 2230, 1747 cm-1; 1H NMR
(CDCl3, 400 MHz) δ: 8.07 (d, J = 8.4 Hz, 1H), 7.86 (dd, J = 5.1, 1.1
Hz, 2H), 7.71-7.65 (m, 3H), 7.47-7.45 (m, 1H), 7.38 (dd, J = 8.1, 0.9 Hz, 1H), 4.98 (s,
1H), 4.19 (dq, J = 10.8, 7.1 Hz, 2H), 2.87 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H), 0.99 (s, 9H);
13C NMR (DMSO-d6, 100 MHz) δ: 172.1 (s), 159.3 (s), 146.8 (s), 144.4 (s), 141.4 (s),
132.2 (d), 131.9 (d), 131.7 (d), 130.6 (d), 129.6 (d), 129.2 (s), 128.8 (d), 127.9 (d), 126.3
(d), 125.4 (s), 118.4 (s), 112.6 (s), 76.2 (s), 70.8 (d), 61.6 (t), 28.0 (q), 24.9 (q), 14.1 (q).

ethyl 2-(4-(4-acetylphenyl)-2-methylquinolin-3-yl)-2-(tertbutoxy)acetate (3.44g): White Solid; mp 135-137ºC; 1H NMR
(CDCl3, 400 MHz) δ: 8.14 (dd, J = 7.3, 1.3 Hz, 2H), 8.06 (d, J = 8.5
Hz, 1H), 7.67 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 7.63 (dd, J = 8.8, 1.7 Hz, 1H), 7.45 (dd, 8.7,
1.5 Hz, 1H), 7.36 (ddd, J = 8.2, 6.8, 1.1 Hz, 1H), 7.23 (dd, J = 8.4, 0.7 Hz, 1H), 5.05 (s,
1H), 4.19 (qd, J = 10.8, 7.1 Hz, 2H), 2.85 (s, 3H), 2.73 (s, 3H), 1.24 (t, J = 7.1, 3H), 0.98
(s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 197.6 (s), 172.3 (s), 159.4 (s), 146.8 (s), 145.3
(s), 141.4 (s), 136.9 (s), 131.3 (d), 130.2 (d), 129.4 (d), 129.3 (s), 128.7 (d), 128.4 (d),
127.9 (d), 126.2 (d), 126.0 (d), 125.7 (s), 76.1 (s), 70.8 (d), 61.5 (t), 28.1 (q), 26.7 (q),
24.9 (q), 14.2 (q).
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ethyl 2-(4-([1,1'-biphenyl]-4-yl)-2-methylquinolin-3-yl)-2-(tertbutoxy)acetate (3.44h): Yellow oil; 1H NMR (CDCl3, 400 MHz) δ:
8.06 (d, J = 8.4 Hz, 1H), 7.79-7.77 (m, 2H), 7.74 (m, 2H), 7.66 (ddd,
J = 8.2, 6.6, 1.5, 1H), 7.58 (m, 1H), 7.53-7.49 (m, 2H), 7.44-7.35 (m,
4H), 5.22 (s, 1H), 4.21 (dq, J = 10.8, 7.1 Hz, 2H), 2.86 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H),
0.99 (s, 9H); 13C NMR (DMSO-d6, 100 MHz) δ: 172.6 (s), 159.5 (s), 146.8 (s), 146.3
(s), 140.3 (s), 135.2 (s), 131.2 (d), 130.4 (d), 129.7 (s), 129.2 (d), 129.0 (d), 128.6 (d),
127.8 (d), 127.1 (d), 127.0 (d), 126.7 (d), 126.5 (d), 126.3 (s), 125.8 (d), 76.1 (s), 70.9
(d), 61.4 (t), 28.1 (q), 24.9 (q), 14.2 (q).
ethyl 2-(4-(4-acetamidophenyl)-2-methylquinolin-3-yl)-2-(tertbutoxy)acetate (3.44i): yellow oil; IR (solid) cm-1 1747, 1673; 1H
NMR (CDCl3, 400 MHz) δ: 8.04 (d, J = 8.4, 1H), 7.93 (s, 1H, N-H),
7.76 (d, J = 8.7, 2H), 7.64 (ddd, J = 8.3, 5.4, 3.1 Hz, 1H), 7.46 (dd, J
= 9.3, 2.2 Hz, 1H), 7.36-7.34 (m, 2H), 7.28 (d, J = 2.1, 1H), 5.19 (s, 1H), 4.19 (dq, 10.8,
7.1, 2H), 2.84 (s, 3H), 2.25 (s, 3H), 1.22 (t, J = 7.1, 3H), 0.97 (s, 9H); 13C NMR
(DMSO-d6, 100 MHz) δ: 172.6 (s), 168.8 (s), 159.4 (s), 146.7 (s), 146.2 (s), 138.5 (s),
131.6 (s), 131.4 (d), 130.6 (d), 129.8 (s), 129.3 (d), 128.3 (d), 126.7 (d), 126.4 (s), 125.8
(d), 119.3 (d), 118.9 (d), 76.1 (s), 70.8 (d), 61.4 (t), 28.1 (q), 24.72 (q), 24.70 (q), 14.1
(q).
ethyl 2-(tert-butoxy)-2-(2-methyl-4-(pyrimidin-5-yl)quinolin-3yl)acetate (3.44j): yellow oil; IR (solid) 1743 cm-1; 1H NMR
(CDCl3, 400 MHz) δ: 9.40 (s, 1H), 8.90 (d, J = 2.8 Hz, 1H), 8.69 (d,
J = 2.8, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.73 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 7.44 (ddd, J =
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8.5, 6.9, 1.2 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 5.04 (s, 1H), 4.16 (dq, 10.9, 7.1, 2H), 2.91
(t, J = 7.1, 3H), 1.23 (s, 3H), 1.04 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 171.7 (s),
158.7 (s), 158.5 (d), 158.4 (d), 156.8 (d), 146.8 (s), 139.3 (s), 130.7 (s), 130.6 (s), 129.9
(d), 129.0 (d), 126.7 (d), 126.1 (s), 125.3 (d), 76.5 (s), 70.5 (d), 61.7 (t), 28.0(q), 24.9 (q),
14.1 (q).
ethyl 2-(tert-butoxy)-2-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)2-methylquinolin-3-yl)acetate (3.44k): The product was isolated as
a mixture of atropisomers. yellow oil; IR (solid) cm-1 1747, 1673; 1H
NMR (CDCl3, 400 MHz) δ: 8.03 (d, J = 8.3, 1H), 7.64 (dt, J = 6.9,
1.4 Hz, 1H), 7.47-7.35 (m, 2H), 7.04-6.96 (m, 2H), 6.84-6.78 (m, 1H), 5.25 (s, 1H), 4.384.30 (m, 4H) 4.24-4.11 (m, 2H), 2.83 (s, 3H), 1.23 (t, J = 7.1 Hz, 3H), 1.01 (s, 9H); 13C
NMR (CDCl3, 100 MHz) δ: [172.7, 172.5] (s), 159.4 (s), 146.8 (s), 146.1 (s), [143.7,
143.6] (s), 143.5 (s), 143.0 (s), 129.8 (s), [129.2, 129.1] (d), [128.47, 128.46] (d),
[126.82, 126.78] (d), [126.55, 126.46] (s), [125.68, 125.64] (d), 124.0 (d), 123.1 (d),
120.0 (d), [119.95, 119.77] (d), 118.95 (d), [117.45, 117.29] (d), 116.7 (d), 115.5 (d),
[76.02, 75.98] (s), [70.83, 70.80] (d), [64.49, 64.47] (t), [64.44, 64.36] (t), [61.38, 61.31]
(t), 28.1 (q), 24.8 (q), 14.13 (q).
General Procedure for Ethyl Ester Hydrolysis (3.21a-k): To a solution of ethyl ester
quinoline (1.0 equiv.) and ethanol (3.5 mL) was added aqueous 50% sodium hydroxide (3
equiv.). The reaction was heated to 60ºC and was stirred until 100% conversion was
observed by HPLC. The solution was cooled to ambient temperature and was neutralized
with 1N HCl to pH 5. The solution was extracted with chloroform-d6 (two 0.5-mL
portions) and the combined organic phase was dried over magnesium sulfate, filtered, and
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examined via 1H-NMR. Carboxylic acid products requiring purification were
chromatographed over 4g of silica gel eluted with dichloromethane-methanol (0%
methanol→5% methanol→10% methanol). Product rich fractions were pooled and
evaporated to afford desired acids(3.21a-3.21k).
2-(tert-butoxy)-2-(2-methyl-4-phenylquinolin-3-yl)acetic acid
(3.21a): yellow oil; IR (solid) 1719 cm-1; 1H NMR (CDCl3, 400 MHz)
δ: 8.96 (s, 1H, O-H), 8.11 (d, J = 8.4 Hz, 1H), 7.73 (d, J = 6.7 Hz, 1H),
7.66 (ddd, J = 8.3, 6.3, 2.0 Hz, 1H), 7.58-7.51 (m, 3H), 7.41-7.33 (m, 3H), 5.29 (s, 1H),
2.88 (s, 3H), 0.97 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 173.2 (s), 158.5 (s), 148.2 (s),
146.1 (s), 135.6 (s), 131.3 (d), 129.77 (d), 129.75 (d), 129.2 (s), 128.8 (d), 128.7 (d),
127.9 (d), 127.8 (d), 126.8 (d), 126.3 (s), 126.2 (d), 70.7 (d), 28.1 (q), 24.1 (q).
2-(tert-butoxy)-2-(4-(4-fluorophenyl)-2-methylquinolin-3-yl)acetic
acid (3.21b): yellow oil; IR (Thin Film) 1730 cm-1 1724; 1H NMR
(CDCl3, 400 MHz) δ: 8.17 (d, J = 8.2 Hz, 1H), 7.75 (dd, J = 5.7 Hz,
1H), 7.66 (ddd, J = 8.0, 5.5, 1.6 Hz), 7.41-7.22 (m, 5H), 5.22 (s, 3H), 2.93 (s, 3H), 0.99
(s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 174.0 (s), 164.1 (s), 161.7 (s), 159.0 (s), 147.5
(s), 144.8 (s), 133.2 (d), 131.5 (d), 131.4 (s), 130.8 (s), 130.1 (d), 126.9 (d), 126.6 (d),
115.9 (d), 115.1 (d), 76.7 (s), 70.7 (d), 28.1 (q), 23.4 (q).
2-(tert-butoxy)-2-(2-methyl-4-(4-(trifluoromethyl)phenyl)quinolin3-yl)acetic acid (3.21d): yellow oil; IR (solid) 1730 cm-1; 1H NMR
(CDCl3, 400 MHz) δ: 10.33 (s, 1H, O-H), 8.18 (d, J = 8.4 Hz, 1H),
7.90-7.82 (m, 3H), 7.70 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.41 (t, J
= 8.2 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 5.14 (s, 1H), 2.94 (s, 3H), 1.00 (s, 9H); 13C
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NMR (CDCl3, 100 MHz) δ: 173.3 (s), 158.8 (s), 146.9 (s), 145.3 (s), 139.5 (s), 131.8 (d),
131.0 (s, 2J = 32 Hz), 130.3 (d), 130.0 (d), 129.9 (s), 127.2 (d), 126.8 (d), 126.3 (d), 125.9
(s), 125.8 (d, 3J = 3.5 Hz), 125.3 (s), 124.9 (d, 3J = 3.5 Hz), 123.9 (s, 1J = 270 Hz), 77.2
(s), 70.7 (d), 28.1 (q), 23.7 (q).
2-(tert-butoxy)-2-(2-methyl-4-(p-tolyl)quinolin-3-yl)acetic acid
(3.21e): clear, colorless oil; IR (solid) 3313, 1607 cm-1; 1H NMR
(CD3OD, 400 MHz) δ: 7.83 (d, J = 8.1 Hz, 1H), 7.69 (m, 1H), 7.51
(ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.35 (dd, J = 8.4, 1.0 Hz, 1H), 7.27-7.24 (m, 3H), 7.12 (m,
1H); 13C NMR (CD3OD, 100 MHz) δ: 178.0 (s), 160.2 (s), 146.5 (s), 145.6 (s), 138.0 (s),
133.9 (s), 133.3 (s), 131.2 (d), 130.2 (d), 128.7 (d), 128.4 (d), 127.8 (d), 126.56 (d),
126.61 (s), 126.4 (d), 125.3 (d), 74.6 (s), 72.3 (d), 27.3 (q), 23.4 (q), 20.0 (q).
2-(tert-butoxy)-2-(4-(4-cyanophenyl)-2-methylquinolin-3-yl)acetic
acid (3.21f): white solid; mp >260 ºC; IR (solid) 3073, 2226, 1713 cm1

; 1H NMR (CDCl3, 400 MHz) δ: 8.12 (d, J = 8.4 Hz, 1H), 7.85-7.83

(m, 3H), 7.70 (dd, J = 7.4 Hz, 1H), 7.47 (d, J = 7.7 Hz, 1H), 7.41 (dd,
7.7 Hz, 1H), 7.22 (d, J = 8.3 Hz, 1H), 5.07 (s, 3H), 2.89 (s, 3H), 0.98 (s, 9H); 13C NMR
(CDCl3, 100 MHz) δ: 172.1 (s), 158.6 (s), 145.9 (s), 140.8 (s), 132.5 (d), 132.3 (d), 131.7
(d), 130.5 (d), 130.2 (d), 129.5 (s), 127.8 (d), 126.8 (d), 125.9 (d), 125.5 (s), 118.3 (s),
112.9 (s), 77.2 (s), 70.7 (d), 28.1 (q), 24.1 (q).
2-(4-(4-acetylphenyl)-2-methylquinolin-3-yl)-2-(tert-butoxy)acetic
acid (3.21g): Yellow oil; 1H NMR (CDCl3, 400 MHz) δ: 8.16-8.11 (m,
3H), 7.85 (d, J = 7.2 Hz, 1H), 7.69 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.47
(m, 1H), 7.39 (ddd, J = 8.0, 6.9, 1.0 Hz, 1H), 7.29 (d, J = 7.8 Hz, 1H),
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5.19 (s, 1H), 2.89 (s, 3H), 2.72 (s, 3H), 1.01 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ:
198.0 (s), 172.5 (s), 158.4 (s), 147.0 (s), 146.3 (s), 140.7 (s), 137.2 (s), 131.8 (d), 130.0
(d), 128.9 (d), 128.7 (s), 128.1 (d), 127.7 (d), 126.5 (d), 126.3 (d), 125.7 (s), 77.7 (s), 70.7
(d), 28.2 (q), 26.7 (q), 24.3 (q).
2-(4-([1,1'-biphenyl]-4-yl)-2-methylquinolin-3-yl)-2-(tertbutoxy)acetic acid (3.21h): white solid mp 198-200ºC; IR (solid)
3356, 1600 cm-1; 1H NMR (CD3OD, 400 MHz) δ: 8.00 (d, J = 8.1, 1H),
7.95 (m, 1H), 7.85 (dd, J = 5.7, 1.6 Hz, 1H), 7.83 (dd, J = 5.7, 1.6 Hz,
1H), 7.75 (d, J = 7.1 Hz, 2H), 7.68 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 7.52-7.37 (m, 6H),
5.22 (s, 1H), 2.92 (s, 3H), 0.97 (s, 9H); 13C NMR (CD3OD, 100 MHz) δ: 177.0 (s), 159.9
(s), 146.6 (s), 145.5 (s), 141.2 (s), 140.2 (s), 135.1 (s), 133.0 (s), 131.6 (d), 130.8 (d),
128.9 (d), 128.6 (d), 127.9 (s), 127.4 (d), 126.7 (d), 126.6 x2 (d), 126.4 (d), 125.9 (d),
125.7 (d), 75.1 (s), 71.8 (d), 27.3 (q), 23.2 (q).
2-(4-(4-acetamidophenyl)-2-methylquinolin-3-yl)-2-(tertbutoxy)acetic acid (3.21i): yellow solid; mp 205-207ºC; 1H NMR
(CD3OD, 400 MHz) δ: 7.99 (d, J = 8.4, 1H), 7.84 (dd, J = 8.3, 2.2 Hz,
1H), 7.79 (dd, J = 8.3, 2.1, 1H), 7.73 (dd, J = 8.3, 4.1 Hz, 1H), 7.59 (dd,
J = 8.3, 2.0 Hz, 1H), 7.46 (dd, J = 4.4, 0.8, 1H), 7.32 (dd, J = 8.3, 2.0, 1H), 5.26 (s, 1H),
2.83 (s, 3H), 2.20 (s, 3H), 0.97 (s, 9H); 13C NMR (CD3OD, 100 MHz) δ: 174.7 (s), 170.5
(s), 159.1 (s), 147.7 (s), 145.4 (s), 139.4 (s), 131.0 (d), 130.8 (s), 130.5 (d), 129.7 (d),
126.6 (d), 126.4 (s), 126.3 (d), 119.4 (d), 119.0 (d), 75.9 (s), 70.5 (d), 27.0 (q), 22.7 (q),
22.5 (q).
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2-(tert-butoxy)-2-(2-methyl-4-(pyrimidin-5-yl)quinolin-3-yl)acetic
acid (3.21j): yellow oil; IR (solid) 1734 cm-1; 1H NMR (CDCl3, 400
MHz) δ: 9.29 (s, 1H), 9.00 (s, 1H), 8.73 (s, 1H), 8.13 (d, J = 8.4 Hz,
1H), 7.72 (dd, J = 7.6 Hz, 1H), 7.42 (dd, J = 7.9 Hz, 1H), 7.15 (d, J = 8.4, 1H), 5.26 (s,
1H), 3.03 (s, 3H), 1.06 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 173.1 (s), 159.6 (d),
155.6 (d), 146.5 (s), 139.8 (s), 130.8 (s), 130.1 (d), 128.7 (d), 126.9 (d), 126.5 (s), 125.1
(d), 77.2 (s), 69.7 (d), 28.0 (q), 24.5 (q).
2-(tert-butoxy)-2-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2methylquinolin-3-yl)acetic acid (3.21k) The product was isolated as a
mixture of atropisomers. yellow oil; IR (solid) 1717 cm-1; 1H NMR
(CDCl3, 400 MHz) δ: 8.22-8.20 (m, 1H), 7.67-7.63 (m, 1H), 7.54-7.31
(m, 3H), 7.05-7.00 (m, 1H), 6.89-6.78 (m, 1H), 5.35 (s, 1H), 4.37-4.34 (m, 4H) 2.94 (s,
3H), 1.00 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 173.7 (s), 158.9 (s), 148.5 (s),
[144.05, 144.00] (s), 143.6 (s), 143.0 (s), [132.2, 132.1] (d), [130.9, 130.6] (s), 130.1 (d),
[128.6, 128.5] (d), [128.4, 128.3] (s), [126.96, 126.93] (d), [126.7, 126.6] (s), [126.5,
126.4] (d), 124.5 (d), 122.9 (d), 120.3 (d), 119.8 (d), [118.9, 118.8] (d), [117.6, 117.4]
(d), [116.9, 116.8] (d), 115.5 (d), 76.9 (s), [70.77, 70.74] (d), [64.50, 64.48] (t), [64.46,
64.44] (t), [28.19, 28.16] (q), [23.23, 23.17] (q).
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CHAPTER IV – THEORETICAL AND EXPERIMENTAL INVESTIGATION OF A
VINYL SULFOXIDE-CARBODIIMIDE ANNULATION VIA [3,3]-SIGMATROPIC
REARRANGEMENT AND RING CLOSURE
4.1 Introduction
4.1.1 Importance of Vicinal Diamines
1,2-Diamines have proven to exhibit a wide variety of applications within many
fields of chemistry and biology. Biologically, vicinal diamines contain great importance
among pharmacological applications and biochemical processes.94 These versatile
compounds have also found use among supramolecular and host-guest chemistry.
Furthermore, organic synthesis has extensively utilized vicinal diamines as intermediates
for heterocycles, construction of nitrogen containing macrocycles, and chiral ligands for
asymmetric synthesis (Figure 4.1).94

Figure 4.1 Examples of vicinal diamines.
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4.1.2 Vicinal Diamines in Organic Synthesis
4.1.2.1 Chiral Auxiliaries in Diastereoselective Synthesis
Significant progress has been made with the use of 1,2-diamines as chiral
auxiliaries in diastereoselective synthesis. Most notably is the discovery of asymmetric
olefination via the Wittig reaction utilizing chiral bicyclic phosphonamides. Hanessian
and coworkers were able to produce olefinated ketones in greater than 80% optical purity
and above when utilizing these chiral auxiliaries.95 A wide variety of processes have also
been examined through the use of chiral 3-acyl-imidazolidin-2-ones. Among these
include alkylation studies of 3-acyl-imidazolidin-2-ones96 (Scheme 4.1) and the use of
imidazolidin-2-ones as chiral auxiliaries. The Davies group utilized dibutylboron enolates
derived from chiral imidazolidin-2-ones in aldol reactions to produce 1,3-diols in
homochiral form.97 There has also been significant progress in the use of boroncontaining chiral auxiliaries derived from 1,2-diphenylethylenediamine (Scheme 4.1).
The resultant diazaborilidine has been extensively studied in enantioselective synthesis of
syn- and anti-aldol reactions, enantio- and diastereoselective synthesis of anti-β-amino
thioesters, anti-α-bromo β-hydroxy esters, and an Ireland-Claisen rearrangement of
achiral allylic esters.98
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Scheme 4.1 Vicinal diamines in diastereoselective synthesis.
4.1.2.2 Chiral Ligands in asymmetric Synthesis
Vicinal diamines have also found to have significant applications as chiral ligands
in asymmetric synthesis. Some of the most influential reactions include aldehyde
alkylations, aldol reactions, and Diels-Alder chemistry. Mukaiyama and coworkers
performed studies employing chiral bipyrrolidines as a ligand for asymmetric alkylation
of aldehydes to yield products in high optical purity (Scheme 4.2).99 These results were
later applied to aldol reactions which utilized achiral silenol ethers and achiral aldehydes
in the presence of chiral diamine-coordinated tin (II) triflate to afford enantiopure aldol
products (Scheme 4.2).100
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Scheme 4.2 Vicinal diamines as chiral ligands.
A chiral aluminum catalyst, diazaaluminolidine, has been utilized by Corey and
coworkers in Diels-Alder chemistry to afford enantiopure adducts.101 Further application
of this concept was achieved by the Evans group through the use of Cu(II) bisimine
ligands to yield product in 94% ee (Schem 4.3).102

Scheme 4.3 Diels-Alder chemistry of the Evans group.
4.1.3 Vicinal Diamines in Medicinal Chemistry
Vicinal diamines exhibit significant biological applications for medicinal
treatments. There are a variety of naturally occurring diamines that have potent
antibacterial effects, including penicillins and cephalosporins.103 Synthetic diamino
compounds have also been utilized as antifilarial and antitubercular agents.104 In the late
1960s, an effective diamino platinum compound named cisplatin was reported for the
effective antitumor properties.105 Since this discovery, the use of alternative 1,2-diamino
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platinum compounds have been employed in place of cisplatin due to decreased toxicity
and ability to prevent tumors from developing resistances.106 Affinity for the µ, δ, and κ
opioid receptor sites has also been expressed by vicinal diamines. Of particular interest is
US-50,488, a diaminocyclohexane derivative, which has expressed high affinity for the κ
receptor site.107 Further studies of the κ receptor site and improvements to diamino
derivatives have been made due to a comparable decrease in dependency complications
that can arise from opioids such as morphine which bind to the µ receptor site.108-109
4.1.4 Vicinal Diamines in Natural Products
Vicinal diamines have a significant presence among a wide range of natural
products. The indications of these natural products include antibiotic activity, anti-cancer
properties, and neurological inhibition/excitation characteristics. Commonly known
antibiotics include penicillin and cephalosporins. Other antibiotics include edeines,
peptides containing five amino acid residues,110 and tuberactomycin derivatives, peptides
effective against tubercular bacilli.111 Chemotherapeutic agents used for treatment of
malignant lymphomas and squamous cell carcinomas include the glycopeptide family
which contain a 2,3-diaminopropanamide residue. These glycopeptides, which are
characterized as bleomycins, have been found to possess DNA cleavage and degradation
abilities112 and have beensynthetically altered to express an even higher affinity for DNA
cleavage versus the naturally occurring bleomycins113.
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Figure 4.2 Examples of vicinal diamines in natural products.
The project being proposed will strictly focus on one particular motif containing a
1,2-diamine structure. Specifically, the compound will be a cyclic urea that contains a
five membered ring. This motif is of interest to our group as a precursor to the synthesis
of cyclic guanidines. There are a wide variety of natural products that contain cyclic
ureas and guanidines which include agelastatin A and dragmacidin E (Figure 4.3). A
wide variety of synthetic techniques have been applied towards the synthesis of these
vicinal diamines. There is a continuing demand for furthering this knowledge and
proposed herein is another contribution to this growing database of methods.
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Figure 4.3 Natural products containing a cyclic guanidine or cyclic urea.
4.1.5 Synthetic Target
The specific compound chosen as our inspiration is the alkaloid titled saxitoxin
(STX). STX, a paralytic shellfish toxin, is found in a variety of marine dinoflagellates
and freshwater cyanobacteria.114 Of particular note is the high toxicity of STX which can
cause fatalities if 1 mg or more is ingested by a human. The lethal toxicity of STX arises
from the high affinity for the receptor sites at sodium channels. Upon binding, the sodium
channels are effectively blocked causing immediate paralysis in the victim.115 A deeper
understanding of this highly toxic alkaloid can lead to pharmaceutical methods of
treatment as well as better methods of detection and removal from water sources. STX
can also provide an excellent opportunity for further studies of the function of sodium ion
channels. Since the molecular interaction of STX within these channels is still not fully
understood. Therefore, a facile synthesis that allows for minor modifications to be made
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to the structure could provide opportunities for the discovery of improved STX target
molecules.
Although the medicinal applications of this molecule hold significant interest,
STX serves as an inspiration for method developments in the synthesis of cyclic ureas
followed by the conversion to the guanidine moiety. STX provides a particularly unique
motif due to the presence of a tricyclic system that is composed of two cyclic guanidines
as well as a spirocyclic carbon located at C4 (Figure 4.4). Due to this dense heterocyclic
skeleton, STX has presented a daunting challenge for the synthetic community. Despite
this, Kishi,116 Jacobi,117 Fleming,118-119 Looper,120 and Nishikawa121 have all completed
elegant total syntheses of this molecule.

Figure 4.4 Structure of Saxitoxin.
4.1.6 Prior Synthetic Methods of Sigmatropic Rearrangements
4.1.6.1 The Marino Rearrangement
To gain an understanding of the proposed work, previously performed syntheses
of related sigmatropic rearrangements are reviewed for perspective. The Marino group
has published a unique [3,3]-sigmatropic rearrangement of vinyl sulfoxides with
dichloroketene. According to Scheme 4.4, this process proceeds in a stereoselective
fashion to produce a functionalized cis-γ-butyro-lactone.122
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Scheme 4.4 Marino rearrangement: vinyl sulfoxide-dichloroketene lactonization.
Marino and coworkers also determined that this reaction proceeded via a [3,3]sigmatropic rearrangement as depicted by the proposed mechanism in. In this
mechanism, the sulfoxide oxygen attacks the electrophilic sp-hybridized carbon in the
dichloroketene (Scheme 4.5). The resultant zwitterion then undergoes bond
reorganization and produces a thionium intermediate. The carboxylate anion then adds
intramolecularly via a 5-exo cyclization to stereoselectively produce the lactone product.

Scheme 4.5 Mechanism of the Marino rearrangement.
The Marino group continued their studies of this lactonization reaction in the
synthesis of physostigmine alkaloids and aflotoxins, both of which are heterocyclic
natural products.123 This work expanded the research to include β-aminovinylsulfoxides
and the incorporation of the double bond into a heterocyclic structure (Scheme 4.6). This
work with β-aminovinylsulfoxides provides further insight into the applicability of our
proposed synthesis.
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Scheme 4.6 Total synthesis of physostigmine via the Marino rearrangement.
4.1.6.2 The Overman Rearrangement
Early studies of the Claisen rearrangement by Otto Mumm and Friedrich Moller
led to an observed [3,3]-sigmatropic rearrangement of N-phenyl benzimidic acid allyl
ester to yield N-allyl-N-phenyl benzamide (Scheme 4.7).124 The Overman group
expanded upon this rearrangement using allylic trichloroacetimidates which resulted in a
1,3-transposition of the alcohol and amine functions (Scheme 4.7).125

Scheme 4.7 [3,3] Rearrangements involving nitrogen.
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The Overman rearrangement can be performed under thermal conditions or in the
presence of mercury(II) salts. This transformation is highly stereo- and regio-selective,
with the (E)-alkene conformation as the favored product, and is irreversible due to the
formation of the strong amide bond. The thermal rearrangement proceeds via a transition
state in a six membered chair conformation and the mercury(II) catalyzed rearrangement
proceeds via an iminomercuration-deoxymercuration mechanism (Scheme 4.8).126-128
Both mechanisms result in the same product.

Scheme 4.8 Thermal and mercury (II) catalyzed rearrangements.
4.1.6.3 The Pfitzner-Moffat Oxidation
The third reaction mechanism of importance to this proposal is the PfitznerMoffat oxidation. In 1963, K.E. Pfitzner and J.G. Moffat synthesized aldehydes and
ketones via oxidation of primary and secondary alcohols utilizing dimethyl sulfoxide and
dicyclohexyl carbodiimide and catalytic amounts of anhydrous phosphoric acid.129 The
main benefit of this mechanism is the mild reaction conditions which provides a desirable
alternative to the use of chromium(VI) oxidants.130
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The mechanism of this oxidation is well understood. The reaction is indicated by
protonation of the alkyl carbodiimide with an acid in the pKa range of 0.7-2.5 which will
then activate the dimethylsulfoxide (DMSO) as shown in Scheme 4.9. The resultant
sulfonium ion is attacked by the alcohol and produces an alkoxysulfonium ylide and a
dialkyl urea byproduct. The ylide then decomposes intramolecularly to yield either the
ketone or aldehyde depending on whether a primary or secondary alcohol was utilized
(Scheme 9).131-132

Scheme 4.9 Pfitzner-Moffat oxidation.
4.1.6.4 Rearrangement of Allylic Phosphorimidates
The Mapp group has disclosed the synthesis of carbon-nitrogen bonds through a
[3,3]-sigmatropic rearrangement of allylic phosphorimidates to phosphoramidates
(Scheme 4.10). Upon synthesis of the phosphorimidate, conversion to allylic amines can
be achieved. Further investigations into this process confirmed the presence of the chairlike transition state similar to that found in a typical Claisen rearrangement and the
expansive scope this method has for preparation of a wide variety of allylic amines.133
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Methods for the synthesis of carbon-nitrogen bonds are highly desired as many
heterocyclic natural products contain them.

Scheme 4.10 Rearrangements of allylic phosphorimidates.
4.2 Research Hypothesis
It is hypothesized that carbodiimides are competent electrophilic partners to engage
vinyl sulfoxides in a [3,3]-sigmatropic rearrangement to synthesize cyclic and guanidines.
The research questions to be addressed are:
1. Can carbodiimides can be activated by exogenous acid for engagement with vinyl
sulfoxides to synthesize cyclic ureas?
2. Can molecular modeling guide the development of reaction conditions that will
favor synthesis of cyclic ureas and guanidines?
4.3 Research Design and Methods
The overall goal of this project is to provide a new synthetic route for the
development of cyclic ureas and guanidines. To achieve this, an investigation of a new
carbon-nitrogen bond forming reaction between carbodiimides and vinyl sulfoxides will
be conducted. It is proposed that the carbon-nitrogen bonds are formed through a [3,3]sigmatropic rearrangement followed by an intramolecular cyclization to produce a cyclic
urea. Furthermore, vinyl sulfoxides containing endocyclic and exocyclic alkenes will be
utilized to form fused bicyclic and spirocyclic structures, respectively. All previously
discussed mechanisms have provided inspiration for the proposed synthesis.
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4.3.1 Overall Scheme
The inspiration of this reaction sequence is based on the work of the Marino
group. Marino’s work uses dichloroketene to achieve the same rearrangement while we
propose to use of carbodiimides. We hypothesize that the sp hybridized carbon located in
the center of the dialkyl carbodiimide has appropriate electrophilicity to undergo
nucleophilic attack by the oxygen anion (Error! Reference source not found.). This
intermediate will then undergo a [3,3]-sigmatropic rearrangement to form the first
carbon-nitrogen bond and produce a reactive intermediate. We postulate that an
intramolecular reaction will then occur via attack of the nitrogen on the sp2 carbon.

Scheme 4.11 Proposed mechanism for cyclic urea synthesis.
4.3.2 Carbodiimide Activation Studies
The Pfitzner-Moffat oxidation discussed previously will serve as the model
system. In the oxidation, the carbodiimide was activated using various weak acids
including pyridinium salts of strong acids130 and phosphoric acid.129 It has been
determined that only mildly acidic compounds can be utilized for carbodiimide
activation.134 Initial studies will involve Brønsted acids of various pKa values. Shown in
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Scheme 4.12 is a mechanistic hypothesis for the activation of carbodiimides via
exogenous acids.

Scheme 4.12 Mechanistic hypothesis for carbodiimide activation.
In addition a list of potential candidates to be used as protonating agents and their
respective pKa values are listed in Error! Reference source not found.. The selected
acids will serve the purpose of determining the most effective pKa range for proper
activation of the central carbon.
Table 4.1
Brønsted acids to be used and associated pKa values
Acid
(CF3)2CHOH
Pyr - OTf
H3PO4
Cl2CCO2H
Pyr - HCl
F3CCO2H
CH3SO3H

pKa
9.3
5.2
2.12
1.29
0.72
-0.25
-2.6
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Furthermore, it is imperative to consider the nucleophilicity of the conjugate base
represented by (A-) that is produced (Scheme 4.13). If the conjugate base is a stronger
nucleophile than vinyl sulfoxide, a competition exists such that the conjugate base may
preferentially add to the activated carbodiimide. In this case, the counterion will be
switched. For example, relatively acidic alcohols such as 1,1,1,3,3,3-hexafluoro-2propanol (pKa = 9.3) would likely produce an alkoxide ion that could act as a competing
nucleophile.

Scheme 4.13 Competing reaction of the conjugate base with the sulfoxide oxygen.
The activation of carbodiimides is not limited to only Brønsted acids. The use of
Lewis acids will also be examined. A variety of Lewis acids have been utilized for
reaction with carbodiimides and include samarium diiodide,135 cupric triflate,136 metal
chlorides,137 and boron (III) derivatives.138 Furthermore, the successful activation of
carbodiimides has been observed through the use of lanthanide and yttrium catalysts.139
4.3.3 Nuclear Magnetic Resonance and In Situ Infrared Spectroscopy Studies
Carbodiimide protonation can be monitored effectively through the use of in situ
IR spectrometry. The Mettler Toledo ReactIR will be utilized for solution phase IR
studies. This analytical technique will provide evidence regarding protonation of the
carbodiimide by monitoring the imide C=N bond stretch located at 2114 cm-1. The
disappearance of the imide stretch will confirm protonation is occurring. Once
protonation of the carbodiimide is observed, reaction progression with vinyl sulfoxides
can also be monitored. If the carbodiimide is sufficiently activated, the appearance of a
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C=O bond will be expected to appear between 1690-1620 cm-1 after the sulfoxide oxygen
reacts and formation of the urea begins.
NMR will also be used as a tool to monitor both the protonation of the
carbodiimide and the reaction of the sulfoxide. Prior to protonation, the sp hybridized
carbon has a 13C shift located at δ 140 ppm.140 It is expected that an upfield shift of this
diagnostic peak will occur should protonation be achieved. NMR can therefore be an
effective method for relative pKa measurements of our carbodiimides according to
Perrin’s NMR titration protocol.141

Scheme 4.14 Carbodiimide protonation.
NMR will be utilized for product analysis with attention on diagnostic peak shifts
of vinyl sulfoxide. Of note are the vinyl hydrogens located on the sulfoxide. If the
proposed rearrangement occurs, the cis-trans relationship will be eliminated and
proximity to the nitrogen will decrease. Therefore, the coupling constant of the hydrogens
in the trans- relationship will not be observed. Also, the vinyl hydrogens will become
diastereotopic following ring closure and appearance of this relationship will be
monitored.
The proposed analytical techniques with further support from the Marino model
system will be utilized as tools for confirmation of the proposed mechanism. Based on
literature precedent of the Claisen rearrangement, stereochemistry of the reagents will be
maintained due to the concerted synchronous characteristic. Therefore, if stereochemistry
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is maintained, it can be inferred that a chair-like transition state typical of the Claisen
rearrangement is present.
Another consideration for carbodiimide activation is the variation of the nitrogen
substituents. Initial studies will involve the use of symmetric dialkyl carbodiimides that
are readily available. Specifically, DIC and DCC have been employed during the reaction
screening process. Once optimum reaction conditions have been determined, the
incorporation of N-Benzyl protecting groups may be utilized as the R groups attached to
nitrogen. This will be beneficial due to ease of removal and further functionalization via
hydrogenolysis (Scheme 4.15).

Scheme 4.15 Hydrogenolysis of benzyl protected nitrogens in the cyclic urea.
Although it is preferred that symmetric dialkyl carbodiimides be used to prevent
the production of regioisomers, as shown in Scheme 4.16, the electrophilicity of the
central carbon could be further increased via preparation of dissymmetric carbodiimides.
For instance, by altering R3 and R4 to be electron donating and electron withdrawing
groups, respectively, a “push-pull” effect can be incorporated into the molecule to
manipulate the electronics at the sp carbon.
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Scheme 4.16 Expected regioisomers via dissymmetric carbodiimides.
The preparation of dissymmetric carbodiimides will be performed via the
Staudinger reaction between an isocyanate and iminophosphorane. The general reactions
portraying this reagent preparation are shown in Scheme 4.17.

Scheme 4.17 Aza-Wittig preparation of dissymmetric carbodiimides.
4.3.4 Stereochemistry of the Sulfoxide
The application of chiral sulfoxides to asymmetric synthesis has found an
increasing interest among the synthetic community.142-144 The initial reaction screening
will involve the use of phenyl vinyl sulfoxide but further application of the project can be
found via a wide variety of enantiopure sulfoxides. Once the sulfoxide has been activated
by the carbodiimide, it is expected that the intermediate will be ordered according to a
Zimmerman-Traxler chair-like transition state. This transition state, shown in Figure 4.5,
provides explanation for the rearrangement and the stereochemistry of the final product.
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Figure 4.5 Zimmerman-Traxler Transition State.
The example provided utilizes an (E)-olefin and contains a sulfoxide with an (S)
stereocenter. This transition state places the carbon-nitrogen double bond within the chair
conformation. This allows the nitrogen to participate in the rearrangement by
suprafacially engaging in the exposed face of the vinyl sulfoxide. It is then expected that
the reactive intermediate will selectively produce the trans-geometry of the cyclic urea.
Following initial studies with phenyl vinyl sulfoxide, a variety of geometrically
pure sulfoxides (R1 = Ph, p-tol, t-Bu; R2 = H, CH3, Ph) will be prepared via the HornerWittig olefination (Scheme 4.18).145

Scheme 4.18 Vinyl Sulfoxide Horner-Wittig Olefination.
4.3.5 Sulfoxide Substituents
The synthesis of fused and spirocyclic ring systems containing urea or guanidine
moieties has significant application to the realm of natural product total synthesis. The
urea cyclization can be extended to the synthesis of these bicyclic systems. This can be
achieved through the incorporation of substituents in the vinyl positions of the sulfoxide.
According to the expected rearrangement, it is proposed that both spirocyclic and fused
ring structures can be obtained. The use of either an endocyclic or exocyclic vinyl
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sulfoxide could be used to yield a fused or spirocyclic ring system, respectively (Scheme
4.19).

Scheme 4.19 Fused and spirocyclic ring synthesis.
To examine this synthesis, the vinyl sulfoxides must first be prepared. A general
procedure has previously been performed by Parham and Edwards via oxidation of
cyclohexenyl phenyl sulfide which is prepared through an SN2 displacement of
cyclohexenyl p-toluenesulfonate with thiophenol146 (Scheme 4.20).

Scheme 4.20 Proposed Synthesis of cyclic vinyl sulfoxides.
NMR will be utilized to determine whether the product is formed according to
significant shifts in 13C and 1H signals. Of note is the spirocyclic carbon that will be
formed as shown in Scheme 4.19. As an sp2 carbon in the starting material, the predicted
location in 13C NMR is near δ 150 ppm. Upon formation of product, the sp3 carbon would
then be predicted to shift much further downfield near δ 60 ppm.
4.3.6 Alternative Electrophiles
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The primary goal of this prospectus is to present new methodology for the
synthesis of cyclic ureas via the use of dialkyl carbodiimides. Alternative electrophiles
can be utilized in a similar fashion. Of particular interest are isocyanates, isothiocyanates,
and trichloroacetimidates which would produce oxazolidinones, thiazolidinones, and
oxazolines, respectively. These three heterocyclic substructures have shown to be useful
in not only pharmaceuticals but a wide variety of chemical applications.147-149 Our
proposed synthesis would provide a method for easy access to these crucial moieties.
4.3.7 Vinyl Sulfinimines
There is also a possibility of utilizing other variants of the vinyl sulfoxide. In
2005, Marino and coworkers reported an extension of their original work with vinyl
sulfoxides to also include vinyl sulfilimines as a method for chemoselective synthesis of
γ-butyrolactones (Scheme 4.21)150.

Scheme 4.21 Synthesis of γ-butyrolactams via vinyl sulfilimines and dichloroketene.
The benefit to this functional group is the ability to use alternative electrophiles to
produce the same cyclic urea as presented in the original proposal. This can be achieved
by reaction of the vinyl sulfilimine with an isocyanate (Scheme 4.22).
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Scheme 4.22 Synthesis of cyclic ureas via vinyl sulfilimines and isocyanates.
The main difficulty with this alternative process is the production of two
constitutional isomers. According to the possible products, there appears to be
competition between the oxygen of the isocyanate and the nitrogen of the sulfilimine to
act as the ring closing nucleophile. It is proposed that alteration of the R2 group may
increase the nucleophilicity of the nitrogen which will improve the yield of the major
product. A variety of both electron withdrawing and electron donating groups will be
utilized to observe effective product yield. Analysis of these products will mostly involve
13

C and 1H NMR shifts and IR absorption bands. The most significant changes that will

be observed can be easily detected via IR. As previously stated, the urea product will
have a signature peak between 1690-1620 cm-1.
4.3.8 Computational Methods
A major component of this work involved the use of theoretical models as a tool
for the guidance of synthetic methodology to achieve the previously discussed cyclization
reaction. In collaboration with Professor Dean Tantillo at the University of California:
Davis, I have developed computational methods for the prediction of the chemical
outcomes. All reported data was acquired with Gaussian 09151 using the Density
Functional Theory (DFT)152-155 B3LYP /6-31G+(d,p) functional and basis set unless
otherwise specified. Considering this project consists of a [3,3]-sigmatropic
rearrangement, implementation of the B3LYP functional is preferred based on its
reported success with modeling sigmatropic rearrangements.156-158
All initial calculations for the development of transition states were performed in
the gas phase and later optimized in diethyl ether using the solvation model density
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(SMD)159 continuum solvation model when specified. Transition-states were
characterized by vibrational states and were subsequently connected to starting materials
and products via intrinsic reaction coordinate (IRC) calculations.160-163 All energies are
reported in Gibbs Free Energy at 298 K and structures have been modeled via Cylview
visualization and analysis software.164
4.3.8.1 Experimental Approach
To begin with the theoretical studies, it was determined that exploration of the
Marino rearrangement would be necessary. It would serve as the model system where the
mechanism could be established and utilized for comparison with carbodiimide
electrophiles. Additionally, it would provide support for the proposed rearrangement
described in the original work by Marino and co-workers.122 First, all starting materials
would be optimized under specified conditions. Once complete, the sum of the energy for
the starting materials will act as the zero-point energy for the system. Following this, the
molecules will be reacted via a transition state (TS) calculation. An IRC will be
performed on the identified TS which will determine if the TS is plausible by connecting
to starting materials and potential intermediates/products. This system of steps will be
repeated until the final product is reached. The mechanistic hypothesis is presented in
Scheme 4.23.
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Scheme 4.23 Mechanistic hypothesis to be studied computationally.
Once the mechanism for the Marino rearrangement has been established
computationally, the carbodiimide system can be examined. For the purpose of reducing
computational demand, the carbodiimide system utilized for all experiments is
dimethylcarbodiimide. Although this is not a previously proposed carbodiimide for the
experimental portion, it is best to begin with simpler models then increase complexity
after a suitable model has been established.
4.4 Results and Discussion
4.4.1 Solvent System Studies
A solvent screen has been performed for the reaction of phenyl vinyl sulfoxide
with dicyclohexyl carbodiimide (DCC) or diisopropyl carbodiimide (DIC) at various
temperatures (Table 4.2). This was performed to first identify the potential for
carbodiimides to react without the need for further activation by an acid. This study was
conducted due to the significant effect solvents can have on reactions. By varying
between polar protic, polar aprotic, and non-polar aprotic solvent systems, reaction
progression can be affected. For example, hydrogen bonding and dipole interactions with
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ionic solutes can alter the activation energy needed for the reaction. Considering the vinyl
sulfoxide is performing nucleophilic attack on the carbodiimide, it would be best to have
polar aprotic solvents because the oxygen anion can better act as the electron donor. It is
also important to consider the dielectric constants as an indicator of the solvents ability to
support charge separation. With this reaction containing charged reactants and
intermediates, it would be desirable to use solvents with high dielectric constants.
Following this screening process, it was concluded that the electrophilicity of the central
carbon will need to be increased to promote reaction.
Table 4.2
Solvent Screen and the associated dielectric constant
Entry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Solvent
DCM
DCM
DCM
DCM
THF
THF
THF
DMF
DMF
DMF
Acetone
Nitroethane
Ethylene Carbonate
Benzene
Benzene/TFA
Dichloroacetic acid
DCM/DCA
HMPA

Temperature
(°C)
25
60
25
80
25
60
80
25
60
80
25
25
25
25
25
25
25
25
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Dielectric
Constant

10.36

7.58

36.7
20.7
28.06
90.5
2.27
8.2
30

4.4.2 In Situ Infrared Results
Preliminary results with 1,1,1,3,3,3-hexafluoro-2-propanol have shown
successful decrease in the absorption band at 2114 cm-1 upon addition of 1.0 equivalent
of 1,1,1,3,3,3-hexafluoro-2-propanol. This implies the protonation of the nitrogen and
subsequent conversion of the πCN double bond to a σCN single bond (Figure 4.6).
DIC absorption Band: 2114 cm-1

Figure 4.6 Waterfall plot ReactIR graph showing protonation of diisopropyl
carbodiimide.
This result implies that the conjugate base of hexafluoroisopropanol has sufficient
nucleophilicity for reaction with the activated carbon (Scheme 4.24). This reaction is
indicated by the new signal appearing at 1694 cm-1 which is due to the imide C=N stretch
of the pseudo-urea, 4.113.

Scheme 4.24 Conjugate base addition to activated DIC.
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This result indicated that other acids with different pKa strengths may produce
similar results. Therefore, both Lewis and Brønsted acids were reacted with DIC to
observe activation of the central sp hybridized carbon (Table 4.3 and Table 4.4). There
was greater success with the use of Brønsted acids with all experiments showing decline
of the C=N stretch at 2114 cm-1. Further investigations with the Lewis acids will be
required which include increased equivalents for cupric acetate as well as increased
temperature.
Table 4.3
Lewis acid activation studies via ReactIR
Entry
1
2
3
4
5

Acid
Cu(OAc)2
Cu(OAc)2
HgCl2
Cu(OTf)2
Cu(OTf)2

Equivalence
0.05
0.20
1.0
0.05
1.0

Solvent
DMF
DMF
EtOAc
DMF
DMF

Time (hr)
8 hr
8 hr
8 hr
2 hr
3 hr

Temp.
ambient
ambient
ambient
ambient
ambient

ReactIR
no change
no change
no change
no change
C=N loss

Table 4.4
Brønsted acid activation studies via ReactIR
Entry
1
2
3
4
5

Acid
DCA
(CF3)2CHOH
(CF3)2CHOH
PyrOTf
PyrHCl

Equivalence
2.0
9.5
1.0
1.0
1.0

Solvent
DCM
(CF3)2CHOH
DCM
DMF
DMF

Time
5 min
3 min
8 hr
4 hr
4 hr

Temp.
ambient
ambient
ambient
ambient
ambient

ReactIR
C=N loss
C=N loss
C=N loss
C=N loss
C=N loss

ReactIR spectra showed complete loss of the imide stretch when using stronger
Brønsted acids such as trifluoromethanesulfonic acid (Figure 4.7). A promising result is
the loss of the imide stretch without appearance of signals implying the nucleophilic
attack of the conjugate base at the electrophilic carbon center. Furthermore, the use of
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cupric triflate in 1.0 equivalent afforded decline in the imide stretch intensity but did not
fully remove the signal. This implicates that there is likely a coordination of the copper
with DIC but no bonds are being broken (Figure 4.8).

Figure 4.7 Waterfall plot ReactIR graph showing protonation of diisopropyl carbodiimide
with trifluoromethansulfonic acid.

Figure 4.8 Waterfall plot ReactIR graph showing coordination of diisopropyl
carbodiimide with cupric triflate.
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Finally, as a control experiment to ensure that what is being observed correlates
with previous work, the Pfitzner-Moffatt oxidation conditions were examined. The results
of DIC reacting with aqueous phosphoric acid confirm that complete loss of the imide
stretch is to be expected with activation of the carbodiimide (Figure 4.9).

Figure 4.9 Waterfall plot ReactIR graph showing protonation of diisopropyl carbodiimide
with phosphoric acid.
4.4.3 Computational Results
4.4.3.1 Marino Rearrangement
TS1 4.104 was identified via transition state calculations and the TS was
confirmed with IRC calculations (Figure 4.10). It was observed that the TS had an
extremely low energy barrier of 1.8 kcal/mol which implies this portion of the
mechanism to be plausible. In addition, the identified intermediate (Int1 4.105) was
within a shallow energy well with a decrease of only 0.5 kcal/mol. With the IRC
successfully implemented, it was decided to take this step and perform the same
calculations with the M06-2X functional. This is a crucial comparison to provide
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evidence that the system can by repeated with alternative methods without significant
deviation from the original results. Although an IRC was not performed with M06-2X, all
three structures were reoptimized and showed minimal deviation from the energy levels
calculated using B3LYP.

Figure 4.10 TS1 identification of the Marino rearrangement.
Furthermore, the system was examined using diethyl ether as solvent. Ether was
chosen as the solvent due to Marino reporting its use in the original publication. When
beginning this set of calculations, the identification of TS1 4.104 was unsuccessful. It
was postulated that the solvent promotes a “concerted” mechanism where no TS exists
between the sulfoxide attack and sigmatropic rearrangement. To support this hypothesis,
a single point energy calculation was performed on TS 4.104 and intermediate 4.105
identified in the vacuum system. The observed result was a 5.0 kcal/mol higher energy
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for intermediate1, supporting the hypothesis that solvent has eliminated the presence of
TS1 4.104.
With the first intermediate and TS identified in the gas phase, an attempt to
discover the second transition state which involves the [3,3]-sigmatropic rearrangement
was attempted. Although TS 4.114 was identified, it was observed to have unexpected
vibrations which implied an alternative reaction pathway. Essentially, an imaginary
frequency was observed but the vibrations are associated with unexpected bond
formation/cleavage considering it is desired to see a sigmatropic rearrangement (Figure
4.11).

Figure 4.11 Ball and stick model of TS2 4.114.
An IRC was performed on this TS which confirmed the hypothesis that this would
lead to an alternative pathway. What is of interest is that neither products of the IRC
connect to the starting intermediate. Rather, two individual products 4.115 and 4.39 were
formed which implies the possibility of a bifurcation from the associated transition state
(Figure 4.12). The forward IRC shows promise in the formation of the desired γ-lactone
but has the unexpected cyclobutene product in the reverse direction. Another significant
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observation of this IRC is the lack of an additional transition state as previously
hypothesized. The slight shoulder in the forward IRC represents the final step of the
mechanistic hypothesis wherein the ring-closing step occurs.

Figure 4.12 IRC of TS2 4.114.
In response to this result, it was attempted to work from the reverse direction to
see if a connection could be made to the pre-[3,3]sigmatropic rearrangement TS (Figure
4.13). TS2a 4.116 was identified and proceeded to the lactone product 4.39 in the forward
IRC. The reverse IRC produced an intermediate 4.117 that had no significant difference
in structure from TS2a.
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Figure 4.13 IRC of TS2 starting from the post [3,3] rearrangement.
The issue presented here is no IRC connects int1 with a TS or other structure that
undergoes the [3,3] rearrangement. It is postulated that this is due to the remainder of the
reaction occurring in a “downhill” process. Once TS1 4.114 is achieved there is never
another significant increase in the energy and therefore no presence of additional energy
wells. Though a TS2 has been identified (4.116) that then proceeds to the lactone
product, there is no IRC that connects the post [3,3] intermediate with a pre [3,3]
intermediate. Based on additional calculations containing solvent, there is enough
supporting evidence to hypothesize that the rearrangement is therefore a concerted
process wherein only one true TS exists prior to the sigmatropic rearrangement and
subsequent lactone formation.
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4.4.3.2 Carbodiimide Studies
After reaching a conclusion with the Marino rearrangement, study of the
carbodiimide system was started based on the mechanistic proposal bearing resemblance
to the Marino rearrangement (Scheme 4.25).

Scheme 4.25 Proposed mechanism for the carbodiimide annulation.
To begin, an experiment to discover the first transitions state was implemented in
the gas phase. Once identified, an IRC was performed to determine the first intermediate
and confirm the connection to starting materials (Figure 4.14). Two observations from the
IRC provided intriguing results. First, the intermediate produced was an unexpected
dissociation of the transition state to urea 4.126 and vinyl sulfide 4.125. The second
observation was the energy requirement to reach TS1 4.119. With an energy barrier of 45
kcal/mol, it can be concluded that without exogenous acid activation the barrier is too
high and this reaction would not occur. This provides further support of the experimental
results which show no reactions occurring during the solvent screen.
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Figure 4.14 IRC for unprotonated TS1 4.119.
With it established that exogenous acid activation was necessary, a study
containing a protonated carbodiimide 4.127 was implemented. TS 4.128 was identified
and an IRC was performed (Figure 4.15). A promising observation of this IRC is the
energy barrier of 19 kcal/mol. This is a significant decrease from the unprotonated
carbodiimide and presents a plausible energy barrier to overcome. Despite this, the
resultant dissociation for the development of vinyl sulfide 4.125 and protonated urea
intermediate 4.129 was still observed.
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Figure 4.15 IRC for protonated TS1 4.128.
With these results, it was decided to continue forward with the identification of
the next TS in the reaction. Considering the first intermediate is a significant deviation
from the original proposed mechanism the following step was designed with influence for
the next needed transition state by placing the negatively charged nitrogen near the
external position of the alkene (Figure 4.16). The identified TS 4.130 was then utilized in
an IRC with promising results for the development of the second intermediate 4.131.
With this potential reaction pathway established, a combined IRC was produced to show
the connection from starting materials to the current intermediate 4.131 (Figure 4.17).

141

Figure 4.16 IRC for TS2 4.130.

Figure 4.17 Combined IRC for the protonated carbodiimide system.
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4.5 Summary and Conclusions
This chapter has demonstrated the important role that vicinal diamines exhibit
within a variety of synthetic and medicinal applications. The role of these diamines in
natural products has also been exemplified and expanded to include cyclic ureas and
cyclic guanidines. It has been realized through the implementation of in-situ reaction
monitoring that an exogenous acid is capable of activating the carbodiimide.
Furthermore, activation with hexafluoroisopropanol (pKa = 9.3) developed a conjugate
base that participated in subsequent nucleophilic attack of the carbodiimide which gave
insight to the necessary acid strength. Once appropriate conditions have been identified
for conversion to cyclic ureas, chiral phosphoric acids can be implemented to study
asymmetric synthesis.
Additionally, theoretical modeling provided support for experimental
observations. Notably, Bronsted acid activation drastically reduced the activation energy
for nucleophilic attack from PVS. Without this activation, it was clear that no reaction
would occur which was validated by initial condition screenings with un-activated
diisopropylcarbodiimide. Additional modeling will be needed to identify a completed
reaction pathway and further studies utilizing Lewis acid activated systems will need to
be examined.
4.6 Experimental
4.6.1 General Methods
Solvent Screen General Procedures: To a 6 mL conical vial equipped with a spin vane
was added the carbodiimide (1.64 mmol) and solvent (1.64 mL). Vinyl sulfoxide (215
µL, 1.64 mmol) was then added to the reaction. When applicable (Error! Reference
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source not found.) the acid catalyst was then added (0.820 mmol). The reaction was then
stirred at the temperature outlined in Error! Reference source not found.. All reactions
were monitored using TLC with a developing solvent of 4:1 Hexanes:Acetone. Plates
were visualized using UV followed by phosphomolybdic acid dye.
Entry

Solvent

Carbodiimide

Acid

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
THF
THF
THF
THF
DMF
DMF
DMF
DMF
CH2Cl2
THF
DMF
Acetone
Nitroethane
Ethylene
Carbonate
Benzene
Benzene
DCA
CH2Cl2

DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DCC
DIC
DIC

19
20
21
22

Time (hr)

TLC

TFA
TFA
DCA
DCA
DCA
-

Temp.
(ºC)
ambient
60
ambient
80
ambient
60
ambient
80
ambient
60
ambient
80
ambient
ambient
ambient
ambient
ambient
ambient

22
22
16
16
22
22
16
16
22
22
16
16
16
16
16
16
16
16

no change
no change
new spots
no change
no change
no change
new spots
no change
no change
no change
new spots
no change
new spots
new spots
new spots
no change
no change
no change

TFA
DCA
DCA

ambient
ambient
ambient
ambient

8
8
0.5
0.5

no change
no change
new spots
new spots

4.6.2 Synthesis of Intermediates
Reaction of diisopropyl carbodiimide with 1,1,1,3,3,3-hexafluoro-2-propanol: NGJ-1080. To a 4 mL vial equipped with a stir bar was added DIC (50.9 µL, 0.328 mmol) and
DCM (328.0 µL, 84.9 mmol). The ReactIR probe was submerged into the solution and
the mixture was stirred. One reading per minute was taken for a total of 3 minutes before
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1,1,1,3,3,3-hexafluoro-2-propanol was added (17.3 µL, 0.164 mmol). The reaction was
stirred for 3 hr. at room temperature with no observed decrease in peak intensity at 2114
cm-1. Another 0.5 eq. of the hexafluoro-2-propanol (17.3 µL, 0.164 mmol) was added for
a total of 1.0 eq. A continual decrease in peak intensity at 2114 cm-1 and appearance of a
new peak at 1694 cm-1 was observed during a time period of 4.5 hr. Phenyl vinyl
sulfoxide (43.1 µL, 0.328 mmol) was added and the solution was stirred for an additional
8 hr. No further changes were observed.
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Supplementary data (NMR, IR, MS, and Elemental Analysis) for Chapter 2 compounds is
provided in the supporting text titled “Supplementary Spectral Data”.
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Supplementary data (NMR, IR, MS, and Elemental Analysis) for Chapter 3 compounds is
provided in the supporting text titled “Supplementary Spectral Data”.
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